Anti-<i>Candida a</i>ctivity of killer toxins from the yeast <i>Williopsis mrakii</i> by Hodgson, Valerie
A n ti-C andida  A ctivity  o f K iller Toxins from  
the Y ea st W illiopsis m rakii
VALERIE J. HODGSON BSc. (HONS).
THIS THESIS IS PRESENTED TO DUNDEE INSTITUTE OF TECHNOLOGY IN 
PARTIAL FUFILMENT OF THE REQUIREMENTS FOR THE AWARD 
OF THE DEGREE OF DOCTOR OF PHILOSOPHY.
DEPARTMENT OF MOLECULAR AND LIFE SCIENCES, 
DUNDEE INSTITUTE OF TECHNOLOGY IN COLLABORATION 
WITH GLAXO GROUP RESEARCH.
AUGUST 1993.
I certify that this thesis is the true and accurate version 
of the thesis approved by the examiners.
Signe
(Dire
Date
DUNDEE INSTITUTE OF TECHNOLOGY
LIBRARY
Reproduction of Project Report
AUTHOR: Valerie J. Hodgson
TITLE: Anti-Candida Activity of the Killer Yeast Williopsis mrakii 
QUALIFICATIONS: Ph.D.
I agree that a copy be made of the whole, or any part, of the above 
mentioned project by the Library of Dundee Institute of Technology at 
the request of any one of its readers without reference to the undersigned, 
on the completion of a Copyright Declaration Form, and on payment of 
the fee currently in force.
Signature
Address 
d
Acknowledgements
I wish to thank my supervisor Dr. Graeme Walker for his advice throughout this 
project and extend my sincere gratitude to Dr. David Button for his constructive 
criticism of this manuscript and support both as an undergraduate and postgraduate. 
The cooperation and advice of the technical staff of the Department of Molecular and 
Life Sciences is also greatly appreciated. I would also like to express my thanks to 
Dr. David Ross for the access given to his personal computer.
I would like to express my sincere gratitude to Glaxo Group Research for the 
financial support given to this project, and myself. The understanding and advice of 
Dr. Russel Williamson is also gratefully acknowledged.
Special thanks must be given to close friends for their continued support, especially 
to Dr. Steve Millam for his time, encouragement and liquid refreshments without 
which the completion of this thesis would not have been possible. I would also like 
to extend my thanks to Anne McLeod for the time spent proof-reading and checking 
references and her artistic talents are greatly appreciated.
Finally, I will always be indebted to my family for their continuing support, 
encouragement and patience in all I do....I made it!
Valerie J. Hodgson.
Abstract
Killer yeasts secrete toxins which are lethal or inhibitory to sensitive yeasts but to which 
they themselves are immune. Williopsis mrakii is a killer yeast but very little is known 
about the physiology of the organism and the characteristics of its toxin. This research was 
concerned with an investigation into killer toxin production by W.mrakii, purification of 
the killer factor and its action against medically important Candida species.
A total of 30 presumptive killer yeast strains were tested in vitro for killing activity against 
a range of sensitive yeast strains, including clinical isolates of Candida, using a standard 
agar diffusion bioassay. Several yeasts, of the genus Pichia, showed widespread activity 
against the sensitive strains assayed but W.mrakii was demonstrated as showing the 
greatest anti-Candida activity.
Cmde W.mrakii killer toxin showed a differential killing action against strains of Candida 
isolated from clinical specimens. No direct correlation between the site of isolation and 
susceptibility to the killer toxin was found. The status of the host and species-type would 
also contribute to the toxin-receptor interaction. It was found that at critical concentrations 
the killer factor of W.mrakii exerted a greater effect on stationary phase cells than cells 
from an exponential phase of growth. At low concentrations, the killer toxin produced a 
fungistatic effect on sensitive yeasts but at higher concentrations there was evidence to 
suggest that membrane damage accounted for the fungicidal effects of the killer factor. 
The cidal nature of the toxin was reflected in a rapid decrease in sensitive cell viability.
W.mrakii is a ‘microaerophilic’ yeast with simple nutritional requirements. In a gently 
agitated system the killer factor was produced in a minimal medium as a consequence of 
cell growth and its activity reached constant levels as the cells entered stationary phase. 
Toxin activity was lost at several stages during processing of the culture supernatants 
because of membrane-binding and losses to the ultrafiltrate. PhastSystem analysis and gel 
filtration chromatography suggested that the active toxin m olecule was an acidic 
polypeptide with a molecular weight of 1800-5000 Da. Rapid purification of the toxin 
using FPLC techniques was hampered by problems in accurately assessing toxin activity 
in the presence of high salt concentrations. This was overcome by the development of a 
novel colourimetric assay of toxin activity.
Anti-Candida Activity o f  Killer Toxins from the Yeast Williopsis mrakii.
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CHAPTER ONE
Introduction
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1.1 The Killer Phenomenon
Antagonism in microorganisms was probably first reported in 1 8 7 7 , by Pasteur and 
Joubert, who observed the inhibitory effect of bacteria isolated from urine on B acillus  
anthracis. Subsequently a wide range of natural antimicrobial substances have been 
successfully characterised which include antibiotics, bacteriolytic enzymes and 
bacteriocins. A similar antagonism was first observed in laboratory yeast strains by 
Bevan and Makower (1 9 6 3 ). They defined three phenotypes of the yeast Saccharomyces 
cerevisiae: killer, sensitive and neutral. When killer and sensitive cells were grown 
together in the same broth or agar, a large proportion of the sensitive yeast were killed. 
No such killing occurred with incubations of neutral cells with either killer or sensitive 
strains. Killer yeasts kill sensitive cells by secreting into the medium a toxic 
proteinaceous factor (Woods and Bevan, 1 9 6 8 ; Bussey, 1 9 7 2 ) to which the killers 
themselves are immune.
To date, killer yeasts have been reported in strains of several genera including 
Saccharomyces, Candida, Cryptococcus, Debaryomyces, Hansenula, Kluyveromyces, 
P ichia  and Torulopsis (Philliskirk and Young, 1 9 7 5 ; Stumm et al., 1 9 7 7 ), U stilago  
(Kandel and Koltin, 1 9 7 8 ), Rhodotorula  and Trichosporon  (Morace et al., 1 9 8 4 ), 
Hanseniaspora (Radler et al., 1 9 8 5 ), W illiopsis and Zygow illiopsis (Kazantseva and 
Zimina, 1 9 8 9 ; Vustin et al., 1 9 9 1 ) and Zygosaccharomyces (Radler et al., 1 9 9 3 ). Further 
reports have addressed the question of the frequency of occurrence and the range of 
specificity of the toxins produced. Studies of standard laboratory stocks of S.cerevisiae 
and of collections of commercial strains have demonstrated a high frequency of killer 
yeasts (Naumova and Naumov, 1 9 7 3 ; Philliskirk and Young, 1 9 7 5 ) presumably because 
of common parentage and extensive in-breeding of such strains. However, the frequency 
in the natural habitat is higher still and strains have been isolated from fruit, 
mushrooms, decaying plants and soils (Stumm et a l., 1 9 7 7 ) and beer and wine 
fermentations (Young, 1 9 8 2 ; Shimizu et al., 1 9 8 5 ). Starmer et al. (1 9 8 7 ) showed there 
were marked differences in the incidence of killing activity seen in yeast species from 
communities associated with the decaying fruits and stems of cacti. Further cross 
reaction studies showed that a limited number of killer-sensitive relationships occurred 
within the same habitat at a particular time and locality but more frequently between 
yeasts from different habitats. Killer toxin production may, therefore, affect the natural
P age 2
distribution of both the killer and sensitive strains and is potentially a mechanism for 
interference competition i.e. preventing a competitor from gaining access to resources 
(Crombie, 1 9 4 7 ; Gill, 1 9 7 4 ). The generally low pH activity profile of the toxins 
complements the natural condition of most yeast substrates during colonisation, 
especially that of fruit (Starmer et al., 1 9 8 7 ).
Possession of killer character could, in all likelihood, be linked to the pathogenicity of 
some yeast strains when it is considered that killer toxins can produce lethality in certain 
sensitive strains. The first detailed report of killer toxin production in pathogenic strains 
was of Torulopsis glabrata (Bussey and Skipper, 1 9 7 5 ) but this phenomenon has since 
been reported in most Candida strains (Rogers and Bevan, 1 9 7 8 ) and in Cryptococcus 
(Middelbeek et al., 1 9 8 0 a). A study by Kandel and Stern (1 9 7 9 ) demonstrated that of 
2 3 6  potentially pathogenic strains of C a n d id a , C r y p to co ccu s , T o ru lo p sis  and 
Trichosporon, obtained from various hospitals and educational establishments, only 3 % 
were found to show killer characteristics. It would appear there is no direct evidence that 
pathogenicity is associated with the possession of killer character and some strains, 
especially C.albicans, are more notable for their high frequency of susceptibilty to killer 
strains of other yeast species than for their ability to kill (Middelbeek et al., 1 9 8 0 b; 
Polonelli eta l., 1 9 8 3 ).
However, several factors may result in an underestimation of the number of killer and 
sensitive isolates identified, including:
(a) the screening methods employed being inappropriate in terms of the choice of 
media, incubation conditions and the indicator strains used (Kandel, 1 9 8 8 ).
(b) the amount of toxin produced may be very low and may require concentration to aid 
detection (Middelbeek et al., 1 9 8 0 b), and
(c) the presence of extracellular enzymes may destroy toxin in culture e.g. acid 
proteases secreted by Candida strains (Kwon-Chung et al., 1 9 8 5 ).
The apparent sensitivity of most natural microbial and fungal isolates and their inability 
to produce killer toxin may sometimes be based on a failure to determine optimal assay 
conditions and to select the appropriate complementary tester strains (Polonelli et al., 
1 9 9 1 a).
✓  y 
(/
x /
V  J
/
l /
{/
/
P age 3
1 .1 .1  Classification of Killer Yeast
The classification of substances which are inhibitory or toxic can be achieved in several 
ways (Young, 1 9 8 7 ), these include:
(a) the determination of their spectrum of activity against sensitive strains.
(b) the assay of their activity against mutants with known resistance to killer toxins.
(c) the determination of the biochemical nature of the toxin.
(d) the assay of the cross-reactivity of the toxin-producing strains.
The simplest and most effective method is to monitor the interaction between killer 
strains, testing their ability to be killers and also their immunity or their resistance to 
one another by cross-reaction studies. The rationale behind such a system is that killers 
are immune to their own toxin, thus, if one killer strain kills another then their toxins 
must be biochemically distinct. Any differences observed are consequently reflected in 
both the nature of the toxins produced and the immunity systems possessed by each 
strain (Rogers and Bevan, 1 9 7 8 ). Young and Yagui (1 9 7 8 ) classified 2 0  killer yeasts in 
this manner, identifying 1 0  distinct types of spectrum of killer activity (K1 -K1 0 ) and 1 0  
different patterns of resistance (Ra-Rj). Subsequent studies (Rogers and Bevan, 1 9 7 8 ; 
Henschke, 1 9 8 0 ) are substantially in agreement with these findings. Whilst the studies 
support the classification of killer yeasts by cross-reactivity they also show that different 
toxins have common properties, although the genetic basis of toxin production may be 
different (Young and Yagui, 1 9 7 8 ).
1 .1 .2  Killer Systems Among Various Yeast Genera
(a) Saccharomyces
Since the first description of the killer phenomenon by Bevan and Makower (1 9 6 3 ), 
different types of killer yeasts have been observed in S.cerevisiae, such as K l, K2  and 
KT2 8  killer phenotypes. The Kl killer system has been the archetype for subsequent 
research (Bussey et a l., 1 9 9 0 ). The K l killer toxin is a secreted, pore-forming 
glycoprotein which kills sensitive yeast cells by altering the permeability of the cell 
membrane, thereby causing uncontrolled efflux of ions across the cell surface (Pfeiffer 
andRadler, 1 9 8 4 ; Bussey, 1 9 9 1 ).
Genetic analysis revealed that the killer trait was determined by two cytoplasmically 
inherited, linear double-stranded ribonucleic acid (dsRNA) virus-like particles (Sweeney
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et al., 1 9 7 6 ). The larger species (3 .8 - 5 3  kb), called LdsRNA, encodes the capsid protein 
and is present in most strains of S.cerevisiae. However, a smaller species (1 .7 -2 . 6  kb), 
called MdsRNA, is present in all killer strains of this type, thus, evidence strongly 
suggests that it determines the killer phenotype (Somers and Bevan, 1 9 6 9 ; Bevan et al., 
1 9 7 3 ; Mitchell et al., 1 9 7 6 ) and in fact encodes the toxin protein (Bostian et al., 1 9 8 0 ). 
This is further supported by evidence that killer cells ‘cured’ of their ability to kill, by 
incubation at elevated temperature, treatment with cycloheximide or acridine orange, 
lose the MdsRNA particle (Vodkin et al., 1 9 7 4 ; Young and Yagui, 1 9 7 8 ; Cansado et al.,
1 9 8 9 ).
The mature K 1 killer toxin is a secreted 2 0 -kilodalton ( 2 0  kDa) heterodimeric protein 
consisting of a- and p-subunits linked by disulphide bonds (Bostian et al., 1 9 8 4 ). It is 
derived from a precursor molecule which is extensively post-translationally processed in 
the yeast secretory pathway (Bussey, 1 9 9 1 ). The toxin precursor enters the endoplasmic 
reticulum where the signal peptide is removed (see Figure 1 .1 ) and the y peptide is N- 
glycosylated. At a late golgi step the molecule is further processed by proteolytic 
cleavage (Bostian et al., 1 9 8 3 ; Bussey et al., 1 9 8 3 ). The mature toxin is then secreted 
via the constitutive secretory pathway to the external environment (Bussey et al., 1 9 9 0 ). 
The action of this killer toxin on sensitive yeast cells, although not fully understood, is 
thought to be a two-stage process involving a series of specific cell surface interactions 
(Figure 1 .2 ). The first stage involves binding of toxin to a (l,6)-p-D-glucan, a 
component of the cell wall receptor (Hutchins and Bussey, 1 9 8 3 ). Both toxin subunits 
appear to participate in cell wall receptor binding. The p-subunit is necessary for glucan 
receptor binding, whereas the a-subunit, also involved in glucan binding, is 
multifunctional (Bussey, 1 9 9 1 ). Initial cell wall binding mediates access of the toxin to 
a secondary receptor (R) on the plasma membrane where the toxin exerts a lethal effect 
(Stage 2 ) by creating a ‘leak pathway’ . The channel-forming domain of the toxin 
appears to be confined to the hydrophobic a-subunit (Zhu and Bussey, 1 9 9 1 ) and, 
following an initial lag period (de la Pena, 1 9 8 0 ) loss of ATP, K+ and cellular 
metabolites follows (Bussey and Sherman, 1 9 7 3 ; Skipper and Bussey, 1 9 7 7 ). The toxin 
reduces the proton gradient across the membrane of the yeast cell resulting in the 
acidification of its contents (de la Pena, 1 9 8 1 ) and cell death follows functional damage 
to the plasma membrane (Vondrejs, 1 9 8 7 ). Kagan (1 9 8 3 ) showed that a crude
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Figure 1.1 - Schematic representation of the toxin precursor molecule and mature 
secreted toxin (Bussey etal., 1990; Bussey, 1991)
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A. Precursor molecule. From N- to C-terminus are the signal sequence (SS) followed by a- and 
P-subunits separated by a glycosylated (G) y peptide. Sites of processing by signal peptidase (SP) 
and proteases (PP) are shown.
B. Toxin subunits, a- and P-subunits which constitute the mature toxin. Two hydrophobic 
domains (in black) may be capable of spanning the membrane and are likely to be involved in 
channel formation. P-subunit is hydrophilic and involved in receptor binding.
C. Mature secreted toxin, a- and P-subunits are covalently linked by disulphide bonds.
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Figure 1.2 - Schematic representation of the action of the K1 killer toxin of S.cerevisiae 
against sensitive yeast strains.
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preparation of P.kluyveri killer toxin could form ion permeable channels in phospholipid 
bilayers, suggesting that such channels would be sufficient to explain the in vivo effects 
of P.kluyveri and S.cerevisiae killer toxins.
It is considered by Douglas et al. (1988) that the precursor of the mature toxin is 
responsible for the specific immunity of the toxin-producing strain. The precursor 
molecule either alters or masks the membrane receptor so that it is incapable of 
interacting with the a-subunit of the toxin. Alternatively the precursor could mediate the 
relocation or removal of the receptor so that it is no longer available for interaction.
The killer toxin, KT28, of S.cerevisiae 28 is a glycoprotein of molecular weight 16 kDa 
(Pfeiffer and Radler, 1982) and shows a degree of homology to the K2-type killer toxin 
(Pfeiffer and Radler, 1984). However, the toxin differs from that of other S.cerevisiae 
killer strains in that it does not bind to a glucan primary receptor but to a mannoprotein 
constituent of the sensitive cell wall (Pfeiffer and Radler, 1982; Schmitt and Radler,
1987). Any minor modifications to the mannan structure result in the prevention of 
toxin binding and confer resistance on the sensitive strain (Schmitt and Radler, 1988). 
KT28 killer toxin interferes with DNA synthesis or with the mitotic separation of DNA 
which leads to an interruption in early G2 phase of the cell cycle (Schmitt et al., 1989).
b. Kluyveromyces
Killer toxin-like inhibitors have been reported by Lehmann et al. (1987) in several 
Kluyveromyces species. However, the most extensively studied has been the killer 
system of the yeast K.lactis which produces a protein toxin that inhibits growth in 
sensitive yeasts (Stark et al., 1990). The secreted heterotrim eric protein toxin is 
associated with two linear double-stranded deoxyribonucleic acid (dsDNA) plasmids of
8.9 and 13.4 kb, and is active against yeast from several genera (Gunge et al., 1981). 
The K.lactis toxin does not elicit leakage of K+ and ATP (Sugisaki et al., 1983) but 
causes an irreversible arrest o f the cell cycle (W hite et al., 1989) by an as yet 
undetermined mechanism. The y-subunit appears to be the only component necessary 
for the arrest of proliferation since intracellular expression of this polypeptide alone 
mimics the action of mature toxin (Tokunaga et al., 1989). Recently the a-subunit of the 
toxin has been demonstrated to show localised sequence similarity to a variety of plant 
and bacterial chitinases (Stark et al., 1990; Bradshaw, 1990). It is thought to be required
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for the entry of the active subunits (y-subunit) into the sensitive cell, or may be involved 
in an interaction with a carbohydrate receptor on the cell wall (Butler et al., 1991) in a 
similar manner to the K1 and KT28 toxins of S.cerevisiae.
Killer character determined by DNA plasmids, once unique to K.lactis, has recently 
been observed in strains of P.acaciae (Worsham and Bolen, 1990) and P.inositovora 
(Hayman and Bolen, 1991). The function of the linear DNA plasmids of the yeasts
S.kluyveri (Kitada and Hishinuma, 1987) and Saccharomycopsis crataegensis (Shepherd 
et al., 1987) has not been determined.
c. W iUiopsis and Others
Williopsis mrakii is an ascosporogenous, apiculate yeast found naturally in soils but 
which has also been isolated from swamp and creek waters. Formerly this yeast was 
classified in the genus Hansenula, as in Kreger van Rij (1984), but it now forms part of 
the genus Williopsis. For taxonomic purposes the genus Hansenula has been divided 
into two: strains with saturn-shaped spores are now termed as Williopsis (Barnett et al., 
1983; Kurtzman, 1984) and those with hat-shaped spores Pichia.
Killer yeasts have been reported to be widely distributed between strains of both Pichia 
and Williopsis (Nomoto et al., 1984; Kazantseva and Zimina, 1989) and that they 
possess a broad range of antimicrobial activity against other yeast and filamentous 
fungi. One strain o f W.mrakii (LKB 169) was isolated and partially purified by 
Yamamoto and co-workers (1986a). This toxin is a molecule of approximately 10.7 kDa 
and was thought to preferentially inhibit p-(l,3)-glucan synthesis in sensitive yeast cells 
(Yamamoto et al., 1986b). A killer toxin of P.anomala (WC65) has been characterised 
as a glycoprotein of molecular weight 83.3 kDa which consisted of 86% protein and 
14% carbohydrate (Sawant et al., 1989). The toxin showed saturation kinetics at high 
toxin concentrations, which is indicative of a receptor-mediated mode of action (Sawant 
et al., 1988) and it was speculated that a p-(l,6)-glucan was involved in receptor 
com position (Sawant and Ahearn, 1990). The toxins of Pichia  and W illiopsis 
(Hansenula) species are broad spectrum, displaying intrageneric activity, and they are 
relatively stable to a range of temperatures and pH’s in comparison to the toxins of 
Saccharomyces spp. (Young, 1987).
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There is no available evidence that the killer character expressed by strains of Williopsis 
and Pichia, or in fact Candida, Debaryomyces, Cryptococcus, and Torulopsis are 
dependant on plasmid encoded systems (see Table 1.1 for summary). None of the non- 
Saccharomyces yeasts studied by Young and Yagui (1978) could be cured of their killer 
activity by treatment with cycloheximide or ethidium bromide or incubation at an 
elevated temperature. Attempts to isolate dsRNA or DNA plasmids by the procedure of 
Gunge et al. (1981) proved unfruitful. This would indicate that the genetic basis for their 
killer character is not cytoplasmic but is chromosomally encoded.
1.1.3 Applications of Killer Yeast
(a) Advances in Fundamental Biological Research
Yeasts regulate their growth in response to numerous and different external signals. 
However, like higher eukaryotes, yeasts progress through a series of predetermined 
events which control the cell cycle and the two systems share many common features. 
Y east can, therefore provide a useful model for the study of many regulatory 
mechanisms. The mechanisms of processing and secretion of yeast killer toxins as well 
as their binding and activity against sensitive cells, closely parallel the production and 
action processes of hormones and neuropeptides in animals (Chan et a l, 1979; Sossin et 
al., 1989). The killer plasmids of S.cerevisiae and K.lactis have the potential to be used 
as cloning vectors for the effective secretion of expressed foreign polypeptides 
(Sugisaki et al., 1985; Dignard et al., 1991).
(b) Fermentation and Food Industries
The presence of killer yeasts as contaminants in brewing processes presents a greater 
threat than the presence of other wild yeast, since not only do they compete for substrate 
but they may eradicate the indigenous brewing stra in  resu lting  in abnorm al 
fermentations and products of poor quality (Young and Philliskirk, 1975). Constructs, 
where the killer character can be conferred into strains (Vondrejs, 1987), can be used 
commercially for beer production (Young, 1981), wine making (Hara et al., 1980; 
Boone et al., 1990) and in the baking industry (Bortol et al., 1986). Brewing strains with 
killer character produced beers very similar to those produced by control brewing 
strains, and were indistinguishable by taste (Young, 1981; Hammond and Eckersley,
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Table 1.1 - The genetic basis of known killer yeasts.
GENETIC BASIS GENUS SPECIES REFERENCE
Saccharomyces cerevisiae Makower and Bevan (1963)
ds RNA
Hanseniaspora uvarum Zorget al. (1988)
Plasmids
Ustilago maydis Hankin and Puhalla (1971)
Kluyveromyces lactis Gunge etal. (1981)
Linear DNA
Pichia acaciae Worsham and Bolen (1990)
Plasmids
Pichia inositovora Hayman and Bolen (1991)
Candida Yokomori et al. (1988)
Pichia farinosa Suzuki and Nikkuni (1989)
Pichia anomala Kagiyama et al. (1988)
Chromosomally
Williopsis mrakii Nomoto et al. (1984)
Encoded ?
Torulopsis glabrata Young and Yagui (1978)
Cryptococcus laurentii Middelbeek et al. (1980a)
Debaryomyces vanrijii Young and Yagui (1978)
Kluyveromyces drosophilarum Young and Yagui (1978)
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1984). Crude toxin preparations have also been used direcly to protect beer from 
contamination by wild yeasts (Young and Talbot, 1979). Toxicity to humans of killer 
factor is judged as negligible and is unlikely to cause any reaction when consumed 
orally because of the vastly disparate pH and temperature conditions encountered 
(Pfeiffer et al., 1988). The major disadvantage may be consumer acceptance of products 
involving ‘killer toxins’.
The production and storage of foods is frequently compromised by growth of yeasts 
such as Kloeckera apiculata (which produces low concentrations of alcohol as an 
undesirable fermentation product) and Saccharomycodes ludwigii (which displays a 
high resistance to SO2). Biological control of these undesirable yeast may be achieved 
using other yeast cultures which produce antifungal metabolites such as yeast killer 
toxins. K .lactis, K .phaffii and K.vanudenii proved to be effective against such 
contaminants (Palpacelli et al., 1991) and may have potential in the food industry.
(c) Biotyping
The growth inhibition produced in sensitive yeast strains by killer yeasts and their toxins 
has been exploited by several groups as a means of biotyping organisms to provide 
valuable epidemiological information concerning microbial infections in patients 
(Polonelli et al., 1989a). A killer system was developed (Polonelli et al., 1983) which 
grouped organisms according to their different sensitivities to a number of killer yeasts. 
The organisms were grouped into categories and their responses to the toxic effect of 
nine killer yeast were reproducible even if other characteristics were heterogenous 
(Morace et al., 1984). Modified killer systems, adapted to the growth requirements of 
the sensitive strains being tested, have been used for intraspecies differentiation of 
C.albicans strains (Polonelli et al., 1983) and other pathogenic Candida  and 
Cryptococcus strains (Morace et al., 1984), and to distinguish between unrelated 
eukaryotes (Polonelli and Morace, 1986) and bacterial isolates (Morace et al., 1989). 
The use of the killer system provides a practical means of biotyping opportunistic yeasts 
and monitoring nocosomial infections. Results have been found to be comparable to 
serotyping studies using monoclonal antibodies and those obtained from commercial 
diagnostic kits (Polonelli et al., 1989a).
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(d) Novel Therapeutics
Polonelli et al. (1989b) found quantitative differences in the sensitivity of both the yeast 
and mycelial form of the dimorphic fungus Sporothrix schenckii to yeast killer toxin. 
Theoretically, this makes possible a therapeutic approach involving killer toxins or their 
derivatives in the treatment of systemic mycoses in which one morphology may be 
found. However, the pH and tem perature lability may render yeast killer toxins 
unsuitable for administration orally or by injection in treatment of yeast infections 
(Kandel, 1988). Topical applications in the treatment of superficial lesions may be 
possible. Experim ental infections were produced in anim als by the cutaneous 
application of cultures of Malassezia furfur  and M.pachydermatis and were treated 
topically with concentrated P.anomala killer toxin. A clear clinical improvement in the 
treated area occurred within 6-7 days of treatment (Polonelli et al., 1986).
Another important consideration when contemplating the therapeutic use of killer toxins 
is the induction of pathological effects. A presumptive toxicity for cells in tissue culture 
was suggested (Polonelli et al., 1991a) and the proteinaceous nature of the toxin is also 
likely to elicit an immune response from the patient (Kandel, 1988). It is hoped that 
natural molecules exploiting a specific physiological target, such as yeast killer toxin 
cell wall receptors, will create fewer adverse effects than the toxins themselves 
(Polonelli et al., 1991a). There is evidence to suggest that certain anti-idiotypic 
antibodies (anti-ids) which structurally express an internal image of the antigen (the 
epitope of the killer toxin) may have significant practical implications (Polonelli et al., 
1991b). Figure 1.3 shows the relationship between killer toxin, its cell wall receptor and 
resulting anti-ids. Anti-idiotypic vaccination may be a possibility where the anti-ids 
mimick the action of a yeast killer toxin in vivo (Polonelli et al., 1991a). Yeast killer 
toxin anti-ids, raised against P.anomala, have been shown to kill C.albicans cells that 
are sensitive to the activity of yeast killer toxin (Polonelli et al., 1991b), and to protect 
mice when challenged with toxin-sensitive C.albicans (Polonelli et al., 1989c).
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Figure 1.3 - Receptor-mediated interactions of yeast killer toxin-like antiidiotypic 
antibodies (Polonelli et al., 1991a).
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1.2 Yeasts Pathogenic to Man
Diseases caused by fungi are collectively called mycoses, and range from very common 
mild infections affecting the skin, through deep cutaneous and subcutaneous infections, 
to acute and chron ic  in fec tio n s o f the v iscera  and tis su e s . O ther than  the 
dermatophytoses, the infections caused by yeast outnumber all other mycoses (Hurley et 
aL, 1987). The important yeast pathogens o f man are Candida and Cryptococcus, and 
becoming increasingly im portant are the so-called ‘m ajor endem ic m ycoses’, 
Coccioides immitis, Paracoccioides braziliensis , Histoplasma capsulatum  and 
Blastomyces dermatitidis, which in their dominant mycelial form are infectious to 
humans by inhalation (Graybill, 1992).
Most of the yeasts that cause disease in man are normally commensals, exerting 
pathogenic effects only when the balance between the host and its indigenous flora is 
disrupted. The opportunity for yeasts to invade tissues is afforded by many factors, 
including procedures of modern medicine and therapy with antibiotics which suppress 
normal bacterial flora (see 1.3.2 (d)).
1.3 Candida and Candidosis
Amongst the yeasts, the most versatile of the pathogens are those of the genus Candida. 
Infections are caused primarily by the single yeast species C.albicans, but C.kefyr,
C.parapsilosis, C.tropicalis, C.glabrata, C.guillermondii, C.krusei and C.lusitaniae also 
command attention as potential pathogens (Odds, 1988). Infections of virtually every 
tissue have been reported (Odds, 1988) but manifestations as superficial lesions are by 
far the most common, especially infections of the mucous surfaces of the mouth and 
vagina, usually term ed as ‘th rush ’. A more serious invasive form may follow  
dissemination of the yeast and direct entry of yeasts into the bloodstream may occur 
(Shepherd, 1985a).
1.3.1 Candida Infections in AIDS Patients
Fungal infections are now widely recognised as common and frequently life-threatening 
opportunistic infections in patients with the acquired immunodeficiency syndrome 
(A ID S ) (S o b e l, 1990). V ario u s  fa c to rs  have in c re a se d  the  n um b ers  o f 
immunocomprom ised patients, none as dram atically as the AIDS epidem ic. A
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progressive decrease in T-cell mediated defence mechanisms has led to an increase in 
mycoses such as candidosis, cryptococcosis, histoplasmosis and coccioidmycosis 
(Dupont, 1992). Table 1.2 shows the incidence of AIDS cases, and the number of deaths 
as a result, in the United Kingdom as a whole between January 1982 and January 1993. 
Retrospective studies have shown that 58-81% of all AIDS patients contract a fungal 
infection and 10-20% have died as a direct result of the contracted mycoses (Holmberg 
and Meyer, 1986).
The first clinical descriptions of AIDS by Gottlieb et al. (1981) mentioned not only 
pneumonia due to Pneumocystis carinii, but also oral candidosis and 90-95% of HIV­
positive patients develop clinical lesions of Candida as their condition progresses 
(Dupont, 1992). A large array of clinical manifestations of Candida are seen, with the 
prevalence of mouth infections approaching 50% and those of the oesophagus being 
greater than 10% (Selik et al., 1987). However, dissemination of the fungus to deep 
organs is considered to be rare (Odds, 1992). Klein et al. (1984) showed that oral 
candidosis is an initial manifestation in high risk patients and usually indicates a 
progression towards full-blown AIDS. Its use, however, as a prognostic marker for 
AIDS is not always straight forward and changes such as faecal derm atitis and 
yellowing of the toenails are seen as much earlier indications of disease progression 
(Mofeldt-Maanson et al., 1989). The presenting symptom of a Candida infection should 
always be regarded as a possible sign of an underlying pathological process, even if it is 
proved later not to be HIV infection (Odds, 1992).
1.3.2 Factors Predisposing the Host to Candidosis
Candida species are strictly opportunistic pathogens which cause infection when the 
equilibrium between the host and yeast microflora, which normally ensures their 
avirulent commensal status, is disrupted. Any alteration in any microbial defence can 
compromise the ability of a host to withstand microbial attack (Mims, 1987). There are a 
large range of situations in which yeast invasion is enhanced, and these include :
(a) Natural Factors
Any person receiving medical attention is more likely to harbour yeast than ‘normal’ 
individuals and apart from the debilitating effects of many illnesses there are certain 
diseases and disorders particulaly associated with candidosis (Odds, 1988). Notably,
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Table 1.2 - Table showing figures for known AIDS cases (and deaths) by exposure category 
between January, 1982 and January, 1993 (data was obtained from AIDS News Supplement, 
prepared and presented by the Communicable Diseases (Scotland) Unit, Ruchill Hospital, 
Glasgow).
Probable Acquisition 
of the Virus
January 1982 - January 1993
Male (Deaths) Female (Deaths)
Sexual Intercourse
Between Men 5333 (3356) - -
Between Men and Women - - - -
High Risk Partner* 24 (10) 49 (29)
Other Partner Abroad^ 339 (177) 192 (71)
Other Partner UK 36 (16) 29 (17)
Under Investigation 6 (4) - -
Injecting Drug Use (IDU) 226 (134) 95 (54)
IDU and Sexual Intercourse - - - -
Between Men 115 (75) - -
Blood
Blood Factor (Haemophiliacs) 
Blood / Tissue Transfer
337 (257) 5 (3)
-U K 19 (14) 19 (14)
- Abroad 15 (9) 30 (18)
Mother to Child 38 (17) 43 (21)
Other /  Underestimated 83 (51) 12 (5)
TOTAL 6571 (4120) 474 (236)
1 - Includes men and women who had sex with injecting drug users, or with 
those infected by contaminated blood and women who had sex with bisexual 
men.
2 - Includes persons without other identified risks from, or who have lived 
in, countries where the major route of HIV-1 transmission is through sexual 
intercourse between men and women.
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genital Candida infections have been described as common symptoms of the onset of 
diabetes in both men and women (Nagesha and Ananthakrishna, 1970) and diabetes has 
also been implicated in 5-15% of reported cases of systemic candidosis (Odds, 1988). It 
is proposed that the high glucose levels in the blood and tissues and the low levels of 
lactate in the skin (Kandhari et al., 1969) may favour the growth of Candida in 
diabetics. Candida species are also frequently associated with endocrine disorders 
(Alteras et al., 1969), with patients suffering from congenital disorders such as cystic 
fibrosis (Jenner et al., 1979), cancer and haematological malignancies (Bodey and 
Fanstein, 1985) and increasingly with patients suffering from AIDS (see section 1.3.1). 
Digressions from normal physiological status may also increase the susceptibilty to 
fungal infections. The relative vulnerability of the young to Candida infections, 
especially of the mouth, probably stems from immature antimicrobial defences and is 
further increased with low birth w eight, birth defects and any subsequent antibiotic 
treatment (Lay and Russel, 1977). Old age itself cannot be cited directly as a factor 
predisposing to candidosis but rather the diseases and treatments associated with old 
age. Vaginal carriage of yeasts is generally greater in pregnant women and they are 
more susceptible to vaginal candidosis. Corticosteroid effects, pH changes associated 
with the vagina, the concentration of vaginal glycogen and the increased receptivity of 
the vaginal epithelium are all considered as single or concerted factors which increase 
their vulnerability to infection (Sobel, 1986).
(b) Dietary Factors
An excess or deficiency of specific foodstuffs in an individuals dietary intake may alter 
the composition of the indigenous microbial flora, allowing an overpopulation of 
Candida species. The presence of high levels of carbohydrate in the gut may favour 
m ultiplication o f yeast rather than bacteria (Cormane and Goslings, 1963) and 
carbohydrate-rich diets have been linked to increased oral Candida colonisation 
(Samaranayake, 1986). Several publications from the Far East suggest a higher 
prevalance of Candida in the malnourished (Gracey et al., 1974; Sunoto et al., 1980) 
and v itam in d efic ienc ies  may fu rth er p red isp ose  th is sec to r to cand id o sis  
(Samaranayake, 1986).
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(c) Mechanical Factors
Severely burned patients are particularly susceptible to colonisation and deep-seated 
infection with yeasts (Spebar and Blindberg, 1979) but the reported incidences of 
Candida colonisation varies from 11.4% (Spebar and Pruitt, 1981) and 54.7% (Law et 
al., 1972). However, candidaemia can often occur in patients without infection of the 
burn itself (Spebar and Pruitt, 1981) suggesting other portals of entry or other factors, 
rather than the trauma itself, increases the likelihood of infection (MacMillan et al., 
1972).
The natural distribution of Candida species within the body suggests a preference of the 
yeasts for moist habitats, such as the groin and toe webs, rather than the general skin 
surface (Somerville, 1969). Therefore, any situation which involves covering or 
softening of the skin, or membranes, so as to raise local humidity may cause yeast 
overgrowth (Odds, 1988). The occlusive effects of nappies have been cited as a cause of 
Candida infection in babies (Dixon et al., 1972), patients immobilised for long periods 
in hospital may show signs of Candida dermatitis (Yaffee, 1973) and higher oral yeast 
numbers are seen in denture wearers (Berdicevesky et al., 1980) which may lead to 
yeast overgrowth between denture and palate.
(d) Iatrogenic Factors
The most cited factors which contribute to the development of candidosis arise from 
medical or surgical treatments. Their impact, however, is often difficult to evaluate 
because it is not easy to distinguish between their contribution and that o f the 
underlying illness.
Antibacterial antibiotics which eliminate bacteria from human microbial habitats will 
allow yeasts to multiply more rapidly and their overgrowth leads to invasive infection 
(Seelig, 1966). Increases in Candida carriage have been attributed to tetracyclines 
(Mehta et al., 1970), penicillin (Meads et al., 1951) and ampicillin (Fitzpatrick and 
Topley, 1966) and a variety of studies have shown antibiotics to enhance colonisation 
and infection by Candida (Odds, 1988). There are no reports which demonstrate that 
antibiotics directly stimulate growth of C.albicans (W inner and Hurley, 1964). 
Treatment with corticosteroids, which produce pronounced anti-inflammatory and 
immunosuppressive effects, are very likely major factors in predisposing to superficial
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(Gale, 1982) and systemic candidosis (Date et al., 1983). The majority of the surveys 
find no statistical evidence for the effect of hormonal contraceptives on the prevalence 
o f Candida  in the vagina, although the oestrogen com ponent o f the horm onal 
contraceptive has a greater effect on Candida carriage than the progesterone component 
(Jackson and Spain, 1968).
With increasing advances being made in surgical techniques systemic candidosis is 
emerging as a clear hazard (Bernhardt et al., 1972). Candida infections have been 
described as complications in bone marrow transplantation (Berkowitz et al., 1985), 
renal transplantation (Gallis et al., 1975), liver transplants (Wajszczuk et al., 1985) and 
heart-lung transplants (Brooks et al., 1985). The use of in-dwelling catheters, especially 
those used in central circulation and parenteral nutrition, are associated with a high risk 
of systemic candidosis. Candida isolates have accounted for anywhere between 2% and 
67% of positive catheter cultures and C.albicans has been identified in 80% of cases 
(Odds, 1988). It is probably realistic to assume that exogenous and endogenous sources 
can lead to contamination of catheters, with the yeasts readily adhering to (Rotrosen et 
al., 1983) and colonising the plastic surface (Locci etal., 1981).
1.3.3 Pathogenicity and Virulence
If a fungus is to be perceived as potentially pathogenic and has the ability to compete 
successfully within a susceptible host, a number of steps are required to be completed to 
overcome specific and non-specific host defence mechanisms. The attributes of a 
successful pathogen, according to Richardson and Shankland (1991), include ;
(a) the ability to adhere to host surfaces.
(b) the ability to penetrate and gain access to target organs.
(c) tolerance of often extreme environmental conditions and the ability to multiply in 
vivo.
(d) inherent resistance to the selective pressure of host defence mechanisms.
(e) the ability to cause damage to host tissues.
A wide range of virulence properties are seen in Candida spp., especially C.albicans, 
and are accounted for by genomic variability. Cutler (1991) attempts to explain this 
variability as a ‘virulence-set hypothesis’. Virulence traits displayed by an organism 
belong to a set of genes and a given isolate will only express a finite number of traits
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which together will constitute its virulence phenotype. Possession of a single trait of the 
set may not be sufficient for virulence to be expressed, and furthermore not all genes 
within the set may be necessary. However, each isolate must express a critical number 
of genes that act in concert to enable the organism to cause disease. Therefore, no single 
factor contributes solely to the success o f C.albicans and other Candida spp. as 
pathogens, however, the formation of hyphae, enzyme production, toxin production and 
adhesion are potentially the most important attributes.
(a) Hyphal Production
C.albicans is a pleomorphic yeast since it can grow in one of at least four definable 
forms. A blastospore is the unicellular form of the fungus, a single yeast cell, that is 
distinguished by its specific process of cell division known as budding (Figure 1.4A). A 
parent blastospore produces a new cellular outgrowth from its surface from which a new 
bud, or daughter cell, develops, ultimately separating to form two blastospores. A hypha 
in C.albicans is a microscopic tube containing multiple fungal units separated by septa. 
Hyphae arise as branches from existing hyphae or blastospores in the shape of a germ 
tube. The hyphae give rise to lateral buds or hyphal branches (F igure 1.4B). 
Pseudohyphae closely resemble hyphae but differ in their formation: each new 
generation of buds remain attached to its parent and the progeny tend towards end-to- 
end aggregation of elongated buds (Figure 1.4C). Chlamydospores are large, refractile, 
thick-walled cells subtended from hyphae or pseudohyphae by specialised ‘suspensor 
cells’. They are only formed, however, in vitro by C.albicans (Figure 1.4D) (Odds,
1988).
A great deal of speculation exists concerning the relationship between the virulence of 
Candida strains and the yeast to hyphal transition. It is presumed that hyphae are 
mechanically better suited than yeast cells for tissue penetration and invasion and may 
express molecular virulence factors which assist in the pathogenesis of candidosis. 
However, conflicting evidence is documented concerning the absolute requirement for 
the hyphal form of the fungus to initiate infection (Odds, 1988).
Shepherd (1985b) examined the relative pathogenicities of the yeast and mycelial forms 
of C. albicans after intravenous injection into mice, kidney sections from the infected 
mice showed the presence of both forms and pseudomycelium. Ryley and Ryley (1990)
Page 21
Figure 1.4 - Schematic diagram showing the formation of different morphological 
forms in C.albicans (adapted from Odds, 1988).
A. Budding process in which new buds develop from the parent blastospore.
B. Hypha formation in which the germ tubes give rise to (i) hyphal branches, or (ii) laterally 
budding blastospores. Septa are laid down by the continuously extending hyphal tip.
C. Pseudohypha formation, a morphogenetic intermediate between budding and hyphal 
growth, where buds tend to elongate and not separate.
D. Chlamydospores developed at the tips of pseudohyphae, subtended from ‘suspensor cells’.
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using morphological mutants, growing solely as one or other form, showed that both 
morphologies had a propensity to cause disease in the murine model and concluded that 
hyphae were not in fact required to initiate disease. It was suggested by Sobel et al. 
(1984) that germination to the hyphal form was important in vaginal colonisation and 
pathogenesis of vaginitis, however, blastospores could also successfully colonise the 
vagina but produce a milder infection.
Hyphae are considered to be responsible for cell penetration and invasion and also have 
been found to adhere more successfully to epithelial cells than the yeast form (Kimura 
and Pearsall, 1978; Sobel et a l, 1984), but there is no existing evidence that one form 
can predominantly cause candidosis. Rather the heightened degree of pathogenicity of 
C.albicans may be a direct consequence of the interconversion between the two forms 
(Odds, 1988).
(b) Adhesion
Adhesion to host surfaces by pathogenic Candida  species is both necessary for 
colonisation and as a prelude to tissue invasion (Douglas, 1987). The extent and strength 
of adhesion will depend on a number of parameters involving the fungus itself and 
macromolecules on its surface (adhesins), host surface receptors or environmental 
factors.
(i) Yeast Factors
Distinct differences are seen in the virulence of Candida sp ecies, C .a lb ica n s  is 
undoubtedly the most virulent followed by C.tropicalis and C.parapsilosis (Douglas, 
1992). These differences are closely parallelled by their ability to adhere to mammalian 
cells (King et al., 1980) and other surfaces (Maisch and Calderone, 1980). Variation in 
adherence between strains is less obvious. C.albicans strains virulent for mice showed 
enhanced adherence, compared to commensal strains, only when grown in medium 
containing high concentrations of certain sugars. Under such conditions, these strains 
synthesise an adhesive fibrillar layer (Kearns et al., 1983; McCourtie and Douglas, 
1984). This phenotypic variation between commensal and invasive isolates is, therefore, 
likely to be an important virulence attribute and sugar-mediated control may be involved 
in establishment of oral infections where high concentrations of dietary sugars are 
present (Douglas, 1987).
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Cell surface hydrophobicity (CSH) is a property of the Candida cell wall which may 
influence the progression of disease. Adherence and CSH expression are both 
temperature-dependant: cells grown at 25°C adhere better and are more hydrophobic 
than those grown at 37°C (Lee and King, 1983a; Hazen et al., 1986) and morphological 
evidence of germination was preceded by the expression of CSH (Hazen and Hazen, 
1988). It may be that surface hydrophobicity provides a mechanism which allows 
evasion of specific immune responses. Cells grown at 25°C were conjugated to and 
engulfed by polymorphonucleated neutrophils (PMNs) more than those grown at 37°C, 
but killed less often. Following engulfment germ tubes were produced more rapidly at 
25°C affording a possible escape from the PMNs (Antley and Hazen, 1988). 
Preliminary studies suggest that surface proteins are involved in the expression of this 
hydrophobicity, and the conversion of hydrophilic to hydrophobic cells is due to 
changes in their mannosylation (Hazen et al., 1990). Most of the experimental evidence 
currently available indicates a role for mannoprotein in yeast attachment to cells, and the 
predominant interaction is one involving the protein portion of the mannoprotein 
adhesin (Critchley and Douglas, 1987a). If the same molecule has hydrophobic 
characteristics the exposure of such a mannoprotein may represent an efficient 
mechanism for adhesion (Hazen et al., 1990).
Klotz (1988) reports that a bioemulsifier enhances yeast adherence to human intestinal 
epithelial cells. A bioemulsifier produced by Candida spp. may change the surface 
characteristics of the target substrate to enhance adhesion and allow metabolism of the 
substrate, providing a nutritional advantage over non-adherent microorganisms (Gerson,
1985).
(ii) Host Epithelial Factors
Jones (1984) has described the adhesion process as a two component system which is 
dependant on the number and distribution of host surface receptors as well as adhesin 
production by the microorganism. A minimum number of adhesin-receptor interactions 
must be achieved for successful adhesion by an invasive fungus (Kennedy, 1988). This 
accounts for the different receptivities of epithelial cells from different sites (King et al.,
1980), from donor to donor, with age of donor (Cox, 1983) and the hormonal status of 
the individual. Vaginal epithelial cells from groups of women known to be predisposed
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to vaginitis (pregnant and diabetic) bound more yeast than a control group, and cells 
from post-menopausal women bound least (Segal et al., 1984).
(iii) Environmental Factors
Environmental temperature can affect the adherence of C. albicans to host surfaces by 
altering the surface properties or by affecting yeast cell germination (Kimura and 
Pearsall, 1980). Adherence is also affected by environmental pH (Ghannoum and Abu- 
Elteen, 1991). The optimal pH for adherence of both bacteria and fungi is reported to be 
in the range pH 6-8. However, when C.albicans was incubated with buccal epithelial 
cells at pH values ranging from 3-8, peak adherence by C.albicans was reported at pH 3 
(Samaranayake and MacFarlane, 1982). This suggests that the effect of pH on adherence 
varies with the source of mucosal cells (Mehentee and Hay, 1989).
For significant adhesion and colonisation in the gastrointestinal tract the ecology of 
endogenous microflora must first be disrupted by antimicrobial treatment or 
chemotherapy (Kennedy, 1988; Macura, 1988) before Candida cells can proliferate, or 
the fungus must be implanted before mucosal flora is established (Field et al., 1983). 
Preformed antibodies to Candida spp. may also inhibit adherence and subsequent 
pathogenesis (Scheld et al., 1983).
(iv) Adhesins and Host Receptors
Ultrastructural studies suggest that an outer floccular-fibrillar layer is responsible for the 
interaction between the fungus and the host surface (Marrie and Costerton, 1981). 
Reports vary as to the physical dimensions of this layer (Lee and King, 1983b; Kennedy 
and Sandin, 1988) and it has been described as being unevenly distributed on the cell 
surface (McCourtie and Douglas, 1981), occasionally as having an ordered alignment 
around the cell (Tronchin et al., 1984) or being localised at an adhesive site (Howlett 
and Squier, 1980).
A number of components of the yeast cell wall have been suggested as possible 
adhesins, and include mannan or mannoprotein (Sandin et al., 1982; Douglas and 
McCourtie, 1983), chitin (Segal et al., 1982) and evidence for the involvement of lipids 
has recently emerged (Ghannoum et al., 1987).
A mannoprotein adhesin of C.albicans is thought to bind via its protein moeity to a 
glycoside on the surface of buccal epithelial cells (Douglas, 1991). Adherence of 
C.albicans can be inhibited by pretreatment of cells with Concanavilin A, which binds
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to a-linked D-mannose residues (Sandin et al., 1982), proteolytic enzymes (Sobel et al.,
1981) or reducing agents such as (3-mercaptoethanol (Lee and King, 1983b). 
Tunicamycin, an antibiotic which specifically inhibits the glycosylation of 
mannoprotein in yeast, inhibits the formation of a fibrillar layer in a high galactose 
medium which results in reduced adherence (Douglas and McCourtie, 1983).
Most known receptors for microorganisms on the surface of animal cells are the 
carbohydrate components of the membrane bound glycoproteins or glycolipids (Jones 
and Isaacson, 1983). Critchley and Douglas (1987b) reported that glycosides containing 
L-fucose, N-acetyl-D-glucosamine and possibly D-mannose can function as epithelial 
receptors for different strains of C.albicans. Rotrosen et al. (1985) proposed that the 
host cell receptor for C.albicans was fibrinonectin, an important modulator of bacterial 
adhesion and colonisation in the mouth, which acts as a receptor for some species but 
not others (Simpson et a l., 1982). A study by Lancaster and Douglas (1986) 
demonstrated that fibrinonectin inhibited the attachment to epithelial cells of several 
Candida species, therefore, fibrinonectin may provide a ‘barrier’ to colonisation and 
infection. It is known that seriously ill hospital patients have a reduced level of 
fibrinonectin on their buccal cell surfaces (Douglas, 1987) which may predispose them 
to fungal infection.
(c) Enzyme Production
Hydrolytic enzyme activities which are expressed at the surface of microbial pathogens 
are always able, at least in theory, to cause damage to host cells in vivo (Odds, 1988). 
Two enzymes with this potential in C.albicans have been described, a proteinase and a 
phospholipase, but their role as virulence factors remains ambiguous.
Staib (1965) first reported extracellular proteolytic activity in C.albicans strains which 
could utilise serum proteins as a source of nitrogen, and consequently related this to 
strain pathogenicity (Staib, 1969). MacDonald and Odds (1980b) suggested such a role 
for extracellular proteinase on the basis of the presence of the enzyme in tissue lesions, 
as determined by indirect immunofluorescence, and the presence of antibodies to the 
enzyme in patients with systemic candidosis (MacDonald and Odds, 1980a). However, 
the enzyme may aid propagation of the fungus in the host, rather than act directly as a 
virulence factor, (Homma et al., 1992) by assisting invasion and degradation of skin or
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mucosa (Negi et al., 1984; Kobayashi et al., 1989), attacking antibodies, granulocytes 
and macrophages (MacDonald and Odds, 1983; Ghannoum and Elteen, 1986) or 
supplying nutrients by digestion of proteins (MacDonald, 1984; Shimizu et al., 1987). 
Phospholipases have been found in many fungi and it has been suggested that they play 
a role in pathogenicity (Barret-Bee et al., 1985). Price and Cawson (1977) demonstrated 
phospholipase activity in C.albicans cell extracts and associated this activity with bud 
formation during growth. During invasion of chick chorioallantoic membranes, yeasts 
showing high levels of phospholipase activity appeared to clear a path for invasion and 
colonisation of tissues by hyphae. Very high levels of enzyme activity were associated 
with the hyphal tips (Pugh and Cawson, 1977). A correlation was found between 
phospholipase levels, pathogenicity and adherence to epithelial cells in several 
C.albicans strains. Non-pathogenic S.cerevisiae and C.parap silo sis showed both lower 
enzyme activity and adherence (Barret-Bee et al., 1985).
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1.4 Use of Antifungal Agents against Candida Infections
The repertoire of available antifungals for the treatment of candidosis is considerable, 
however, an "ideal" compound is not a reality. Most of those available are suitable only 
for topical application and those to treat systemic infections are few. In short, none is yet 
so effective, so safe or so convenient that it can be used without qualification (Odds, 
1988).
The potential targets for the currently available antifungals include the cell wall, plasma 
membrane, endoplasmic reticulum and the nucleus (see Table 1.3 for summary).
(a) Antifungals Impairing Barrier Function of the Plasma Membrane
The polyene macrolide antibiotics are the natural products of filamentous bacteria, 
usually Streptomyces species, and include Amphotericin B and nystatin. The polyenes 
selectively interact with the ergosterol-containing plasma membrane of the fungus, 
changing its physical state and causing impairment of barrier function. This results in 
enhanced permeability to protons and leakage of K+, Ca^+ and PO ^' (Vanden Bossche 
et a l., 1987). However, this alone does not appear to account for all aspects of polyene 
action and Medoff (1988) suggested the involvement of oxidative processes in the 
fungicidal activity of Amphotericin B.
Amphotericin B has been the "gold standard" for treatment of systemic or life- 
threatening Candida infections since its discovery (Gold et al., 1956). Resistant strains 
in clinical material are very rare, and seem only to arise in species of C.lusitaniae which 
affects neutropenic patients (Athar and Winner, 1971). Applied topically it has been 
successful in the treatment of oral, genital and cutaneous candidosis, however, because 
of its poor absorbance from the gut it must be administered intravenously for the 
treatment of systemic infection. However, Amphotericin B has proved to be highly toxic 
producing kidney damage and uremia in patients, therefore, a firm diagnosis of systemic 
candidosis should be made before administration.
Nystatin was the first-ever described polyene (Hazen and Brown, 1950) and the first- 
ever specific antifungal agent to be used therapeutically for candidosis. It is a popular 
treatment for oral and vaginal forms but its toxicity and its insolubility have reduced its 
use to only topical treatments. No more than trivial side effects have, however, been 
reported (Odds, 1988).
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Table 1.3 - Summary table of the potential targets for host-anti fungal interactions 
(adapted from Vanden Bossche, 1991).
Antifungal Target Localised Effect Antifungal Agent
PLASMA MEMBRANE Impairment of 
barrier function
Polyenes: Nystatin and 
Amphotericin B 
Azoles: Clotrimazole and 
Fluconazole
ENDOPLASMIC
RETICULUM
Ergosterol
biosynthesis
Azoles: Miconazole 
and Itraconazole
CELL WALL 
SUBUNITS
Chitin synthase 
Chitinase enzyme
Polyoxin and Nikkomycin 
Allosamidin
B-(l,3)-D-glucan
synthase
Papulacandin, Cilofungin 
and Echinocandin
Mannoprotein
synthase
Tunicamycin
NUCLEUS Inhibition of 
DNA and RNA 
synthesis
Flucytosine
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(b) Antifungals Affecting Enzymes of the Endoplasmic Reticulum
An important group of modem antifungals, the azoles, interfere with the biosynthesis of 
ergosterol the main sterol component of fungal cell walls. The azoles can be considered 
in three broad groups with respect to their historical development (Odds, 1988);
(1) 1st generation azoles are topically active imidazole derivatives and include 
clotrimazole and miconazole. In common with all azoles, they cause alterations in the 
composition of Candida  membranes by their action on cytochrome P450 during 
ergosterol biosynthesis. At high concentrations they can also be fungicidal by directly 
damaging the cell membrane (Sud and Feingold, 1981).
(2) 2nc* generation azoles are orally active N-substituted imidazoles, exemplified by 
ketoconazole, but they do not have the direct membrane-damaging capabilities of the 
1st generation azoles.
(3) 3rc* generation azoles are the triazole derivatives, which again are not direcly 
membrane damaging.
Differences in the extent of inhibition of fungal and mammalian cytochrome P450’s 
accounts for the selective toxicity of azoles for fungi (Vanden Bossche et al., 1984) and 
they are thought to bind to the haem portion of the fungal cytochrome via their 
imidazole or triazole moeity, thus blocking the site normally occupied by oxygen. At 
higher concentrations 1st generation azoles can damage membranes and induce changes 
in amino acid transport (Vanden Bossche, 1974), cause leakage of intracellular contents, 
reduction of cellular ATP (Ansehn and Nilsson, 1984) and inhibit DNA and RNA 
synthesis (Iwata et al., 1973). The differential membrane-damaging effects of the azoles 
are probably due to the extent of the reorganisation of membrane lipids produced in 
each case (Vanden Bossche et a l., 1982). They can also prevent or perturb hyphal 
development (Odds et al., 1985), therefore, since the hyphal form may be an important 
attribute to the pathogenicity of the fungus, the azoles may prevent development of 
invasive candidosis in the host.
With several of the azoles, clotrimazole and miconazole, there are problems associated 
with absorption from the gastrointestinal tract so they are mainly used therapeutically, 
like Amphotericin B, in the treatment of cutaneous Candida infections.
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Ketoconazole was the first truly active azole antifungal (Heeres et al., 1979) and given 
orally is suitably well absorbed to give rise to useful blood and tissue levels, unless 
patients are receiving antacids or H2 blockers (Van Tyle, 1984) when absorption is 
reduced. Ketoconazole is the drug of choice for chronic cutaneous candidosis (Graybill,
1989) and for the treatment of documented thrush (Van Tyle, 1984). However, several 
reports suggest the drug may be teratogenic (Fromtling, 1984) or cause male sterility 
and a few cases of hepatotoxicity have been reported (McNair et al., 1981).
Fluconazole is an orally active triazole antifungal which has lower protein binding, 
slower clearance than ketoconazole and excellent penetration of tissues, including 
cerebrospinal fluid (Humphrey et al., 1985; Arndt et al., 1988) and a broad spectrum of 
activity (Graybill, 1989). Fluconazole is systemically active as an oral agent with proven 
activity against Candida infections in AIDS (Chave et al., 1990), however, the drug has 
been increasingly associated with selection of azole-resistant species and strains of 
Candida (Kitchen et al., 1991).
(c) Antifungals Interfering with Macromolecular Synthesis
Flucytosine was initially developed as an anti-cancer drug and of all the compounds that 
inhibit macromolecular synthesis in fungi it is the only one that has been exploited in 
the treatment of patients suffering from fungal disease (Vanden Bossche, 1991). 
Flucytosine is actively transported into sensitive yeast cells by a cytosine permease 
(Polak and Scholer, 1973) where it is converted to 5-fluorouracil by the enzyme 
cytosine deaminase. The latter compound is metabolised by the pyrimidine salvage 
pathway to 5-fluorouridine triphosphate (5-FUTP) and 5-fluordeoxyuridylate (5- 
FdUMP). 5-FUTP is incorporated into fungal RNA, with consequences for protein 
synthesis (Polak and Scholer, 1975) and 5-FdUMP is a potent inhibitor of thymidylate 
synthetase, a key enzyme in DNA synthesis (Diasio et al., 1978). Selectivity arises from 
the fact that man lacks a cytosine deaminase to convert cytosine to uracil (Vanden 
Bossche, 1991).
The drug is less toxic than Amphotericin B with the most common, and less serious 
side-effects being nausea, diarrhoea and skin rashes, liver toxicity is very rare. Good 
oral absorption and this comparitive safety are, however, offset by the high prevalence 
of resistance among Candida species (Scholer, 1980). C.tropicalis, C.parapsilosis and
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C.krusei seem to show a higher prevalence of resistant strains than C.albicans (Nobre et 
al., 1981) and because of this flucytosine is used primarily in the treatment of systemic 
infections of the lungs, urinary tract, central nervous system and disseminated 
candidosis (Odds, 1988).
(d) Antifungals Interfering with the Synthesis or Hydrolysis of Cell Wall Subunits
Any impairment in the balance between the synthesis of new cell wall components and 
the controlled and localised hydrolysis of pre-existing polysaccharides will lead to an 
imbalance in growth, bud formation and septation. Chitin, mannan and several glucans 
of the Candida  cell wall are not found naturally in the human host, so they can, in 
theory, be targeted without toxicity to the host (Vanden Bossche, 1991). Thus, the cell 
wall would appear to be an ideal target for antimycotic action and is the current focus of 
several new antifungals.
Polyoxins, analogues of UDP-N-acetyl-D-glucosamine produced naturally from 
Streptomyces cacoi var. asoenis (Ryley et al., 1981), inhibit chitin synthase in cell-free 
systems (Emmer et a l., 1985). These compounds cause a reduction in septal 
fluorescence with chitin-specific stains (Hilenski et al., 1986) and other morphological 
effects (Shenbagamurthi et al., 1983) at high concentrations. However, most polyoxins 
are rapidly degraded by whole cells of Candida. Similarly, the nikkomycins show 
strong chitin synthesis inhibition in v itro  (Hector and Braun, 1986) and the 
tunicamycins, a third group of the UDP-N-acetyl-D-glucosamine analogues, prevent 
glycosylation of cell wall proteins. They have been shown to prevent incorporation of 
mannoproteins into regenerating sphaeroplasts of C.albicans (Murgui et al., 1986) but 
like polyoxins are less effective against whole cells.
Chitinase inhibitors may have an advantage over chitin synthase inhibitors as a target 
because chitinase may be accessible without requiring transport across the membrane 
(Vanden Bossche, 1991). Allosamidin, a Streptom ycete antibiotic, was reported to 
inhibit insect chitinase (Koga et al., 1987) and the chitinase of N eurospora crassa  
(Vanden Bossche , 1991), so it may be that it also has the potential to inhibit C.albicans 
and other pathogenic fungi.
A further potential target is the plasma membrane associated synthesis of glucans. The 
papulacandins, metabolites of Papularia sphaerosperma, are glycolipids which inhibit
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p-(l,3)-D-glucan synthetase in yeasts, thus, weakening cell wall structure (Rommele et 
al., 1983). Two related antifungal antibiotics are the echinocandins, produced by various 
Aspergillus species, and aculeacin A. They are both cyclic-peptides which inhibit glucan 
synthesis resulting in cell wall deformation and cell lysis (Cassone et a l., 1981; 
Yamaguchi et al., 1982). Cilofungin is an echinocandin derivative which competively 
inhibits p-(l,3)-D-glucan synthase activity of C.albicans isolates and is at least 20-fold 
less toxic than Amphotericin B (Gordee et al., 1988), however, other Candida species 
such as C.glabrata  and C.parapsilosis are less susceptible to its action (Hall et al., 
1988). Thus, the spectrum of activity of the antifungals affecting glucan synthesis may 
be too narrow for treatment of mycoses other than candidosis due to C.albicans.
1.4.1 Antifungal Prophylaxis
Preventative measures against life-threatening invasive mycoses requires serious 
consideration in order to halt further increases in the numbers of patients dying as a 
direct result of fungal infection. However, the direct benefits of chemoprophylaxis are 
controversial (Meunier, 1992) and the use of antibacterials and antifungals to prevent 
the overgrowth of commensal microbes is a complex and controversial area (Odds, 
1988). No drug or combination of drugs have been successful in the total eradication of 
yeast microflora. However, several studies with Amphotericin B (Guiot et al., 1981), 
nystatin (Carpentieri et al., 1978), ketoconazole (Meunier et al., 1989) and fluconazole 
(Samonis et a l., 1990) have reported a reduction in yeast carriage and risk of 
disseminated candidosis.
Perhaps total eradication of the pathogen is unrealistic and interference with virulence 
mechanisms, such as the morphological switch (Bennett, 1984) or adherence to host 
cells (Sobel and Obedeanu, 1983), will be sufficient to reduce the risk of serious 
infection.
As an alternative to specific antifungal agents, other potentially effective measures 
should be considered. These include the education of patients and their families, further 
training of medical staff and the use of surveillance cultures (Pfaller et al., 1987) to aid 
bedside diagnosis and management (Meunier, 1992).
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1.4.2 Identification of New Antifungal Targets
The identification and exploitation of new antifungal targets will undoubtedly rely on 
the ability to apply recombinant-genetic techniques to aspects of fungal cytology, 
metabolism and gene expression which are important in fungal pathogenesis but have no 
mammalian counterpart (Tuite, 1992). The virulence factors (section 1.3.3) of 
C.albicans, the most pervasive fungal commensal, warrant such attention.
Strong evidence exists for the involvement of a secreted aspartic protease in fungal 
pathogenesis and its presence in the human host has been detected from an early stage 
(MacDonald and Odds, 1980a). Recent identification of the aspartic proteinase-encoding 
gene from C .albicans (Hube et al., 1991) and C .trop ica lis  (Togni et a l., 1991) has 
provided important information concerning the protease structure. This knowledge may 
facilitate the rational design of protease inhibitors.
Fungal-cell-wall biosynthesis is an attractive target for antifungal chemotherapy since 
the mammalian host cell presumably has no analogous pathways. The fungal cell wall is 
not an inert structure but one in continuous flux, undergoing profound changes as a 
consequence of budding, apical extension or hyphal development. Therefore, there are 
many functions which are possible points of interference as a result of the involvement 
of synthetases and hydrolases in cellular processes (Nombela et al., 1991). Protein 
kinase involvement in cell-wall biogenesis has been identified in S.cerevisiae (Torres et 
al., 1991) and it is feasible that it may act in a similar role in C.albicans. Although the 
kinases may not be directly targeted themselves, the proteins they phosphorylate may 
provide an alternative site of action for antifungals (Tuite, 1992).
Other aspects of the fungal cell wall also demand further attention, in particular the 
morphogenic switch in C .albicans and its ability to adhere to host cells. A diverse 
collection of signals (pH, temperature and nutritional factors) can induce the yeast- 
hyphal transition, yet these signals do not appear to share any common properties. The 
receipt and transmission of these signals to their intracellular targets may involve a 
second-messenger system. A role for the involvement of calcium and calmodulin in 
morphogenesis has been suggested (Sabie and Gadd, 1989) and Paranjape et al. (1990) 
found that calmodulin activity increased during hyphal development. However, the level 
of transcription of the calmodulin gene does not appear to vary between the two forms 
(Saporito and Sypherd, 1991) so control may lie at the post-translational level (Tuite,
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1992). The nature of the C.albicans adhesins remains undefined, but elucidation of their 
structure may provide an opportunity to develop an antifungal which inhibits the host- 
pathogen interaction.
Identification of a potential target, however, is only the first step in producing an 
effective antifungal agent. A high throughput screen must then be developed to identify 
potential inhibitors which act on the target, and the structure of the latter must be well- 
defined to facilitate rational drug design (Marriot, 1990).
1.5 Aims and Objectives
Initially the project was planned to involve the screening of a number of putative killer 
yeasts, using traditional agar diffusion bioassays, to identify a strain with strong 
antimicrobial activity against pathogenic strains of C an dida. Subsequently the 
objectives were to produce the extracellular killer factor in a series of fermentations for 
an investigation into the pharmacology of the selected killer yeast strain. Studies were to 
involve;
(a) the determination of the spectrum of action of the killer yeast against clinical isolates 
of Candida,
(b) the determination of the biochemical and physico-chemical activity of the killer 
factor produced, and
(c) the elucidation of the possible mode of action of the killer toxin against sensitive 
yeast strains.
Purification of the killer factor to homogeneity using chromatographic techniques would 
potentially allow the bioactive peptide to be determined. It was hoped that this 
information would contribute to the understanding and synthesis of a novel antifungal 
with the potential for therapy of Candida infections.
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CHAPTER TWO
Materials and Methods
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2.1 Culture Collection and Maintenance
Yeast strains held at the Institute were obtained from the National Collection of Yeast 
Cultures (NCYC, England), the American Type Culture Collection (ATCC, U.S.A) and 
the Centraalbureau voor Schimmelcultures (CBS, Netherlands). W.mrakii LKB-169, 
was kindly donated by Dr. Kodama (Laboratory of Kodama Brewing Co. Ltd., Japan) 
and S.cerevisiae 28, by Dr. Pfeiffer (Institut fur Mikrobiologie und Weinforschung, 
Germany). Clinical isolates of Candida  were obtained from Glaxo Group Research 
(Middlesex, England), Ninewells Hospital (Dundee, Scotland) and Trinity College 
(Dublin, Ireland).
All yeasts were inoculated and subcultured monthly on Sabouraud Dextrose Agar (SDA, 
Oxoid, Unipath Ltd., Basingstoke, UK) slopes at 25°C for 48 hours and then maintained 
at 4°C until required.
2.2 Identification of Clinical Isolates
Microring YT (Medical Wire and Equipment Co. (Bath) Ltd., Wiltshire, England) was 
an in vitro diagnostic system used to identify the isolates obtained from Ninewells 
Hospital. Each Microring device carried six tips which were impregnated with a range 
of antimicrobial agents and dyes, each tip performed as an individual disc test because 
of an isolating hydrophobic barrier. The components of each tip were; 1 Janus green 
(156 jag); 2 Ethidium bromide (37 qg); 3 Triphenyl tetrazolium bromide TTC (150 qg); 
4 Brilliant green (200 qg); 5 Cyloheximide (45 qg) and 6 Rhodamine G (60 qg).
A single colony of each isolate was removed using a sterile swab (BDH Laboratory 
Supplies, Merck Ltd., Lutterworth, UK) and plated on fresh SDA. Using sterile forceps, 
a Microring was placed in the centre of the plate and each tip pressed firmly to ensure 
contact with the surface of the agar. The plates were incubated at 37°C for 24 hours and 
the response and zone sizes recorded. After an additional incubation for 24 hours, the 
presence and absence of brown or red colouration around the TTC tip was noted. The 
results allowed a six-digit code to be assigned to each isolate and these were compared 
to the profiles of known yeasts.
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2.3 Determination of Cell Numbers
•i
Yeast cell numbers were estimated using an Improved Neubauer haemocytometer 
(Weber, England) or an Industrial D Coulter counter (Coulter Electronics Ltd., Luton), 
for which the cells were suspended in Isoton II (Coulter Electronics Ltd., Luton), an 
osmotically balanced electrolyte solution, and passed through an aperture of 100 pm 
diameter for counting. To avoid clumping and, therefore, underestimation of cell 
numbers, solutions were sonicated (Transsonic T310 bath, Camlab) for 2 minutes prior 
to counting.
2.4 Estimation of Protein Content
Pierce Protein Assay Reagent (Pierce Chemical Company, USA), a ready-to-use 
Coomassie blue G-250 reagent solution, was used for the quantitative determination of 
protein concentration. The micro assay procedure was followed which determined 
protein concentrations in the range of 1-25 pg/ml.
A known protein concentration series was prepared by diluting a stock (2.0 mg/ml) 
bovine serum albumin standard (BSA, Pierce Chemical Company, USA) in distilled 
water. The protein standard series covered the range of concentrations between 1 and 25 
pg/ml. One ml of standard protein, or toxin-containing sample, was pipetted into a test 
tube and 1.0 ml of Coomassie Assay Reagent was added. The solutions were mixed well 
and after 2 minutes the absorbance of the solution at 595 nm was measured using a 
Novaspec II spectrophotometer (Pharmacia LKB Biochrom Ltd., Milton Keynes, UK), 
against a distilled water blank. A standard curve was prepared from the values for each 
BSA standard and this was used to determine the protein concentration of each 
unknown toxin sample.
2.5 Estimation of Carbohydrate Content
The colourimetric phenol-sulphuric acid assay of Dubois etal. (1956) was followed. A 
known glucose concentration series was prepared in distilled water. The glucose series 
covered the range of concentrations between 5 and 300 pg/ml. Two ml of the sugar 
solution (standard or sample) was pipetted into a test tube and 1 ml of 5% phenol (BDH) 
in water was added. Then 5 ml of concentrated H2SO4 (BDH) was added rapidly, the 
stream of acid being directed at the liquid surface rather than against the side of the test
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tube in order to obtain good mixing. The tubes were allowed to stand for 10 minutes 
then were shaken and placed in a water bath at 25-30°C for 15 minutes, the absorbance 
of the solutions was read at 490 nm against a distilled water blank. The amount of 
carbohydrate present was then determined by reference to a standard curve previously 
constructed. All solutions were prepared in triplicate to minimise errors.
2.6 Assessment of Killer Toxin Activity
2.6.1 Streak-Plate Agar Diffusion Bioassay
A modification of the streak-plate assay of Stumm et al. (1977) was developed to screen 
for killer yeast activity. Methylene blue agar (MBA) was prepared in citrate-phosphate 
buffer, pH 4.5 by the addition of 2% bacteriological agar (Oxoid), 2% Sabouraud Liquid 
Media (SLM, Oxoid) and 1% tryptone (Oxoid). They were heated to 100°C prior to the 
addition of 0.003% methylene blue (BDH) and 5% glycerol (Aldrich). After 
autoclaving, (121°C, 15 psi, 15 minutes) 15 ml aliquots were cooled to 45°C before 
addition of the sensitive yeast at a density of 5x10^ cells/ml. The cells were mixed 
gently with the agar to prevent formation of air bubbles and poured into plastic 90 mm x 
15 mm Petri dishes (Sterilin). A single colony of the presumptive killer was streaked on 
the agar surface using a flamed metal loop. Plates were incubated at 25°C for 2-3 days. 
The sensitive strain grew as a background lawn and killer activity was evident as a zone 
of clearing surrounding the streak, which was marked by dead blue-stained colonies. 
Plates were scored using a visual system as outlined below:
- No killer activity
* Trace activity
** Weak activity 
*** Moderate activity 
**** Good activity 
***** Excellent activity 
(+) Undefined zone of clearing
0 Absence of blue-stained colonies
1 Staining beneath streak only
2 Distinct border of stained colonies
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2.6.2 Agar Diffusion Well Bioassay
To assay crude toxin preparations, wells were cut in the seeded agar using a sterile well- 
borer (5 mm diameter) and removed with a sterile scalpel. Samples of cell-free
supernatants (30-100 pi) were pipetted into the wells and the plates were incubated at 
250C for 2-3 days. Subsequent zones of inhibition produced around the wells were
measured to the nearest 1.0 mm. The killing activity of each sample was measured as 
the mean zone of inhibition of five replicate wells in two plates. Plate 3.2 (page 56) 
shows the typical zones of inhibition produced.
2.6.3 Microtitre Plate Assay
Aliquots (180 pi) of SLM, seeded with 1x10^ cells/ml of the sensitive strain, were 
pipetted into microtitre wells (Nunc MicroWell Modules, Denmark) and 20 pi of control 
solution, or the appropriate dilution of toxin, was added and mixed using the pipette tip. 
The wells were incubated at 30°C for 18-20 hours and the absorbance of each was 
measured at 450 nm using an automatic plate reader (Titertek Multi-Scanner, Flow 
Laboratories, Irvine). Toxin activity was expressed as the percentage reduction in 
growth of the sensitive with respect to a toxin-free control. Where possible, samples 
were assayed in duplicate and compared to the mean absorbance of at least five control 
incubations.
At toxin levels below the ‘threshold limit’ of the assay, the ratio of toxin sample : 
seeded media was increased to 100 : 100 pi so that lower levels of toxin activity could 
be detected.
2.6.4 MTT-Colourimetric Assay
A 10% inoculum from an overnight culture of C.glabrata (S-388) was transfered to 
fresh SLM and incubated, with shaking, at 30°C until late log-phase was reached. One 
ml samples containing approximately 1x10** cells/ml were aliquoted into Eppendorf 
tubes to which was added 250 pi of toxin solution, or toxin-free Yeast Nitrogen Base- 
Glucose-Salts (YNBGS). The suspensions were incubated at room temperature for 90 
minutes. The cells (500 pi) were mixed with 50 pi of 5 mg/ml [3-(4,5-dimethylthiazol- 
2-yl)-2,5-diphenyl tetrazolium bromide] (MIT Sigma Chemical Company, Ltd., UK) 
and incubated at 30°C for 2 hours. The suspension was then mixed with 500 pi of
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isopropanol, (BDH) containing 0.04 M HC1 (BDH). The mixture was vigorously 
vortexed (Whirlimixa, Fisons Scientific Equipment, Leicestershire, UK) to remove 
MTT-Formazan from the cells and then centrifuged at 12,000 rpm for 2 minutes. The 
absorbance of the supernatants at 570 nm was measured against a cell-free control 
solution using a Novaspec II spectrophotometer.
The results were calculated as:
% viability measured = OD£ontroi - O^Toxin x 100 % 
by MTT assay ODControl
The viability of the sensitive cells was also determined by colony forming activity on 
SDA after a 10^  dilution of cell suspensions.
2.6.5 Membrane Damage Assay
The sensitive strain was grown overnight at 30°C in 50 ml of Glucose Nutrient Broth 
(GNB), comprising 2% glucose (BDH) and 1.3% nutrient broth (Oxoid). A 3 ml sample 
of cells was transfered to 50 ml fresh GNB and incubated, with shaking, at 30°C until 
mid-log phase was reached. Cells were harvested by centrifugation (IEC Centra-4B 
Centrifuge, International Equipment Company, USA) at 4,000 rpm for 2 minutes and 
washed with 10 ml buffer S comprising 100 mM sodium phosphate (Fisons) and 2% 
glucose, pH 6.0. The pellet was resuspended in 5 ml buffer S and incubated at 30°C for 
30 minutes, 100 pi of 2-amino[^C]isobutyric acid (Sigma) was then added and the 
cells were incubated for a further 30 minutes. The cells were harvested (4,000 rpm for 1 
minute), washed twice with buffer S containing 5 mg/ml sodium azide (BDH) and 
resuspended in 5 ml of the same buffer. The cell suspension (25 pi) was added to 
microtitre wells with 100 pi of toxin, or control solution. The plate was incubated for 60 
minutes at 30°C in a Dynatech shaker (Dynatech Laboratories Ltd., Billingshurst, UK) 
before cells were harvested onto filtermats (Skatron Instruments Ltd., Newmarket, 
Suffolk), using a Skatron harvester (Model 11055 Micro96), and were counted on a 
betaplate 1205 scintillation counter (LKB Scintillation Counter).
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The results were calculated as :
% Membrane Damage = 100 - Sample Count x 100 %
Control Count
2.7 W.mrakii (K-500) Killer Toxin Production
2.7.1 Static Culture Conditions
The rate of killer toxin production was compared in three media types:
(a) complex medium - comprising 0.3% SLM prepared in citrate-phosphate buffer, pH
4.5. The medium was autoclaved at 121 °C for 15 minutes.
(b) semi-synthetic medium - YEPD, comprising 1% yeast extract (Oxoid), 2% 
mycological peptone (Oxoid) and 2% glucose was made up in distilled water and 
autoclaved at 110°C for 20 minutes (the reduced temperature was used to prevent 
glucose caramelisation).
(c) minimal medium - YNBGS, comprising 0.67% Yeast Nitrogen Base with amino 
acids (Difco Laboratories, Detroit, Michigan, USA), 2% glucose, 0.5% (NH4)2S04 
(BDH) and 0.25% MgS04 .7H20  (Fisons). YNB and glucose were prepared as a (xlO) 
strength solution and filter sterilised through a 0.45 (xm cellulose acetate membrane 
(Whatman Ltd., Maidstone, UK). The ‘salts’ were autoclaved and the glucose and YNB 
added aseptically.
Conical flasks containing 50 ml of the appropriate media were inoculated with W.mrakii 
and incubated under static conditions at 25°C. Samples were removed and centrifuged 
at 13,000 rpm for 5 minutes (MSE, Micro Centaur) to produce cell-free supernatants, 
crude toxin preparation.
2.7.2 Small-Scale Fermentations
Overnight seed cultures (100ml) of W.mrakii were grown in YNBGS in 250 ml conical 
flasks at 25°C. A 10% inoculum was used to initiate fermentations in one litre
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(Gallenkamp Modular Fermenter, London, UK) or two litre (Electrolab Ltd., 
Tewkesbury, UK) fermenters. The pH and dissolved oxygen were monitored throughout 
the fermentation, if required, and the temperature was maintained at 25°C. Samples 
were removed to estimate cell numbers, protein content and to determine the activity of 
the killer factor produced.
During exponential growth the mean generation time, was calculated from the following 
equation:
mgt = logjQ 2 x t (hours ) 
log10 N -log10 No
t = time interval (hours)
N0 = starting cell population (cell numbers per ml)
N = final cell population (cell numbers per ml)
2.7.2.1 Effect of Agitation and Aeration on Toxin Production
Seed cultures of W.mrakii (K-500) were prepared by resuspending a slope culture in 1 
ml of YNBGS to inoculate 100 ml of the same media. These were grown for 3 days at 
25°C prior to inoculation of each fermenter. Anaerobiosis was achieved in fermenter A 
by bubbling nitrogen gas through the fermenter for 1 hour, resulting in ‘0%’dissolved 
oxygen. Fermenter B was continuously aerated at a rate of 200 cm /^min to produce a 
system with ‘100%’dissolved oxygen. A third fermenter C was gently agitated prior to, 
and after, inoculation to produce low residual levels of oxygen. The killer yeast was 
cultured for 161 hours at a temperature of 25°C.
2.7.3 Large-Scale Fermentations
Preliminary inoculum development involved the transfer of a colony of the killer yeast 
W.mrakii (K-500) to YNBGS media (50 ml), which was incubated overnight at 25°C 
under static conditions. Samples (10 ml) were transfered to eight 500 ml flasks 
containing 250 ml of the same media. The flasks were incubated for eight hours at 
25°C. The two litre starting inoculum was added to a 70 litre Biolafitte fermenter
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containing 40 litres of YNBGS. The running conditions of the fermentation were as 
follows;
(a) temperature - 25°C
(b) pressure - 0.5 bar
(c) aeration - 3.5 litre/min
(d) agitation -150 rpm
Silicone 520 antifoam was also added to the fermenter.
During the fermentation, samples were removed to monitor possible contamination, cell 
growth, protein levels and toxin production. After 48 hours, the fermentation broth was 
processed as outlined below.
2.8 Downstream Processing of W.mrakii (K-500) Killer Toxin
2.8.1 Small-Scale Processing
The culture broth of the killer strain K-500 was centrifuged at 4,500 rpm for 10 minutes 
to produce a cell-free supernatant. The crude toxin was then microfiltered through 0.45 
gm cellulose acetate membranes to further clarify the preparation. During the early 
stages of the project, Amicon stirred ultrafiltration units (Amicon Corp., Lexington, 
Massachusetts, USA) were used to concentrate the extracellular medium. A PM 10 
membrane (Diaflo, Ultrafiltration Membranes, Amicon Corp., Scientific Systems 
Division, USA) was washed, to remove the glycerol coating, and inserted into the cell. 
Nitrogen gas (40 psi) was passed into the unit, which was continuously stirred, and 50 
ml of the supernatant was reduced to 10 ml (retentate). The concentrated sample was 
then freeze-dried (Micromodulyo 1.5K freeze-dryer, Edwards High Vacuum 
International, England) and the lyophilisate reconstituted in a reduced volume of 
distilled water. Permeate samples were also collected for further analysis.
2.8.2 Large-Scale Processing
A similar procedure was followed for the processing of large-scale fermentation 
products. 40 litres of fermentation broth was continuously centrifuged (Sharpies 
A516PY, Sharpies Scientific Ltd., Coventry, UK) at 15,000 rpm to remove all cellular 
material. The supernatant was further clarified by microfiltration through 0.45 gm
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cassettes (20 ft?) in a Millipore Pelicon unit. The supernatant was concentrated by 
Millipore Pelicon ultrafiltration (10 kDa cut-off) to 3.5 litres. The retentate was then 
freeze-dried using an in-house designed and built system (Glaxo Group Research, 
Greenford).
2.8.2.1 Dialysis of Freeze-Dried Material
The dialysis tubing (Medicell International Ltd., London, UK) was submerged in a 
solution of 2% sodium bicarbonate (BDH) and 0.05% EDTA (BDH) and boiled for 10 
minutes. The solution was discarded and the tubing boiled for a further 10 minutes in 
distilled water. This was repeated, and prior to use the inner and outer surfaces of the 
tubing were washed with distilled water. One end was sealed with a double knot and 5 
ml of toxin preparation added. The air was expelled from the bag and the top end sealed. 
The bag was placed in 500 ml distilled water and agitated gently for 19 hours at 4°C. 
On removal, the bag was washed with 10 ml distilled water and the washings, along 
with the dialysate and dialysing solution, were assayed for toxin activity using a 
microtitre assay (section 2.6.3). The carbohydrate content of each solution was also 
determined (section 2.5).
2.9 Characterisation of W.mrakii (K-500) Killer Toxin
2.9.1 Temperature Stability of W.mrakii Killer Toxin
Crude toxin was concentrated 20-fold by freeze-drying cell-free supernatants and 
reconstituting the lyophilisate in distilled water. Samples of the killer toxin were 
incubated at a range of temperatures; 4, 18, 25, 30, 37, 50, 70 and 100°C. At specific 
intervals, dependant on the incubation temperature, aliqouts (100 pi) were removed and 
assayed for toxin activity against C.glabrata (S-388) using a microtitre plate assay.
2.9.2 Optimum pH of Killing Activity
The effect of pH variation on the killing action of W.mrakii killer toxin in agar diffusion 
bioassays was investigated. Crude toxin from a 72 hour static fermentation was added to 
wells in methylene blue agar plates seeded with the sensitive strains C.glabrata (S-388) 
and C.albicans (S-214392), see section 2.5.2. The plates were buffered over a range of
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pH 3.5 to 8.0. Following an incubation at 25°C for 2-3 days, the zones of inhibition 
produced by the killer factor were measured.
2.9.3 pH Stability of W.mrakii Killer Toxin
Concentrated toxin was diluted in 0.1 M citrate-phosphate buffer at a range of pH’s and 
the resultant pH of the solutions was measured using a micro-electrode (BDH Glass + 
electrode). The solutions were incubated at 18°C for a period of 18 hours and the toxin 
activity remaining was measured against C.glabrata (S-388), using a microtitre assay. 
The percentage reduction in growth of the indicator strain was assessed in each case, 
with respect to toxin-free buffer controls of equivalent pH.
2.9.4 Effect of Proteolytic Enzymes on Toxin Activity
Pepsin (pepsin A from porcine stomach mucosa, Sigma), pronase (from Streptomyces 
griseus, Fluka BioChemika) and trypsin (Type I from bovine pancreas, Sigma) were 
standardised using haemoglobin (bovine, Sigma) as a substrate. To assay trypsin and 
pepsin the enzymes were dissolved in distilled water, pronase was dissolved in 5 mM 
CaC^ (Fisons) and papain in 15 mM L-cysteine (Sigma), 6 mM EDTA (BDH). To 1 ml 
of enzyme, over a range of concentrations, 1 ml of 0.1 M sodium citrate buffer, pH 4.2 
and 1 ml of 2.5% (w/v) haemoglobin were added. After incubation for 18 hours at 20°C, 
5 ml of 4.0% (w/v) trichloroacetic acid (TCA, Sigma) was added. The solutions were 
centrifuged (5,000 x g for 10 minutes) to remove TCA-insoluble material and the 
supernatants passed through 0.2 pm syringe filters (Whatman). The absorbance of the 
filtrates were measured at 280 nm, which gave an indication of the extent of hydrolysis 
produced by each enzyme. The concentration of enzymes which hydrolysed the 
haemoglobin substrate to the same extent were used to further characterise the killer 
toxin.
One ml of crude toxin was incubated with 0.5 ml of the enzyme solution for 18 hours at 
20°C and residual toxin activity was measured against C.glabrata (S-388) using a 
microtitre assay. The effects of native and denatured enzymes (autoclaved for 15 
minutes) were also investigated and compared to the effects of control solutions of 
distilled water (pepsin) and 5 mM CaC^ (pronase).
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2.9.5 PhastSystem Analysis of W.mrakii (K-500) Killer Toxin
(a) PhastSystem Electrophoresis
The gels (Pharmacia, 10-15% gradient gel) were placed on the separation bed on a 
volume (100 pi) of ultrapure water to create a good electrical contact. On top of the gels 
was placed the buffer strip holder and the electrode assembly. An equal volume of 
boiling mix (see Appendix 9.1) was added to the solutions and they were heated to 
100°C for 3 minutes. The toxin samples and molecular weight markers (Low Molecular 
Weight SDS 7-Sigma) were cooled, centrifuged at 12,000 rpm and applied using the 
PhastSystem applicators which applied 2 pi to the gel. The small, comb-like pieces have 
a series of wells which take up samples by capillary action. The samples are held until 
they are applied to the gel at a programmed time (see Appendix 9.1). The comb was 
positioned at the base of the gel i.e. at the cathode end. The gels were run 
electrophoretically for 20-45 minutes, depending on the concentraion of the samples. 
The gels were removed and placed in the separate developmental unit where they were 
silver stained, destained and preserved according to a preset method (see Appendix 9.1). 
This procedure took approximately 40 minutes and the gels were dried on a hot-plate.
(b) PhastSystem Isoelectric Focussing
The PhastGel IEF 3-9 (Pharmacia) was placed on the separation bed as before. With this 
procedure no buffer strips were required and the positions of the electrodes were altered 
accordingly. After prefocussing to form the pH gradient across the gel, the toxin 
samples and calibration markers (Pharmacia IEF 3-9) were applied to the centre, as 
previously described. After focussing (see Appendix 9.1 for program) the gels were 
removed and silver stained as described above.
2.10 Purification of W.mrakii (K-500) Killer Toxin
2.10.1 Analysis using Fast Protein Liquid Chromatography (FPLC)
A Mono Q HR 5/5 column (Pharmacia Fine Chemicals AB, Uppsala, Sweden) was 
washed and equilibriated at a flow rate of 1.5 ml/min with two buffers A and B (buffer 
B = buffer A + 1M NaCl) using a programmed procedure (see Appendix 9.2). 
Concentrated crude toxin was filter sterilised through a 0.22 pm pore-size syringe filter 
and 500 pi applied directly to the column. The material was eluted at a flow rate of 1.0
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ml/min using a linear gradient of buffered NaCl (0-30% buffer B), strongly bound 
protein was removed using 100% buffer B (see Appendix 9.2 for complete elution 
programme). The eluate from the column was monitored by a single path UV monitor 
(Pharmacia UV-1) and chart recorder (LKB Bromma 2210 1-channel recorder) and 1 ml 
samples were collected (Pharmacia Frac-100) and assayed for activity. Elution profiles 
were obtained for different buffer systems over the range of pH 4.0 - 8.0.
2.10.2 Analysis using Gel Filtration Chromatography
Three column sizes were used for the analysis of killer toxin;
(a) commercial pre-packed Pharmacia Sephadex G-25M column (bed volume = 9ml)
(b) small, prepared Sephadex G-25 column (bed volume = 70ml)
(c) large, prepared Sephadex G-25 column (bed volume = 500ml)
For columns b and c the Sephadex powder (Pharmacia) was mixed with excess distilled 
water and allowed to stand at room temperature overnight. The swollen gel was 
degassed under vacuum to remove any dissolved air and the slurry was poured directly 
into the vertically mounted column using a glass rod. The space above the gel was filled 
with distilled water and the top-piece inserted.
Flow-rates of the columns were determined by measurement of the through-flow of 
water over a fixed time period. The rate of the pump (Eyela Microtube Pump MP-3, 
Tokyo Rikakikia Co., Ltd.) was adjusted accordingly and the fraction collector (LKB 
Bromma 2112 Redirac) programmed to collect appropriate sample volumes. Distilled 
water was pumped through for 1 hour to wash and equilibriate the columns. The 
homogeneity of the bed was checked by observing the progress of a Blue dextran- 
chromate mix (25 [ig/ml). Blue dextran was used to determine the void volume of the 
column since it is excluded from the matrix of the gel by virtue of its high molecular 
weight (2 x 10^  Daltons), and potassium dichromate to determine the exclusion volume. 
Freeze-dried material from a large-scale fermentation (see 2.7.3) was used for initial 
studies by gel filtration chromatography. A specific amount of material was 
reconstituted in distilled water, filter sterilised and applied directly to the column. Each 
column was eluted with distilled water and fractions were collected to assay for activity
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using a microtitre assay. The absorbance at 280 nm of each fraction was measured 
(Pharmacia LKB-Ultrospec III) to monitor the protein profiles of each separation.
2.10.2.1 Adsorption of W.mrakii Killer Toxin to Sephadex G-25
Concentrated (20-fold) cell-free supernatant was diluted 1:10 in distilled water to a final 
volume of 4.5 ml. A sample was removed to assess its killing activity against the 
sensitive strain C.glabrata (S-388) using a microtitre assay (Al). The solution was 
mixed with 0.2g (equivalent to a 1 ml bed volume) of pre-swollen Sephadex G-25 and 
incubated for one hour at 18°C. The slurry was centrifuged for 10 minutes at 4,500 rpm 
and the supernatant removed for assay (A2). The Sephadex was washed with 4.5 ml of 
distilled water for 30 minutes with continuous stirring. The supernatant was removed 
(A3) and the Sephadex washed for a second time with distilled water (A4), followed by 
a salt wash with 0.1 M NaCl. The supernatant (A5) was assayed for killing activity and 
the effect of 0.1 M NaCl (A6) on the assay system also determined.
2.11 Mode of Action o i W.mrakii (K-500) Killer Toxin Against Sensitive Yeast 
Strains
2.11.1 Effect of Growth Phase on Sensitivity to Killer Toxin
Stationary phase cells (5 ml) of an overnight culture of C.glabrata were inoculated into 
fresh SLM (50 ml) and incubated, with shaking, at 30°C. At one hourly intervals, over 
the normal growth cycle, cells were removed and their sensitivity to W.mrakii killer 
toxin assessed using a microtitre assay. Increasing volumes (10-100 pi) of toxin 
preparation were made up to 100 pi with sterile distilled water and added to an equal 
volume of SLM seeded with 1x10  ^cells/ml of the sensitive strain. The microtitre plate 
was incubated at 30°C for 18-20 hours and the absorbance of each measured at 450 nm 
using an automatic plate reader.
The percentage reduction in growth of each phase of cells produced by increasing 
volumes of toxin was calculated (section 2.6.3) and used to plot ‘sensitivity profiles’.
2.11.2 Effect of Killer Toxin on Growth Kinetics in the Sensitive Yeast
Three strains of C.albicans, 2005E, 2402E and C316, were incubated in the wells of a 
microtitre plate with increasing amounts of crude W.mrakii killer toxin, as above. The
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plate was placed in an automatic spectrophotometer (Titertek Multi-Scanner) which 
monitored the growth of the cells in each well by measurement of the absorbance at 450 
nm at 15 minute intervals over a 24 hour period. The plate was mixed at the same 
interval prior to growth measurements.
The information was collated in situ to produce a growth curve for each individual well. 
The growth rates of each sensitive strain in the presence of increasing amounts of the 
killer factor was determined.
2.11.3 Effect on Sensitive Cell Viability
The sensitive strain C.glabrata (S-388) was grown overnight in SLM at 30°C. A 5 ml 
sample of cells was transfered to fresh SLM and grown in a Gallenkamp orbital 
incubator (140 rpm at 30°C) until mid-log phase was reached. Cells were harvested by 
centrifugation (4,000 rpm for 5 minutes) and resuspended at a cell density of 3x10  ^
cells/ml in a concentrated toxin solution (crude freeze-dried material reconstituted in 
YNBGS). Over a period of 64 hours at 18°C, samples were removed and the number of 
viable cells was determined by colony forming activity on SDA plates after a 10^  
dilution of the cell suspension. The percentage of viable cells remaining in suspension 
was measured by comparison with colony forming units (CFU) from a toxin-free 
control.
Toxin-binding to sensitive cells was assessed by measurement of the killer activity 
remaining in the supernatant after removal of cells by centrifugation (12,000 rpm for 2 
minutes). The degree of toxin binding was expressed as a percentage of the initial killer 
activity in the supernatant.
Residual activity of the concentrated toxin solution was monitored at room temperature 
over the period of incubation to confirm that there was no loss of activity under these 
conditions.
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CHAPTER THREE
Broad Spectrum Activity of the Killer Yeast 
Wilttopsis mrakii
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3.1 Introduction
Killer yeasts secrete toxins which are lethal or inhibitory to other sensitive yeast strains 
but to which they themselves are immune. The killer phenomenon, which was 
previously thought to be a specific yeast-yeast interaction, has been observed among 
unrelated eukaryotic microorganisms and bacteria (Polonelli and Morace, 1986; Mo race 
et al., 1989). However, this broad spectrum of action affords considerable interest in the 
use of killer toxins not only as anti-yeast preparations but also as a diagnostic system for 
yeast isolates.
One of the main objectives of this research was to identify killer yeast strains which 
suppressed or killed clinically important Candida species. Initially, work concentrated 
on the screening of yeasts to identify potential killer strains, and to further investigate 
their spectrum of activity. The yeast, W illiop sis m rakii {K-500) displayed a broad 
spectrum of action against yeast of several genera and was consequently chosen for 
further study.
3.2 Determination of the Killer Character of Yeasts Held in the Culture Collection
A search was conducted for killer strains among certain yeast species held in the 
Institute’ s culture collection: the spore-forming ascomycetes (P i c h i a , 
Schizosaccharomyces, Saccharomyces, Kluyveromyces, Williopsis and Debaryomyces) 
and the asporogenous yeasts (Candida and Phaffia). The activity of the presumptive 
killers was assessed using a standard methylene blue agar diffusion bioassay (see 
section 2.6.1). The agar was seeded with the sensitive strain and each killer strain tested 
was streaked on the surface. After incubation, a positive result was indicated by a zone 
of clearing around the killer, bounded by stained blue (i.e. dead) colonies, or colonies of 
reduced size. The potential killers were tested against several strains of S.cerevisiae and 
C.glabrata, which had known sensitivities to killer yeasts and their toxins, and against 
clinical isolates of Candida from vaginal swabs. Plates were scored using the visual 
system outlined in section 2.6.1 and the results recorded in Tables 3.1a and 3.1b.
In all 21 killers were found among the 24 strains tested and several of these possessed 
high activity and a broad spectrum of action. The strongest killing was observed in
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T able 3.1a - Screening o f yeasts held in the culture collection for killer character
using the agar diffusion bioassay.
SENSITIVE STRAINS
KILLER STRAINS C.glabrata Candida isolates S.cerevisiae
S-388 21101F 214392 21408J 1006 381
P.anomala +++ ++ ++ ++ ++++
(K-432) 2 1 1 0 2 0
P.anomala ++ ++ + (+) + ++
(K-434) 1 1 1 1 2 1
P.anomala ++ + + _ + +++
(K-435) 1 1 1 1 1 1
P.anomala ++ (+) _ ++ (+)
(K-750) 2 1 0 0 1 0
P.membranae- ++ (+) _ _ +++ (+)
faciens (K-333) 2 1 1 1 2 0
P.subpellicosa
(K-436) 1
n.d n.d n.d n.d n.d
W.californica
(K-496)
+++
2
n.d n.d n.d n.d n.d
W.mrakii ++++ (+) + +++ +++
(K-LKB) 2 0 1 0 2 2
W.mrakii +++++ +++ +++ ++ +++++ ++++
(K-500) 2 2 2 1 2 2
W.saturnus _ _ _ (+) _
(K-22) 0 1 0 0 1 0
W.saturnus . + . ++ +
(K-23) 0 0 1 0 1 0
W.saturnus
(K-979)
n.d (+)
1 1 1
+++
2
n.d
D.vanrijii (+) (+) _ _ _
(K-577) 1 0 1 1 0 1
For key to symbols see Table 3.1b.
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Table 3.1b - Screening of the yeasts held in the culture collection for killer character
using the agar diffusion bioassay.
SENSITIVE STRAINS
KILLER STRAINS C.glabrata Candida isolates S.cerevisiae
S-388 21101F 214392 21408J 1006 381
K.drosophilarum n.d (+) (+) + +++ n.d
(K-575) 1 1 1 2
K.fragilis _ _ _ _ _
(K-1425) 0 0 1 1 1 1
K.marxianus (+) _ (+) _ (+) ++
(K-587) 1 0 1 1 0 1
S.cerevisiae ++ (+) (+) + +
(K-28) 1 1 1 1 1 1
S.cerevisiae _ _ + _ _
(K-679) 0 0 1 0 0 0
S.cerevisiae _ . +
(K-761) 1 1 1 1 0 0
S.cerevisiae ++ + _ . ++
(K-1001) 1 1 0 1 0 2
S.cerevisiae _ _ _ (+) ++
(K-1109) 0 0 0 1 1 2
S.pombe _ _ _
(K-1354) 0 1 1 1 1 1
P.rhodozyma (+) + (+) (+) (+). (+)
(K-PR1) 1 1 1 1 1 1
C.glabrata n.d _ _ _ n.d
(S-388) 0 0 0 1
KEY : - indicates no killer activity and + to +++++ is indicative of trace to good killer activity. 
(+) signifies an undefined ("fuzzy") zone of clearing, 0 an absence of blue-stained colonies, 1 
stained colonies beneath the streak only and 2 a distinct border of stained colonies. In some 
cases killer character was not determined (n.d).
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species of the genera P ichia  and W illiopsis and it is apparent from the results that 
W.mrakii (K-500) was the predominant strain, showing moderate to extensive killer 
activity against all the sensitive strains tested. Plate 3.1 shows the typically large zones 
of inhibition produced and, in all but one case, there was an accumulation of methylene 
blue around this lethal zone. A second strain of W.mrakii (K-LKB) displayed a narrower 
range of activity, being active against C.glabrata (S-388) and the strains of S.cerevisiae, 
yet it showed little or no activity against the clinical isolates of Candida. In general only 
weak killer activity was displayed by strains of W.saturnus. They too, were largely 
inactive against the strains of C a n d id a , but showed a degree of activity against 
S.cerevisiae  (S-1006). With the exception of P .subpellicosa  (K-436), all isolates of 
Pichia  showed good killer activity. The 4 strains of P.anom ala assayed showed quite 
different patterns of activity and the strongest killers were K-432 and K-434. However, 
in common with P.membranaefaciens (K-333), all were more active against strains of 
S.cerevisiae. Similarly, Kluyveromyces species were also largely inactive against the 
Candida strains, but K.drosophilarum  (K-575) and K.marxianus (K-587) showed weak 
to moderate activity against S-1006 and S-381, respectively. Strains of S.cerevisiae  
tended to show intrageneric, rather than interspecific killing activity. All of these strains 
were more active against S-381 than S-1006, however, both K-28 and K-1001 showed 
weak activity against C.glabrata (S-388). D.vanrijii (K-577) showed only trace activity 
against S-388 and the clinical isolate 214392 and P.rhodozyma (K-PR1) displayed signs 
of activity against all sensitive strains tested. No toxic effects were displayed by 
S.pombe (K-1354), K.fragilis (K-1425) and C.glabrata (S-388).
Of the seeded strains used, C.glabrata  (S-388) and S.cerevisia e  (S-381) were most 
sensitive to the action of the killer yeasts, displaying a response to 13 and 14 of the 
killers respectively. None of the sensitive strains tested were resistant to all of the killer 
strains, however, the clinical isolate 21408J, showed the least susceptibility to their 
toxic action.
Page 55
yeast W .m rakii (K-500).
1 = W illiop sis killer yeast, 2 = C a n d id a  sensitive, 3 = non-killer yeast.
Plate 3.1  - Growth inhibition of the sensitive strain C.glabrata (S-388) by the killer
Plate 3.2 - Agar diffusion well bioassay to show the effects of 50 pd of cell-free 
supernatant from 48 hour batch cultures of W .m rakii. Mean zones of inhibition (z) were 
measured to the nearest 1.0 mm from 5 replicate wells.
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3.3 Classification of Killer Yeasts Based on Cross-Reaction Studies
Possible killer-sensitive relationships of a selection of killer yeasts (see Table 3.2) were 
examined using a streak-plate bioassay. Each killer yeast was tested for its ability to kill 
and for its sensitivity to the killing activity of each other killer strain. The assay medium 
(section 2 .6.1) was seeded with an appropriate volume of an overnight culture of each 
killer and samples of the killer yeasts were taken from SDA plates and streaked on the 
surface. After incubation they were scored for the presence (+) or absence (-) of killing 
activity (Table 3.3).
From the results it can be seen that there were nine distinct patterns of killer activity 
against other killer yeasts, designated Ka-Kj (Young and Yagui, 1978). All of the 
S.cerevisiae strains were found in the first two killer types, with none of the strains 
showing any other type of activity. Those yeast in type Ka were active only against 
another strain of S.cerevisiae, K-28 whereas type were inactive against all strains 
tested. This killer phenotype was also shown by K.m arxianus (K-587). Type Kc was 
shown by a strain of W.mrakii (K-LKB), which was active against six of the other 
killers, five strains of S.cerevisiae and K.marxianus (K-587). Two strains of P.anomala 
(K-432 and K-435) showed the same killer phenotype K ,^ and were active against a 
single strain of K.drosophilarum  (K-575). W.mrakii (K-500), type Kjr showed the most 
extensive activity against seven of the 12 killers tested. With the exception of killing
P.anomala (K-435), the spectmm of activity of this strain was identical to W m rakii (K- 
LKB). Types K ,^ Ke, Kg and Kj were shown by the single strains P.anomala (K-434), 
P.anomala (K-750), K.drosophilarum  (K-575) and K.lactis (K-1368) respectively, each 
displaying a different spectrum of activity.
Results in Table 3.3 also demonstrate the resistance to killer action of the different killer 
yeasts, and ten patterns of resistance were observed ( R a -Rj). K - 5 0 0  and K - 1 3 6 8  (Rj) 
were resistant to the action of all of the killers, and the remaining strains showed 
resistance to at least nine of the others. Yeasts which demonstrated the same killer 
phenotype ( K a, K ^  and K f )  all exhibited different resistance patterns (1006, K aR a ; 28, 
K ^ R ^ ;  1001, K ^ R C; 587, K ^ R ^ ;  435, K ^ R g ) .  The resistant phenotypes of K - 2 3 2  and K -  
7 6 1  were not determined because of their failure to grow as seeded strains and K - 4 3 2
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Table 3.2 - Killer yeasts used in cross-reaction studies.
Genus Species Code Number Source
Saccharomyces cerevisiae K-28 Dr. Pfeiffer
K-232 N.C.Y.C
K-761 N.C.Y.C
K-1001 N.C.Y.C
K-1006 N.C.Y.C
Pichia anomaia K-432 N.C.Y.C
K-434 N.C.Y.C
K-435 N.C.Y.C
K-750 N.C.Y.C
Williopsis mrakii K-500 N.C.Y.C
K-LKB Dr. Kodama
Kluyveromyces drosophilarum K-575 N.C.Y.C
lactis K-1368 N.C.Y.C
marxianus K-587 N.C.Y.C
N.C.Y.C - National Collection of Yeast Cultures, Redhill, Surrey, 
England.
Cultures were kindly donated by Dr. Pfeiffer, Institut fur Mikrobiologie 
und Weinforschung, Germany and Dr. Kodama, Laboratory of Kodama 
Brewing Co. Ltd., Japan.
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Table 3.3 - Killer / sensitive relationships of selected killer yeast strains.
Tested
Yeast
Strains
Seeded Yeast Strains
Killer
Type
1006 28 1001 LKB 434 432 750 435 587 575 500 1368 232 761
R a Rb Rc R d Re Rf Rs Rh Rj _____ 5 i_____ n.d
1006 . + . _ - _ - _ - _ n.d n.d * a761 - + - - - - - - - - - - n.d n.d
28 n.d n.d
1001 n.d n.d Kb587 n.d n.d
232 - - - - - - - - - - - - n.d n.d
LKB + + - - + + + - + - - - n.d n.d R c
434 - + + - - - - - + - - n.d n.d R d
750 - + - - - - - - + - - n.d n.d R e
432 . . . _ . . _ + - - n.d n.d K f435 - - - - - - - - - + - - n.d n.d
575 + n.d n.d
500 + + - - + + + + - + - - n.d n.d R h
1368 - - - - - - + - - - - - n.d n.d R i
+ Killing activity; - No killing activity; Ka-Kj Killer phenotype; 
Ra-Rj Resistance phenotype; n.d not determined
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had the resistance pattern (Re) in common with K-434. The remaining three yeast 
strains displayed unique killer and resistant phenotypes (LKB, K^R ;^ 750, KgRf and 
575, KgRj). All of the killer yeasts screened were immune to the action of their own 
toxin and K.drosophilarum  (K-575) was most sensitive to the action of the other killer 
yeast.
3.4 Anti-Candida Activity of W.mrakii Killer Yeasts
Clinical isolates of Candida were used to further assess the potential of killer yeasts and 
their toxins as antifungal agents against pathogenic yeast strains.
An initial screen of the activity of W.mrakii (K-500) killer yeast against a small number 
of isolates (obtained from Ninewells Hospital, Dundee) was conducted using the agar 
diffusion and microtitre bioassays (see sections 2.6.1 and 2.6.3). The isolates included 
those from vaginal swabs, lung and tracheal aspirates and blood and urine samples. The 
killer activity expressed against each isolate (see Tables 3.4a and 3.4b) was compared to 
the effect of the killer strain and its toxin on the standard sensitive, C.glabrata (S-388).
The results further emphasised the differential killing activity of the yeast W.mrakii and 
highlight the potential action of killer toxin preparations against medically important 
yeast strains. Results from the two bioassays produced very similar responses between 
the killer yeast, its toxin and the sensitive isolate being tested. Results in Table 3.4a 
showed that the killer yeast was most active against the lung and tracheal aspirates, 
causing pronounced inhibition of their growth in the agar diffusion bioassay. Isolate S- 
00659H from a nasal swab, was also relatively sensitive to the action of K-500. Two of 
the three vaginal isolates were essentially resistant to the killer yeast, however, isolate S- 
214392 displayed susceptibility to its action. An isolate from a blood sample, identified 
as C.pseudotropicalis, was also resistant to its action.
The microtitre bioassays (Table 3.4b) similarly showed that vaginal Candida  were 
resistant to the action of the killer toxin, showing less than 10 % reduction in their 
growth (see Figure 3.1). Isolates taken from blood and nasal swabs showed little or no 
sensitivity (Figure 3.2), however, lung and tracheal isolates were sensitive to toxin 
action resulting in 40-65% reduction of their growth (Figure 3.3).
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Table 3.4a - Results of an agar diffusion bioassay showing the differential 
sensitivity of clinical isolates to the killer yeast W.mrakii (K-500).
Seeded Strain Clinical Source Killer Sensitivity
S-01563X Tracheal aspirate +++
2
S-21408J Vaginal swab
0
S-00659H Nasal swab ++
2
S-214392 Vaginal swab +++
2
S-07278S C.pseudotropicalis _
blood sample 1
S-018179 Lung aspirate +++
2
S-091834 Tracheal aspirate +++
2
S-21101F Vaginal swab +
2
S-388 Standard sensitive +++++
2
KEY: - indicates no killer activity and + to +++++ is indicative of trace 
to good killer activity. 0 signifies an absence of blue-stained colonies, 1 
stained blue colonies beneath the streak only and 2 a distinct border of 
stained colonies.
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Table 3.4b - Results of a series of microtitre bioassays showing the percentage reduction 
in growth produced by W.mrakii (K-500) killer toxin against clinical isolates of Candida.
Seeded Strain
% Reduction in Growth of the Seeded Strains 
Produced by K-500 Killer Toxin With Respect to 
Total Amount of Protein (ug) per Well of Assay
0.120 0.240 0.336 0.384 0.432 0.480
C.glabrata
(S-388)
0.1 2.9 95.0 94.1 94.1 90.5
Tracheal aspirate 
(S-01563X)
13.7 4.6 17.6 38.5 52.9 69.6
Vaginal swab 
(S-21408J)
5.2 3.8 5.9 10.1 7.3 9.8
Nasal swab 
(S-00659H)
10.3 10.9 14.0 18.8 25.1 25.4
Vaginal swab 
(S-214392)
5.3 9.2 8.0 8.7 11.9 14.6
Blood sample 
(S-07278S)
2.8 1.5 0 0.4 0.7 5.0
Lung aspirate 
(S-018179)
5.2 6.2 18.2 38.1 45.2 61.0
Tracheal aspirate 
(S-091834)
1.7 2.0 2.4 31.0 40.0 45.0
Vaginal swab 
(S-21101F)
5.5 7.2 5.8 7.2 8.9 11.9
Page 62
red
uct
ion
 in
 g
row
th
Figure 3.1 - Effect of W.mrakii (K-500) killer toxin on vaginal isolates of Candida. 
The percentage reduction in growth of each isolate was measured using a microtitre 
assay and the response compared to the standard sensitive strain, C.glabrata (S-388).
0.00 0.12 0.24 0.36 0 .48
Total protein in assay (jig)
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Figure 3.2 - Effect of W.mrakii (K-500) killer toxin on lung and tracheal isolates of 
Candida. The percentage reduction in growth of each isolate was measured using a 
microtitre assay and the response compared to the standard sensitive strain, 
C.glabrata (S-388).
0.00 0.12 0.24 0.36 0.48
Total protein in assay (jig)
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Figure 3.3 - Effect of W.mrakii (K-500) killer toxin on nasal (00659H) and blood 
(07278S) isolates of Candida. The percentage reduction in growth of each isolate 
was measured using a microtitre assay and the response compared to the standard 
sensitive strain, C.glabrata (S-388).
0.00 0.12 0.24 0.36 0.48
Total protein in assay (pg)
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These results suggested a possible relationship between the sensitivity of the isolates to 
W.mrakii (K-500) killer yeast, and its toxin, and their physiological niche. A more 
extensive screen was performed to investigate this hypothesis further. The effect of 
crude toxin preparations (cell-free supernatants from a 4 day static culture) of two 
W.mrakii killer strains, K-500 and K-LKB, on 51 clinical isolates of C andida  was 
investigated using the agar diffusion well bioassay (section 2 .6 .2) and microtitre 
bioassay (section 2.6.3) and the results compared to a streak-plate agar diffusion 
bioassay (section 2.6.1). The isolates from the initial study were re-assayed in 
conjunction with further samples obtained from Ninewells Hospital.
Results obtained from the series of bioassays (Tables 3.5a, 3.5b, 3.6a and 3.6b) 
confirmed that the majority of vaginal isolates tested were resistant to the action of both 
K-500 and K-LKB killer yeast strains. In microtitre assays (Table 3.5a) eight of the 
isolates tested against K-500 showed less than 20% reduction in their growth, and a 
further four isolates displayed less than 40% reduction. 13 isolates tested against K- 
LKB showed little or no susceptibility to the toxin (Table 3.6a). Results from a well 
bioassay (Table 3.5b) displayed similar responses to the action of the killer toxins, 
however, the streak-plate bioassay suggested that as many as 14 isolates were resistant 
to K-500 killer yeast. Only a very weak killer activity by K-LKB was demonstrated 
against the same number of isolates (Table 3.6b).
Microtitre assays (Table 3.5a) showed that all aspirate isolates tested displayed 
moderate sensitivity to the K-500 killer toxin, with a range of 37-63% reduction in their 
growth. This compared well with the initial screen where a range of 40-67% was 
observed (Table 3.4b). The agar bioassays confirmed these findings, and further 
emphasised that no isolate was completely resistant to toxin action. A different spectrum 
of activity was displayed by K-LKB and the isolates were, on the whole, less sensitive 
to this killer yeast and its toxin.
The response of sputum isolates to the action of K-500 killer toxin in microtitre and well 
bioassays was less pronounced, a broad range of sensitivity to its action was observed. 
The majority of the isolates showed a resistance to the killer yeast in the streak-plate 
bioassays. However, in each assay four isolates were consistently seen to be highly 
susceptible to the toxin. In particular isolate 26602K, which was completely inhibited by
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Table 3.5a - Results of a series of microtitre assays showing the effects of 
W.mrakii (K-500) killer toxin on clinical Candida. Figures are relative to the 
total protein in the assay (0.52|ig).
Clinical
Isolates
No. of 
Isolates 
Tested
No. Showing % Reduction in Growth
0-20% 21-50% 51-70% 71-100%
Aspirates 5 0 3 2 0
Vaginal3 17 8 6 1 2
Sputum 15 4 3 4 4
Oral5 7 2 3 1 1
Bloodc 2 1 0 0 1
Oesophageal 1 0 1 0 0
Ear 1 0 1 0 0
Urethral 1 0 0 0 1
Abdominal 1 0 0 0 1
Urine 1 0 0 0 1
a - this includes both vaginal swabs and endocervical smears 
b - this includes both mouth and throat swabs
c - isolates previously identified as C.pseudotropicalis and C.parapsilosis
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Table 3.5b - Results of a series of streak-plate and well bioassays showing the numbers of clinical isolates of C a n d id a
which were sensitive to the action of the yeast W .m rakii (K-500) and its killer toxin.
Clinical
Isolates
No. of 
Isolates 
Tested
Sensitivity Patterns 
of Streak-Plate Bioassays
Sensitivity Patterns of Well Bioassay 
(zone of inhibition mm)
resistant weak sensitive 0-4 5-8 9-12
Aspirates 5 0 5 0 0 3 2
Vaginal 17 14 3 0 9 7 1
Sputum 15 11 1 3 6 5 4a
Oral 7 6 0 1 3 3 1
Blood 2 2 0 0 2 0 0
Oesophageal 1 1 0 0 0 1 0
Ear 1 1 0 0 1 0 0
Urethral 1 1 0 0 0 0 1
Abdominal 1 1 0 0 0 0 1
Urine 1 1 0 0 0 1 0
a - sputum isolate 26602K showed a zone of inhibition of 22.0mm
Pa
ge
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8
Table 3.6a - Results of a series of microtitre assays showing the effects of 
W.mrakii (K-LKB) killer toxin on clinical Candida. Figures are relative to the 
total protein in the assay (0.56gg).
Clinical
Isolates
No. of 
Isolates 
Tested
No. Showing % Reduction in Growth
0-20% 21-50% 51-70% 71-100%
Aspirates 5 2 3 0 0
Vaginal3 17 13 2 0 2
Sputum 15 9 2 0 4
Oralb 7 4 1 0 2
Bloodc 2 1 0 0 1
Oesophageal 1 0 1 0 0
Ear 1 0 1 0 0
Urethral 1 0 0 0 1
Abdominal 1 0 0 0 1
Urine 1 0 0 0 1
a - this includes both vaginal swabs and endocervical smears 
b - this includes both mouth and throat swabs
c - isolates previously identified as C.pseudotropicalis and C.parapsilosis
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Table 3.6b - Results of a series of streak-plate and well bioassays showing the numbers of clinical isolates of C a n d id a
which were sensitive to the action of the yeast W .m rakii (K-LKB) and its killer toxin.
Clinical
Isolates
No. of 
Isolates 
Tested
Sensitivity Patterns 
of Streak-Plate Bioassays
Sensitivity Patterns of Well Bioassay 
(zone of inhibition mm)
resistant weak sensitive 0-4 5-8 9-12
Aspirates 5 1 4 0 3 1 1
Vaginal 17 1 13 3 12 5 0
Sputum 15 5 6 4 9 3 3a
Oral 7 3 3 1 6 1 0
Blood 2 2 0 0 2 0 0
Oesophageal 1 1 0 0 1 0 0
Ear 1 1 0 0 1 0 0
Urethral 1 0 1 0 0 1 0
Abdominal 1 0 0 1 0 1 0
Urine 1 0 1 0 0 1 0
a - sputum isolate 26602K showed a zone of inhibition of 21.5mm
Pa
ge
 7
0
the toxin in microtitre assays, and produced a zone of killing of 22 mm in a well 
bioassay. In general, K-LKB showed little activity against the isolates which were 
sensitive to K-500 killer toxin in microtitre and well assays, yet a broad spectrum of 
action in agar diffusion bioassays. The elevated response of 26602K to K-LKB toxin 
was in common with that seen with the K-500 killer yeast strain.
Oral isolates (from throat and mouth swabs) displayed a weak sensitivity to the action of 
K-500 killer toxin with only two of the seven isolates tested showing greater than 50% 
reduction in growth. The results from agar bioassays confirmed the limited killer 
activity of K-500 against these isolates. Similar patterns of sensitivity to K-LKB were 
observed with the killer toxin producing greater than 70% reduction in growth in only 
two of the isolates. A greater response was seen to the killer yeast in the streak-plate 
assay than killer toxin in a well bioassay.
Two isolates from blood, previously identified as C .p s e u d o t r o p ic a lis  and 
C.parapsilosis, were tested for their sensitivity to both K-500 and K-LKB killer yeasts. 
In agar bioassays neither isolate was sensitive to their action, however, the killer toxins 
produced quite different responses in microtitre assays. C.pseudotropicalis showed little 
sensitivity to K-500 killer toxin (10% reduction in growth) but was very susceptible to 
K-LKB toxin, which completely inhibited its growth. C.parapsilosis, however, was 
moderately sensitive to K-500 (50% reduction in growth) but completely resistant to K- 
LKB.
Only single isolates from the oesophageal, ear and urethral swabs, abdominal drain sites 
and urine were available for assay. Identical patterns of sensitivity to the two killer 
toxins was observed in microtitre assays. In streak-plate bioassays the isolates from the 
abdomen, urethra and urine were more sensitive to the killer yeast K-LKB, whereas in 
the well bioassay isolates from the abdomen, oesophagus and urethra were more 
susceptible to the action of K-500 killer toxin.
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3.5 Identification of Clinical Isolates of Candida
Isolates received from Ninewells Hospital were identified only as strains belonging to 
the genus Candida, with the exception of the two isolates taken from blood samples 
which had been formerly identified as C.pseudotropicalis and C.parap silo sis. Attempts 
were subsequently made to characterise the remaining isolates and further investigate 
the relationship between toxin action and isolate sensitivity.
Microring YT is an in vitro diagnostic testing system and was used to further identify 
the clinical isolates (see section 2.2). Conventional methods for the identification of 
yeasts rely on fermentation and assimilation tests. Microring YT identifies unknown 
organisms by comparison of their susceptibility patterns to the various agents on the 
ring with a table of known susceptibility profiles. Microrings carry six tips which are 
impregnated with a range of antimicrobial agents and dyes. Each tip performs as an 
individual disc test because of an isolating hydrophobic barrier. SDA plates were 
inoculated with each isolate and the rings placed securely on the agar surface. After 
incubation at 37°C, susceptibilities were read at 24 and 48 hours, and the subsequent 
profiles were compared to those of known yeast isolates.
Results in Table 3.7 showed that 73% of the isolates used in previous studies were 
positively identified using the commercial YT Microrings. Of the 37 isolates identified, 
32 were characterised as strains of C.albicans, 2 as C.glabrata, 2 as C.parap silo  sis and 
1 as C.pseudotropicalis. The 14 remaining isolates were not conclusively identified 
using this system, in several cases the Microrings failed to distinguish between a 
number of possible species.
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Table 3.7 - Table showing the identification of Candida species isolated from various sites of the body. Isolates were identified using 
the Microring YT in vitro diagnostic testing system which identifies unknown organisms by their susceptibilities to various 
antimicrobial agents and dyes.
Site of Isolation No. of Isolates C.albicans C.glabrata C.pseudotropicalis C.parapsilosis Unknown
Aspirates 5 5 0 0 0 0
Vaginal 17 11 1 0 0 5
Sputum 15 10 1 0 1 3
Oral 7 4 0 0 0 3
Blood 2 0 0 1 1 0
Oesophageal 1 1 0 0 0 0
Ear 1 0 0 0 0 1
Urethral 1 1 0 0 0 0
Abdominal 1 0 0 0 0 1
Urine 1 0 0 0 0 1
Pa
ge
 7
3
3.6 Discussion
The killer phenomenon in yeast was first described for a number of laboratory strains of 
S.cerevisiae  (Bevan and Makower, 1963). Killer strains released a substance which 
produced a lethal response in sensitive strains (Woods and Bevan, 1968). Several 
studies have since been conducted to determine the occurrence of killer character in 
yeasts of various genera which were obtained from laboratory culture collections 
(Philliskirk and Young, 1975), natural habitats (Stumm et al., 1977), fermentation 
processes (Rosini, 1983) and clinical specimens (Kandel and Stem, 1979). Killer strains 
have consequently been reported in a number of genera (see section 1.1).
It was evident from the results in section 3.2, that vast differences exist between killer 
yeasts both in terms of the extent of killing produced and the range of organisms which 
are sensitive to the action of the toxin. It was also clear that the killer trait was not 
specific to any one particular genera or species. Killers strains were found in six of the 
eight different genera tested from yeast held in the Institute’s culture collection, only 
Candida and Schizosaccharom yces were not represented. The highest proportion of 
killers were found in the genera of P ich ia  and W illiopsis (formerly taxonomically 
defined as Hansenula), 10 of the 12 strains assayed from the above genera displayed 
killer activity against the selected sensitive strains (Table 3.1a). This was in agreement 
with several earlier reports (Philliskirk and Young, 1975; Morace et a l., 1984; 
Kazantseva and Zimina, 1989). Although active against Candida isolates, intrageneric 
killing between strains of S.cerevisiae was also observed (Table 3.1b).
Apart from differences seen in the patterns of activity between species, considerable 
variability in killer activity was observed between strains, notably within P.anom ala, 
S.cerevisiae  and W.mrakii. The results in Tables 3.1a and 3.1b show that although 
similarities were seen between the strains in their action against specific sensitive 
strains, overall different patterns of activity were observed. Kazantseva and Zimina 
(1989) reported an 85% incidence of killers within strains of P.anomala, however, also 
observed very different spectra of activity.
Selection of putative sensitive strains to be used in an assay system holds great 
significance for the identification of killer activity in yeast strains. Consequently, results
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from different studies will vary considerably depending on the selection of such strains. 
The sensitives C.glabrata, S-388 (Young and Yagui, 1978), S .cerev isia e, S-1006 
(Philliskirk and Young, 1975) and S.cerevisiae, S-381 (Pfeiffer and Radler, 1982) were 
used in the screening of the culture collection because of their known sensitivity to a 
number of killer yeast. One of the main objectives of this research was to highlight a 
yeast strain with potential anti-Candida activity, therefore, three strains of Candida  
isolated from clinical specimens were also used as seeded indicator strains in the agar 
diffusion bioassays. An increase in the number of sensitive strains used, and 
representatives of different species and genera, would have undoubtedly led to different 
spectra of action being observed and perhaps would have highlighted additional killer 
yeasts.
The conditions of the bioassay used may have led to an underestimation in the numbers 
of killer strains. The assay employed in the initial screen was a modification of the 
streak-plate assay of Stumm et al. (1977). Media containing SLM and tryptone was used 
which was designed to prevent overgrowth of the sensitive strain, a problem associated 
with some strains of Candida (O’Leary, 1987). The growth medium also contained 
methylene blue dye, which is known to differentiate between live and dead colonies of 
S .cerevisia e  (Woods and Bevan, 1968), and glycerol which has been reported to 
stabilise the killer factor (Lehmann et al., 1987). The medium was buffered to pH 4.5, a 
standard used since the observations of Bevan and Makower (1963) revealed that killing 
activity was expressed only under acidic conditions. Attempts were made to optimise 
the assay conditions, however, it is possible that they may be sub-optimal for a number 
of the killers tested and the incubation temperature of 25°C may be lower than the 
optimal growth temperature for either the sensitive or killer yeast strains. Some 
variation may exist in the amount of toxin that is produced by each killer strain when 
streaked on the surface of the agar plates. Although care was taken to streak single 
colonies of comparable size, each yeast may have showed different growth 
characteristics and in some cases produced a very small, if not undetectable amount of 
toxin. Therefore, poor growth of the streak may have led to some yeasts being given a 
lower score or in fact being scored as a non-killer.
Results in section 3.4 suggested that quite different patterns of activity were obtained if 
toxin preparations, rather than whole cell cultures, were used in assay systems. The
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effect of the killer yeasts, K-LKB and K-500, against clinical Candida was investigated 
using a streak-plate assay, and the effect of their toxins using well and microtitre 
bioassays. The streak-plate bioassays provided a preliminary qualitative determination 
of the spectra of activity of the killer yeasts and the response of each isolate was scored 
visually (Table 3.5b and 3.6b). The assay was limited by the growth of the killer yeast 
on the surface of the plates and by the growth of the clinical isolates within the agar. 
Microtitre and well bioassays of the killer toxin preparations provided a quantitative and 
more critical assessment of killer activity, allowing a greater definition of the sensitivity 
of the isolates to the action of the killer toxins. Results from the two assays compared 
well, however, the microtitre assay provided a rapid (24 hours) assessment of killer 
toxin activity and was favoured to the more traditional agar diffusion bioassays (2-3 
days) for future assessment of toxin action.
The diversity of action displayed by the killer yeasts suggests that the toxins produced 
by each may be biochemically distinct from one another. Several killer toxins of varying 
molecular sizes have, thus far, been characterised as being either proteins (S.cerevisiae  
K1 toxin, Palfree and Bussey, 1979) or glycoproteins (P .k lu y v e r i killer toxin, 
Middelbeek et a l., 1979). It may also be possible that multiple toxins are capable of 
being produced by a single yeast strain in response to being challenged by different 
sensitives (O’Leary, 1987). In either case, the assay system may not compensate for 
differences in the composition of the toxin produced.
Expression of killer character by killer yeast strains results from the synthesis and 
excretion of killer toxin. If the nature of this killer factor is determined this will give an 
effective means of classification, since strains with identical patterns of action against 
sensitive strains will probably synthesize identical toxins. Cross-reaction studies allow 
interactions between killer yeasts to be analysed. Each killer yeast assayed was in fact 
immune to its own killer factor (Table 3.3) indicating that they possessed no site of 
action for their own toxin, or the site was unavailable for toxin binding. It is 
understandable that the killer strains are immune to the action of their own toxin so that 
when one killer yeast kills another, the killed strain has no immunity to the toxin to 
which it is susceptible, thus, the killer toxin must be biochemically distinct from that 
produced by the sensitive strain (Young, 1987). The results in Table 3.3 indicated that
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nine of the 14 yeasts produced structurally distinct killer factors, and they were 
designated Ka-K^ .
The results of the cross-reaction studies were, only in part, in agreement with a similar 
study conducted by Young and Yagui (1978) which included several of the same killer 
strains (see Table 1.1). A similar grouping of S .cerev isia e  strains was observed, 
however, in the earlier study these strains had a much broader pattern of activity, albeit 
against other strains of S.cerevisiae. In the present study Ka killers were found to be 
active only against S.cerevisiae (K-28), whereas, type killers appeared to produce 
no, or undetectable amounts of killer factor. However, their activity against two further 
strains of S .cerevisia e  (K-232 and K-761) was not determined. In both studies no 
intrageneric killing was seen between strains of Pichia , W illiopsis and Kluyveromyces. 
However, a number of interactions were observed between the closely related strains of 
W illiopsis and Pichia, which may indicate some similarity in the killer factor produced 
or in the receptors for toxin action on their cell surface.
The yeasts were also assigned the resistant phenotypes R a-Rj. Several strains of the 
same killing group showed different resistance patterns and several strains belonging to 
different killing groups showed the same resistance patterns. The property of resistance 
is based on both immunity, which in the case of S.cerevisiae strains is plasmid-encoded 
(Somers and Bevan, 1969; Sweeney et al., 1976) and for non-Saccharom yces strains 
encoded on nuclear genes (Young and Yagui, 1978), and also inherent differences in the 
composition of the cell wall (Young, 1987). The findings of the overall resistance 
observed in W.mrakii (K-500) to every other killer strain is in agreement with Young 
and Yagui (1978). On the other hand, K.drosophilarum  (K-575) was the most sensitive 
to the action of the other killer factors, which contradicted their findings.
Nine killer phenotypes and 10 resistance phenotypes were recognised. Classification 
using both descriptions (e.g. W.mrakii K ^ R j )  provides 12 unique categories for each 
killer tested (discounting K - 2 3 2  and K - 7 6 1  for which resistant phenotypes were not 
determined). Further examination of these and other killer yeasts, in all likelihood, 
would provide further categories and additional members to those described.
The activity of W.mrakii (K-500) killer yeast and its killer toxin was assessed against a 
small number of isolates from various sites of the body and the results suggested a
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niche-specific response to the killer factor produced. The toxin was more active against 
lung and tracheal aspirates (45-70% reduction in growth) than nasal, blood or vaginal 
isolates (10-25% reduction in growth). This implied an inherent genetic variation and 
adaptation amongst opportunistic pathogenic flora. The little or no activity of W.mrakii 
killer toxin observed against the vaginal isolates may be due to their adaptation to the 
acidic conditions prevalent in the vagina. The pH in the vaginal lumen is controlled 
primarily by lactic acid produced from cellular glycogen or carbohydrates by the action 
of the normal bacterial micro flora. The pH varies between 4.0 and 5.0 during the 
menstrual cycle and this acidity plays a clinically important role in preventing the 
proliferation of pathogenic strains (Okada, 1991). Under these conditions, strains of 
Candida may have undergone morphological changes and acquired a resistance, or loss 
of sensitivity, to the action of the killer toxin. Conditions encountered within the lung 
and tracheal cavities of the body, however, are less extreme and it is unlikely that 
aberrant morphological changes have resulted to enhance the survival of the Candida  
strains.
The expanded screen showed that both killer yeast strains were active, to varying 
degrees, against a range of clinical isolates of Candida and the toxin from K-500 was 
predominantly more active than that produced by the brewing isolate K-LKB. Under the 
conditions of the assay it would appear, therefore, that the two strains produce toxins 
which are biochemically distinct and exert their action against different sensitive strains. 
This confirmed the findings of earlier work (see section 3.3).
Similar patterns of sensitivity of the isolates to toxin action were apparent between the 
initial, and expanded, screens. However, with an increase in the number of isolates 
tested, the relationship between their sensitivity and their physiological niche became 
less pronounced. It was possible that the sensitivity to toxin action is a species-specific 
phenomenon. The isolates obtained from Ninewells Hospital for this screen were 
classified only as belonging to the genus Candida, with the exception of the two isolates 
from blood which were positively identified as C.pseudotropicalis and C.parapsilosis. 
Attempts were made to identify the clinical isolates to enhance investigations into the 
relationship between toxin action and isolate sensitivity. 74% of the clinical samples 
were identified using a commercial diagnostic kit and of these 86% were found to be 
strains of C.albicans.
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Table 3.8 - Table showing the combined percentages of the predominant species of Candida found at various sites of the 
body (data collated from numerous surveys conducted in Europe and the U.S.A between 1962 and 1987, (Odds,1988)).
Candida
Strains
Oral
Cavity G.I.Ta Anorectal
Vaginal
(unselected
groups)*3
Vaginal 
(with local 
diseases)c
Blood Urine
C.albicans 69.6 56.5 50.9 69.7 84.2 50.4 54.4
C.glabrata 6.6 16.1 9.1 11.7 5.5 9.7 20.2
C.guilliermondii 0.4 0.5 0.7 0.5 0.5 0.9 1.9
C.kefyr 1.0 0.7 0.1 0.4 0.4 0.2 0.2
C.krusei 1.7 2.6 2.9 2.6 1.7 1.1 2.1
C.parapsilosis 1.9 6.1 5.4 1.9 1.2 12.1 4.1
C.tropicalis 6.9 9.7 2.3 4.7 5.3 18.5 8.9
Other Candida 7.0 1.4 7.1 2.1 0.5 2.0 2.7
Unidentified 4.5 6.4 22.0 6.3 0.7 4.9 4.5
a - yeasts isolated from the gastrointestinal tract.
b - Distribution of species among yeasts isolated from the vagina of subjects without vaginitis, or presence or absence was 
not recorded.
c - Distribution of species among yeasts isolated from the vagina of subjects exclusively with signs and symptoms of 
vaginitis.
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Table 3.9 - Table showing the frequencies of yeasts and/or C.albicans isolated 
from different sites in various types of subject (table collated from data 
presented by Odds, 1988).
Site of 
Isolation
Status of 
Subject
Yeasts Recovered 
(% range)
C.albicans Recovered 
(% range)
Oral Healthy 2.0-71.3 1.9-62.3
Cavity Patient 12.7 - 76.2 6.0 - 69.6
Anorectal Healthy
Patient
8.0 - 60.0 
5.7-83.1
8.0 - 20.0 
1.0-53.1
Vaginal Healthy
Patient
4.3 - 27.3 
7.8 - 76.2
2.2 - 68.0 
4.5 - 60.0
Skin Healthy
Patient
0.0 - 44.0 
4.7 - 63.6
0.0 -17.4 
0.4 - 25.0
Outer Eye Healthy 3.9 - 20.6 0.0 - 2.3
Surface Patient 3.8 - 16.9 0.0 - 5.4
Urine Patient 1.4-60.0 0.0-21.1
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The proliferation of various species of Candida in the body is dependent not only on the 
site of isolation (Table 3.8) but also on the status of the individual i.e. whether they are 
healthy or predisposed to increased yeast invasion (Table 3.9). As Table 3.8 shows 
C.albicans is by far the most proliferate yeast found. In general it accounts for 60-80% 
of oral isolates with C.glabrata and C.tropicalis being found in only low frequency. In 
vaginal isolates there is a higher occurrence of C .a lb ica n s  in patients with known 
vaginal pathologies (84%) than surveys of unselected groups (69%). This increase over 
the normal vestigial flora is further highlighted in Table 3.9. The percentage of 
C.albicans recovered from the vagina of healthy individuals was 11% compared with 
84% in those showing signs of local disease. In blood cultures isolation of C.albicans is 
rather lower at 50%. This is close to the prevalence found in the stomach, intestine and 
faeces which is compatible with the suggestion that the gut is the portal entry for 
C.albicans into the bloodstream (Young, 1987). C.tropicalis and C.parapsilosis have a 
heightened incidence in blood cultures which implies a selection process in their favour 
over other Candida spp. in visceral sites. Yeasts can enter the urine from the blood 
stream or the urethra and the distribution pattern of Candida closely resembles that seen 
in the gut.
A differential sensitivity to the action of K-500 and K-LKB killer toxins was found 
amongst isolates of the same species type (section 3.4). Some strains were found to be 
resistant to toxin action whereas growth of others was completely inhibited. Of the two 
strains identified as C.glabrata one was resistant and the other showed 95% reduction in 
growth. Grouping of the isolates with respect to their response to the killer toxin of 
W.mrakii (K-500) could be used to biotype the Candida strains, as previously reported 
by Polonelli et al. (1983) and other opportunistic yeast isolates including C.glabrata, 
C .parapsilosis and Cryptococcus neoform ans (Morace et a l., 1984; Caprilli et al., 
1985).
The patterns of sensitivity observed were likely to be as a result of a number of factors, 
including;
(a) the site of isolation, which will undoubtedly influence the species and strain type 
which is found.
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(b) micro-environmental conditions within the niche, which may produce 
morphological changes in the isolates, thus, affecting their sensitivity to toxin action.
(c) the status of the individual which may also influence isolate type and cell wall 
characteristics and, therefore, their subsequent mode of action and inaction.
A combination of these factors will affect the interaction between the toxin molecules 
and their cell surface receptors. The type and number of receptors available may differ 
between isolates and their accessibility to toxin molecules may be influenced by any 
aberrations in cell envelope morphology.
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3.7 Conclusions
Yeast strains of the ascomycetous genera of Pichia  and W illiopsis showed the broadest 
range of killer activity against a limited number of sensitive strains of S.cerevisiae and 
Candida spp. Wmrakii (K-500) consistently displayed the strongest interstrain lethality 
and extensive anti-Candida  activity. As a consequence this killer yeast strain was 
selected to further investigate toxin production and toxin action against sensitive yeasts 
and attempts were made to determine the biochemical nature of the toxin produced.
No direct correlation was observed between isolate collection site and toxin sensitivity, 
however, the results highlighted the potential use of killer yeast and toxin preparations 
in the epidemiological typing of pathogenic yeast strains.
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CHAPTER FOUR
Production of Williopsis mrakii Killer Toxin
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4.1 Introduction
Killer toxin protein is known to be secreted during the exponential phase of growth in 
the K1 killer yeast S.cerevisiae  (Young and Philliskirk, 1977; Palfree and Bussey, 
1979). Growth-associated secretion of proteins from microbes will, therefore, be 
affected by biomass concentration (Grafe, 1982). Any factors which directly influence 
cell growth such as culture media composition, available carbon and nitrogen sources 
and oxygen and pH requirements, will subsequently affect the synthesis of microbial 
metabolites.
It was the aim of this area of research to investigate the growth of the killer yeast 
W.mrakii (K-500) in different media, and the effect of static, agitated and oxygenated 
propagation systems on toxin production. It was hoped, therefore, to maximise toxin 
production in large-scale fermentations. Attempts were made to partially purify the 
killer factor produced by ultrafiltration and dialysis.
4.2 The Effect of Media Composition on Toxin Production by the Killer Yeast 
W.mrakii (K-500)
A comparison was made of the effect of complex (YEPD), synthetic (SLM) and 
minimal (YNBGS) media on the growth of the killer yeast W.mrakii (K-500) and on 
toxin production (see section 2.7.1). Each media type was inoculated with 5 ml (10% 
inoculum) of a 24 hour starter culture. Cells were grown statically at 25°C and samples 
were taken over a 48 hour period. Cell numbers were estimated (section 2.3) and the 
mean generation time, the time for one cell to divide into two during active growth, was 
calculated (section 2.7.1). The extent of toxin production was assessed by measurement 
of the killing activity of the culture supernatant against the indicator strain C.glabrata  
(S-388), using an agar diffusion well bioassay (section 2.6.2).
The results are presented in Figures 4.1 (YEPD), 4.2 (SLM) and 4.3 (YNBGS). All of 
the media investigated produced comparable growth and toxin production from the 
killer yeast W.mrakii. In all three, typical growth of the yeast was observed with cells 
entering a stationary phase after a period of 24 hours. However, growth of the killer 
yeast was best supported by the minimal medium YNBGS (mean generation time of 2.6
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Figure 4.1 - Cell growth and toxin production by the killer yeast W .m rak ii (K-500) in a
complex medium, YEPD. Toxin production was monitored using an agar diffusion well
bioassay.
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Figure 4.2 - Cell growth and toxin production by the killer yeast W .m rakii (K-500) in a
synthetic medium, SLM. Toxin production was monitored using an agar diffusion well
bioassay.
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Figure 4.3 - Cell growth and toxin production by the killer yeast W .m rak ii (K-500) in a
minimal medium, YNBGS. Toxin production was monitored using an agar diffusion
well bioassay.
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hours), rather than by the richer media, SLM and YEPD (mean generation times of 3.1 
hours and 4.9 hours respectively). Toxin activity, as measured by zones of inhibition in 
the agar diffusion bioassay, reflected cell growth. In each case, the killing activity of the 
toxin produced increased during the exponential phase of growth and plateaued when 
stationary phase was reached. The richer medium YEPD, produced killer factor with the 
greatest activity against the sensitive strain tested, whereas toxin produced in SLM and 
YNBGS was less active.
4.3 Toxin Production in W.mrakii (K-500) Under Static Culture Conditions
(a) Growth
Continued investigations into the production of killer toxin by the yeast W.mrakii (K- 
500) used the minimal medium, YNBGS, as described in section 2.7.1. The yeast was 
grown in 50 ml of the above media at 25°C, and samples were removed aseptically to 
determine cell counts (section 2.3), protein content of the extracellular medium (section
2.4) and toxin activity, against the indicator strain C.glabrata (S-388), using a microtitre 
plate assay (section 2.6.3).
The culture broth was sampled at intervals over a period of 186 hours and the results are 
shown in Figures 4.4 and 4.5. From a loop-inoculum, it was observed that cells of K- 
500 progressed into exponential growth between 24 and 72 hours, and into stationary 
growth following an incubation of 90 hours. The mean generation time was calculated 
as 13.4 hours. Toxin production, in part, reflected cell growth, however, it appeared that 
the levels of the killer factor continued to increase as cells entered stationary phase. The 
increase of protein in the extracellular medium mirrored the cell growth of the killer 
yeast.
(b) Processing of Fermentation Media
Initial investigations had suggested that the killer toxin produced by W.mrakii (K-500) 
was a protein with a molecular mass greater than 16 kDa. Therefore, a scheme for 
downstream processing of the killer factor was designed to incorporate an ultrafiltration 
step which would concentrate material greater than 10 kDa in size.
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Figure 4.4 - Cell growth and toxin production by the killer yeast W .m rak ii (K-500)
under static conditions. Toxin production was monitored against the sensitive strain
C .g la b ra ta  (S-388), using a microtitre plate assay.
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Figure 4.5 - Protein content of the extracellular media during growth of the killer 
yeast W.mrakii (K-500), under static conditions.
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The downstream processing of cultures of W.mrakii is outlined in section 2.8.1. A 240 
hour static culture (50 ml) of the killer yeast was centrifuged and filtered through a 0.45 
pm membrane (SI), to remove cellular material. The cell-free supernatant was 
concentrated to 5 ml (S2) by Amicon stirred ultrafiltration using a PM 10 membrane. 
The retentate was freeze-dried and a sample of the permeate (S3) retained for analysis. 
The lyophilisate was reconstituted at a concentration of 60 mg/ml dry weight (S4) and 
all samples were assayed against the indicator strain C.glabrata (S-388), using an agar 
diffusion bioassay. Results are shown in Table 4.1.
Extracellular medium from a culture of W.mrakii displayed killing activity against the 
sensitive strain C.glabrata, producing a zone of inhibition of 16.5 mm. Concentration of 
the cell-free supernatant by ultrafiltration yielded two fractions, the retentate (>10 kDa) 
and the permeate (<10 kDa). The retentate showed increased lethality (a zone of 19.0 
mm) against S-388, whereas the permeate showed negligible activity. The retentate was 
freeze-dried and also tested for killing activity. Further concentration of the toxin 
activity at this stage was displayed by an increase in inhibition of the sensitive strain (a 
zone of 19.5 mm).
4.4 Effect of Oxygenation and Agitation on Toxin Production in W.mrakii (K-500)
It was hoped to gain an insight into the oxygen demand of the killer yeast W.mrakii (K- 
500) for subsequent growth and toxin production studies on a larger scale. Three 
fermenters were set up as described in section 2.7.2.1. Fermenter A was essentially 
anaerobic because of a continuous flow-through of nitrogen prior to inoculation. 
Fermenter B was continuously aerated at a rate of 200 cm /^min and fermenter C was 
gently agitated. After inoculation, fermenter A was maintained under static conditions 
whilst fermenters B and C were continuously agitated. Each system was kept at a 
temperature of 25°C, and samples were removed to determine cell numbers (section
2.3), protein content (section 2.4) and the toxin activity present in culture broths, using a 
microtitre assay (section 2.6.3).
The resultant cell growth and toxin activity observed in each fermenter is shown in 
Figures 4.6 to 4.8. The amount of dissolved oxygen available greatly influenced the
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Table 4.1 - Toxin activity measured during the downstream processing of small, 
static cultures of W.mrakii (K-500). Samples SI to S4 were assayed for activity 
against C.glabrata (S-388), using an agar diffusion bioassay.
Sample Zones of Inhibition (mm)
Cell-free Supernatant 
(SI)
16.5
Ultrafiltration Retentate (>10 kDa) 
(S2)
19.0
Ultrafiltration Permeate (<10 kDa) 
(S3)
slight staining 
around well
Retentate Lyophilisate (60 mg/ml) 
(S4)
19.5
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Figure 4.6 - The effect of ‘0%’ dissolved oxygen (fermenter A) on the growth and 
toxin production in the killer yeast W .m rakii (K-500). Toxin activity in a fixed 
volume of cell-free supernatant (100 pi) was measured against C.glabrata (S-388), 
using a microtitre assay.
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Figure 4.7 - The effect of direct aeration (fermenter B) on the growth and toxin 
production in the killer yeast W.mrakii (K-500). Toxin activity in a fixed volume of 
cell-free supernatant (100 |il) was measured against C.glabrata  (S-388), using a 
microtitre assay.
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Figure 4.8 - The effect o f agitation (fermenter C) on the growth and toxin 
production in the killer yeast W.mrakii (K-500). Toxin activity in a fixed volume of 
cell-free supernatant (100 pi) was measured against C.glabrata (S-388), using a 
microtitre assay.
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growth and division of the cells. In C (Figure 4.8), under gentle agitation, the mean 
generation time of the cells was 4.3 hours, in A (anaerobic) it was 10.4 hours (Figure 
4.6) and in B (aerated) 4.0 hours (Figure 4.7). The maximum cell growth achieved was 
reduced in the anaerobic and aerated cultures in comparison to fermenter C.
Cell growth can be closely correlated to production of an active toxin. In each case, 
toxin activity increased markedly during the exponential phase of growth o f the cells 
and the maximum toxin activity for the volume assayed (100 p,l) was reached at the 
same time as cells progressed into stationary phase.
As a more critical assay of toxin activity, reduced volumes (100 to 10 pi) o f cell-free 
supernatants from the 4, 24, 64 and 160 hour samples, were assessed for their killing 
activity against the indicator strain C.glabrata (S-388). From these‘sensitivity profiles’ 
(similar to those described in section 6.2) an estimate of the number of units o f toxin 
activity present in each sample was possible (data not shown). One unit of activity was 
defined as the volume of cell-free supernatant which produced approximately 100% 
reduction in the growth of the sensitive strain. By calculation the number of units 
present in each culture (total volume 900 ml) could be made.
In fermenter C (Figure 4.11) the levels of toxin in the culture appeared to mirror 
production of protein by the killer yeast under these conditions. Beyond 72 hours, when 
cells had reached mid to late stationary phase, no further increase in toxin activity was 
observed. At this stage there was only a small increase in the concentration of protein 
detected (4.0 to 5.0 pg/ml). In fermenter A (Figure 4.9), the appearance of high levels of 
protein was coincident with only a very small increase in toxin activity. No further toxin 
appeared to be produced by the cells after mid-stationary phase was reached yet the 
protein in the culture increased from 6.8 to 10.4 pg/ml. In fermenter B (Figure 4.10), 
toxin activity was only 50% of that seen in fermenters A and C. In the latter, this 
activity was maintained throughout the fermentation but in fermenter B it fell to 
minimum levels after 72 hours. In the aerated culture the the concentration of protein 
present in the extracellular medium rose to a maximum level of 8.2 pg/ml at 64 hours 
and fell steadily to 6.2 pg/ml by the end of fermentation.
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Figure 4.9 - The effect of ‘0%’ dissolved oxygen on protein levels during growth of 
the killer yeast W .m rakii (K-500) and its relationship to toxin production in 
fermenter A. Toxin activity in a fixed volume of cell-free supernatant (100 |il) was 
measured against C.glabrata (S-388), using a microtitre assay.
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Figure 4.10 - The effect of direct aeration on protein levels during growth of the 
killer yeast W.mrakii (K-500) and its relationship to toxin production in fermenter B. 
Toxin activity in a fixed volume of cell-free supernatant (100 pi) was measured 
against C.glabrata (S-388), using a microtitre assay.
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Figure 4.11 - The effect of agitation on protein levels during growth of the killer 
yeast W.mrakii (K-500) and its relationship to toxin production in fermenter C. 
Toxin activity in a fixed volume of cell-free supernatant (100 pi) was measured 
against C.glabrata (S-388), using a microtitre assay.
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4.5 Small-Scale Fermentations of the Killer Yeast W.mrakii (K-500)
Fermentation with the killer yeast was carried out in the minimal medium YNBGS 
(section 2.7.1), over a three day period. Overnight seed cultures (100 ml) were used to 
inoculate two one litre fermenters containing 800 ml of fresh media (Figure 4.12). 
Cultures were incubated at 25°C with gentle agitation and then processed as outlined 
above.
At completion, cell growth in both fermenters was comparable, 8.87x10  ^and 1.03x10  ^
cells/ml respectively and, toxin activity and protein levels in the extracellular media 
were very similar (Sl^ and S2g in Table 4.2). The two cultures were combined and 
cellular material was removed by continuous centrifugation and microfiltration. The 
working volume at this stage was reduced from 1.6 to 1.2 litres. The protein content of 
the cell-free supernatant (S2), was approximately half (0.70 fig/ml) of that observed in 
the initial cultures (an average of 1.55 pg/ml) and showed reduced killing activity (25% 
less) in the microtitre assay. The supernatant was then concentrated by ultrafiltration. 
Samples of both the permeate, material less than 10 kDa (S3), and the retentate, material 
greater than 10 kDa (S4), were assayed for protein and toxin activity. Negligible 
amounts of protein were detected in the permeate and it showed no lethality against the 
indicator strain in a microtitre assay. The retentate contained 1.60 (ig/ml of protein, only 
22% of that expected from a 6-fold concentration of the cell-free supernatant (S2). In the 
concentrate, one unit of toxin activity was equivalent to 70 jxl of the sample which 
indicated an 80% loss of killing activity at this stage. The retentate was further 
concentrated (20-fold) by freeze-drying and reconstituting of the lyophilisate in a 
reduced volume of distilled water. This process resulted in a slight loss of protein (5%) 
and further reduction in the lethality of the toxin preparation (42%).
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Figure 4.12 - Flow-diagram showing the fermentation of W.mrakii (K-500) killer 
yeast and subsequent downstream processing of the killer factor. Samples S l^  to S5 
were removed for assessment of toxin activity and protein content (see Table 4.2).
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Table 4.2 - Table showing the maintenance of W.mrakii (K-500) killer toxin activity during downstream processing. At each stage 
of the fermentation and processing of the extracellular medium (see Figure 4.12), samples were assayed for protein content and 
toxin activity against C.glabrata (S-388), using amicrotitre assay.
Sample Volume of Toxin 
Producing 100% 
Growth Reduction 
(= 1 Unit of Activity)
Volume
of
Sample
(ml)
Total
Activity
(units)
Loss of 
Activity 
(%)a
Protein
Content
(ug/ml)
Total
Protein
(mg)
Loss of 
Protein 
(%)a
Specific
Activity
(units/mg)
S1A 60 800 13333 0 1.30 1.04 0 12820
S1B 60 800 13333 0 1.80 1.44 0 9259
S2 80 1200 15000 25 0.70 0.84 66 17857
S3 0 1000 0 100 0 0 100 0
S4 70 200 2857 80 1.60 0.32 76 8928
S5 6 10 1666 42 30.20 0.302 5 5517
a - the percentage losses in toxin activity and protein content at each stage were calculated with respect to the previous 
sample
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4.6 Large-Scale Fermentations of the Killer Yeast W.mrakii (K-500)
In order to increase the amount of toxin preparation available for future studies it was 
proposed to perform two large-scale (40 litre) fermentations of the killer yeast. The 
fermentations were carried out under the guidance of the Fermentation Section of the 
Microbiology Division of Glaxo Group Research.
Fermentation 1
Based on earlier studies, the parameters for the initial fermentation were decided as 
outlined in Figure 4.13. W.mrakii killer yeast was grown at 25°C in the minimal 
medium YNBGS and the culture was gently agitated during fermentation. In light of the 
studies reported in section 4.4, there was no direct aeration of the culture and nitrogen 
was passed over the base seal to prevent contamination. Several samples were taken 
over the first 24 hour period to monitor cell growth by absorbance measurements at 600 
n m .
Under the above conditions there was very poor growth of the yeast over 24 hours, an 
absorbance of 0.1 was measured compared to 0.5 in a static culture initiated at the same 
time, therefore, the fermentation was prolonged for a further 24 hours. Cell growth 
increased with the change in culture conditions, i.e. aeration of 1.5 1/min, but the cell 
density of 3.67x10  ^cells/ml was only approximately 40% of that expected. The toxin- 
containing extracellular medium was harvested and processed, as described in section 
2 .8.2, to yield 59.87 g of freeze-dried material. Samples were taken for assessment of 
killing activity against a sensitive strain of C.albicans (C316), using a microtitre assay 
(section 2.6.3). The toxin activity was compared to that observed in a static fermentation 
of the killer yeast which was run simultaneously (Table 4.3).
Unconcentrated samples (1-3), obtained during large-scale toxin production displayed 
no killing activity against the sensitive strain C316 (data not shown). The maximum 
toxin activity achieved was an 85% reduction in growth of C316. This was detected in 
the 24 hour static culture of the killer yeast when concentrated 10-fold by freeze-drying 
(sample 4). No increase in killing activity against this strain was observed in the 48 hour 
sample (sample 6). However, a marked increase (28 to 83% growth reduction) was
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Table 4.3 - Toxin activity during the first large-scale fermentation and processing of 
the killer yeast W.mrakii (K-500). Activity was assessed against a sensitive strain of 
C.albicans (C316), using a microtitre assay. Results were compared to a static 
fermentation of the same yeast.
Samples assayed:
(1) cell-free supernatant from 48 hour large-scale fermentation*
(2) microfiltrate from large-scale fermentation1
(3) permeate (<10 kDa) from large-scale fermentation*
(4) 10-fold concentrate from 24 hour static fermentation
(5) 10-fold concentrate from 24 hour large-scale fermentation
(6) 10-fold concentrate from 48 hour static fermentation
(7) 10-fold concentrate from 48 hour large-scale fermentation
(8) lyophilised retentate (>10 kDa), 500 mg/ml dry weight, from 48 hour large-scale 
fermentation
Volume of Sample 
Assayed (nl)
Percentage Reduction in Growth of C316 
Produced by Each Sample
4 5 6 7 8
100 84.6 27.9 84.3 78.8 79.2
75 74.3 0 84.0 79.6 80.3
50 0 0 85.1 81.8 82.1
25 0 0 67.8 59.5 19.7
10 0 0 0 0 0
1 - unconcentrated samples 1, 2 and 3 did not show significant killing activity 
against the sensitive strain C316.
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Table 4.4 - Protein and carbohydrate analysis of the lyophilisate from the initial 
large-scale fermentation of W.mrakii (K-500). ^
Analysis Concentration in 
lyophilisate (mg/ml)
Total Yield 
(g)
Percentage of 
Dry Weight (%)
Protein 0.032 0.00383 0.06
Carbohydrate 383 45.86 76.6
Lyophilisate was reconstituted at a concentration of 500 mg/ml dry weight prior to 
analysis
Table 4.5 - Protein and carbohydrate analysis of samples before and after dialysis. 
Lyophilisate was reconstituted at a concentration of 500 mg/ml and dialysed against 
distilled water. Dialysates were recovered for protein and carbohydrate analysis.
Sample Protein Content 
(ug/ml)
Carbohydrate Content 
(mg/ml)
Lyophilisate 
(before dialysis)
47.2 383.0
Dialysate 13.6 3.2
Dialysis Tubing 
Washings
negligible 2.5
Dialysing Solution negligible 260.0
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observed between the 24 and 48 hour samples removed from the large fermentation 
(samples 5 and 7). Freeze-dried material (sample 8) was not significantly more active, 
even at lower assay volumes, despite the large concentration step involved.
Sample 8 was also assayed for protein (section 2.4) and carbohydrate content (section
2.5). Lyophilisate reconstituted at a concentration of 500 mg/ml contained 32 pg/ml 
protein and 383 mg/ml of carbohydrate. Table 4.4 shows the total yield of protein and 
carbohydrate in the lyophilisate.
In view of the large amounts of media carbohydrate remaining in the lyophilisate (76% 
of the final dry weight), attempts were made to dialyse the preparation to remove 
unwanted material. The lyophilisate was reconstituted at a concentration of 500 mg/ml 
and dialysed against distilled water at 4°C for 19 hours (section 2.8.2.1). At completion 
the tubing was washed with distilled water and the dialysates recovered. Protein (section
2.4) and carbohydrate (section 2.5) assays were conducted on the preparation, before 
and after dialysis, on the tube washings and the dialysing solution.
The results in Table 4.5 demonstrated that dialysis resulted in the loss of 99% of the 
carbohydrate and 70% of the protein present in the preparation. Levels of protein in the 
dialysing solution were presumably too low for detection by the assay, however, the 
majority of the carbohydrate removed was detected.
The toxin activity present in each sample was measured using a microtitre assay. No 
lethality against the indicator strain C.albicans (C316) was detected in the dialysate, 
washings or dialysing solution (data not shown).
Fermentation 2
Low toxin activities in the initial fermentation were attributed to poor cell growth of the 
killer yeast. In an attempt to overcome this problem aeration of the culture was 
increased to 3.5 1/min . All other fermentation parameters remained unchanged and the 
procedure outlined in Figure 4.14 was followed. Samples were taken over 48 hours for 
cell counts (section 2.3) and protein analysis (section 2.4).
Good cell growth (1.25x10** cells/ml), when compared to earlier small-scale studies, 
was produced under the above conditions and the profile in Figure 4.15 demonstrated
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Figure 4.15 - Cell growth of the killer yeast W.mrakii (K-500) and protein levels in 
1 . 0  ml of the extracellular medium during the second large-scale fermentation.
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that the killer yeast W.mrakii showed typical growth characteristics. Cells grew 
exponentially over a 28 hour period before entering a stationary phase. The mean 
generation time was calculated as 4.07 hours. Low residual levels of protein (>1.0 
fxg/ml) were present in the fermentation media at inoculation and did not increase 
appreciably over the first 22 hours. Within 4 hours the levels of protein present in the 
extracellular medium increased considerably to a concentration of 4.5 jag/ml. As cells 
entered stationary phase there was a further detectable increase to 5.8 pg/ml before the 
levels fell to 5.5 pg/ml.
Protein levels and toxin activity against C.glabrata (S-388) were also monitored during 
downstream processing of the culture. The results in Table 4.6 show that 44% of the 
protein present at the end of fermentation was lost during filtration through a 0.45 pm 
cellulose acetate membrane. Concurrent with this result, there was a 20% loss in toxin 
activity to 8.0x10  ^units. Of the 168 mg of protein present in the microfiltrate, 102 mg 
(60%) was detected in the permeate and 45 mg (27%) in the retentate following 
ultrafiltration. 65% of the toxin activity was detected in the permeate sample (5.2x10  ^
units) and only approximately 1% in the retentate fraction (1000 units).
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Table 4.6 - Protein content during each stage of the downstream processing of 
W.mrakii (K-500) killer toxin produced in the second large-scale fermentation.
Sample Protein
Gig/ml)
Sample Volume 
(ml)
Total Protein 
(mg)
Total Units of 
Activity a
Cell-Free
Supernatant
7.4 40.0 296 1.0 x 105
Microfiltrate 4.2 40.0 168 8.0 x 104
Ultrafiltrate
(Permeate)
2.8 36.5 102 5.2 x 104
Ultrafiltrate
(Retentate)
12.8 3.5 45 1.0 x 103
a - total units of activity were calculated on the basis that one unit of activity 
was equivalent to the volume of toxin required to produce 100% reduction in 
growth of the sensitive strain C.glabrata (S-388). Each solution was 
concentrated 10-fold prior to assay.
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4.7 Discussion
The experiments of Bevan and Makower (1963) showed that the killer toxin was a 
diffusable factor, secreted into the medium. Production of killer toxins is strongly 
affected by culture conditions (Woods and Bevan, 1968; Middelbeek et al., 1979), 
therefore, optimal conditions for each killer yeast studied have to be found empirically.
The production of toxin by the killer yeast W.mrakii (K-500) in complex (YEPD), 
synthetic (SLM) and minimal (YNBGS) media was compared. In each medium, 
accumulation of the killer factor followed cell growth (Figures 4.1 to 4.3). The 
measured killing activity increased with cell titre during the exponential phase of growth 
and levelled off as stationary phase was reached. Detectable levels of toxin activity were 
apparent at time zero because a 24 hour starter culture was used to initiate growth. It is 
likely, therefore, that a proportion of toxin was transfered within the inoculum. During 
the first six hours of growth there was no significant increase in the killing activity, 
however, as cells progressed through exponential phase and into early stationary phase 
toxin activity increased, resulting in larger zones of inhibition. It was perhaps surprising 
that the richest medium, YEPD, did not support the best cell growth (mean generation 
time of 4.9 hours) yet appeared to induce the greatest killing activity against the 
indicator strain. Cultures supplemented with yeast extract and peptone have previously 
been reported to enhance toxin production (Woods and Bevan, 1968; Palfree and 
Bussey, 1979) which suggested that either, or both, of these components stimulated 
toxin production or stabilised the killer factor produced. SLM supported growth of the 
killer yeast (mean generation time of 3.1 hours), however, reduced the activity of the 
killer factor secreted into the extracellular medium. W.mrakii has simple nutritional 
requirements (Barnett et al., 1983), so good cell growth (mean generation time of 2.6 
hours) in the chemically-defined YNBGS was not unexpected. The presence of 
magnesium sulphate in the medium was thought to potentiate toxin production 
(O’Leary, 1987), although this effect may be secondary to improved cell growth and 
biomass accumulation. Its addition to growth media for the production of killer toxins 
has been reported by other groups (Palfree and Bussey, 1979; Ohta et al., 1984). An 
improvement in ammonium assimilation can stimulate protein synthesis by the 
promotion of glutamic acid availibility as a basic intermediate of amino acid precursors
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(Grafe, 1982). Therefore, ammonium sulphate was also added to the medium as an 
additional nitrogen source. Sugisaki et al. (1984) had previously reported that its 
addition induced a five-fold increase in toxin yield and Ouchi et al. (1978) that it 
stabilised the toxin produced.
Use of a minimal medium for toxin production was preferred because potentially it 
would yield a very high initial specific activity and would allow an integration of the 
fermentation with downstream processing. A reduction in the amount of extraneous 
polypeptides and proteins present in the extracellular medium would be beneficial to 
any subsequent purification steps and throughput on ultrafiltration membranes. The 
minimal medium YNBGS, was selected as the growth medium for further studies of the 
killer yeast W.mrakii despite the reduced toxin activity detected in comparison to cell- 
free extracts from cultures in YEPD.
The results in Figure 4.4 further emphasised that the killer factor produced by W.mrakii 
was a growth related response. From a loop-inoculum cell growth was initially very 
slow and progression of cells into the exponential phase of growth did not occur for 
approximately 24 hours. The mean generation time of 13.4 hours also reflected the slow 
growth rate observed. Toxin was produced as cells entered mid to late exponential 
phase, indicated by the increased growth reduction in a sensitive strain. The data in 
Figure 4.4 suggested that toxin levels continued to increase as the cells entered 
stationary phase, however, no firm conclusions could be made because of the low 
number of samples taken in the latter stages of the fermentation. Levels of protein in the 
extracellular media reflected both cell growth and toxin production (Figure 4.5) but only 
very small amounts (1.2 pg/ml) were detectable after 186 hours. It would appear that 
under these conditions active killer toxin was produced, but because of the poor starting 
inoculum residual levels of the toxin remained very low. Initiation of future 
fermentations were made with starter cultures so that biomass accumulation was 
improved for greater toxin production.
Initial processing of small-scale static cultures of W.mrakii involved several stages. 
Centrifugation was an important first step to remove the bulk of the cellular material 
produced. Under static conditions the killer yeast grew with a surface pellicle and 
centrifugation alone failed to remove all viable cells, therefore, a fine filtration step
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through 0.45 pm cellulose acetate membranes was necessary. Some loss of activity 
occurred but at this stage the extent of the loss was not fully appreciated (see section
4.5). The cell-free supernatant was then concentrated five-fold using Amicon 
ultrafiltration. Preliminary findings (see section 5.5b) suggested that the toxin of 
W.mrakii (K-500) had a molecular weight of approximately 16 kDa and that of another 
strain of W.mrakii (LKB 169), a molecular weight of 11 kDa (Yamamoto et al., 1986a). 
Therefore, a PM 10 membrane was used for ultrafiltration, which had a molecular weight 
cut-off of 10 kDa. The retentate, material larger than 10 kDa, was further concentrated 
by freeze-drying and reconstitution of the lyophilisate in a reduced volume of distilled 
water. Toxin activity was assessed at each stage against the indicator strain C.glabrata, 
using an agar diffusion bioassay (Table 4.2). The results demonstrated successive 
increases in killing activity in the cell-free supernatant, retentate and in the lyophilisate. 
Essentially no activity was detected in the permeate, material smaller than 10 kDa, 
although there were signs of stained (dead) cells around the wells in the assay. This 
presented us with further evidence that the active toxin molecule was larger than 10 kDa 
and this simple scheme could be used routinely to produce a partial purification of the 
killer factor of W.mrakii.
To facilitate the production of substantial titres of active killer factor under static 
conditions, it was necessary to grow the yeast over extended periods of time. In an 
attempt to reduce fermentation times, a study was conducted to investigate the effect of 
agitation and oxygenation on toxin activity.
The amount of dissolved oxygen available to the yeast during growth affected the 
accumulation of the toxin produced by W.mrakii. The yeast was grown in three 
fermenters; fermenter A had ‘0%’ dissolved oxygen present at inoculation (essentially 
anaerobic), fermenter B was continually aerated and fermenter C was gently agitated for 
2 hours prior to inoculation. After addition of the starter cultures, fermenter A was 
maintained under static conditions, whilst fermenters B and C continued to be gently 
stirred. The latter was sufficient to prevent pellicle formation on the surface of the broth. 
Three different patterns of growth were produced, as shown in Figures 4.6 to 4.8. In 
fermenter C (Figure 4.8), typical growth was produced with cells entering exponential 
phase after 4 hours and stationary phase at approximately 24 hours. The mean
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generation time of cells during active growth was 4.3 hours. Growth of the killer yeast 
in an essentially anaerobic environment was possible, as demonstrated in fermenter A 
(Figure 4.6). However, there was a reduction in the maximum cell growth achieved and 
an increase in the mean generation time to 10.4 hours. The growth of W.mrakii with 
direct aeration, in fermenter B (Figure 4.7) was comparable to that observed in 
fermenter C. Cell division occurred at a mean generation time of 3.9 hours during 
exponential growth, however, there was a reduction in the final cell numbers as 
stationary phase was reached. Assessment of toxin activity during fermentation further 
exemplified the pattern of killer toxin production as cells progressed through their 
growth cycle. Measurable levels of the killer factor were observed in each fermentation 
at approximately the same point, as cells entered their stationary phase of growth. It was 
not possible, however, to correlate the detected toxin activities with an exact amount of 
toxin produced by assay of a single volume of cell-free supernatant. If a critical number 
of toxin molecules were required for inhibition of the sensitive strain, it was possible 
that at this volume a ‘saturation point’ had been reached where excess toxin molecules 
were present (see section 6.6). Therefore, if reduced volumes of supernatants were 
assayed it would give an indication of any increase in the amount of active toxin present 
in the extracellular media. By calculation, an estimate of the total units of toxin activity 
in each fermenter could be made and this was compared to the total amount of protein 
present (Figures 4.9 to 4.11). A clear relationship was demonstrated between toxin 
production and the accumulation of extracellular proteinaceous material. In fermenter C, 
cells entered a definite stationary phase following a period of 48 hours, at which point 
there was no further production of active toxin and very little increase in extraneous 
protein (Figure 4.11). However, in fermenters A and B the growth cycle of the killer 
yeast was affected by the extremes of oxygen available to the cells. In fermenter A the 
lack of dissolved oxygen present in the media at inoculation, led to a prolonged 
exponential phase, a reduction in cell numbers and a slow progression of cells into 
stationary phase. This was reflected in the levels of protein and residual toxin activity 
detected in the cultures (Figure 4.9). The larger amounts of protein produced in 
fermenter A suggested that not all protein present could be attributed to active toxin. A 
response of the cells to the experimental conditions may have led to the synthesis of 
‘stress proteins’. A variety of stressful treatments, including anoxia, nitrogen starvation,
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exposure to ethanol, high temperatures, and the presence of chemical inhibitors, all 
induce the synthesis of heat-shock proteins in a wide range of organisms (Craig, 1985; 
Walker and McWilliams, 1989). The anaerobic conditions could, therefore, have 
induced the production and secretion of additional proteins from the killer yeast. The 
maximum toxin activity achieved in fermenter B, however, was only 50% of that seen in 
fermenters A and C, and as fermentation progressed the activity fell to minimum levels 
after 72 hours (Figure 4.10). These observations can not be explained by the reduction 
in cell biomass alone, but suggest that the killer factor produced by W.mrakii became 
unstable in the presence of high levels of oxygen and toxin activity was lost. Oxidation 
of amino acids present in the primary structure of the protein may lead to abberations in 
the folding and terminal structure of the toxin molecule. It is also possible that the 
culture conditions led to an increase in the production of extracellular proteases which 
resulted in the proteolytic breakdown of toxin molecules. The loss of toxin activity 
observed in the aerated culture was correlated with a reduction in protein in the 
extracellular medium.
Measurement of the pH throughout the course of a fermentation of the killer yeast 
W.mrakii showed a drop in pH from approximately 5.5 to 2.7 (data not shown). It was 
possible, therefore, that the killing activity displayed in agar diffusion and microtitre 
assays, was due to a pH effect rather than the toxin acting directly on the sensitive yeast 
cell or affecting a metabolic pathway. A simple comparison was made of toxins from 
killers and non-killers in an attempt to discover if growth inhibition was simply due to 
acidification of the assay medium. Fermentation supernatant from the non-killer
P.subpellicosa (NCYC 436) showed a similar pH to that of W.mrakii (K-500) yet, did 
not produce the same degree of killing in the indicator strain C.glabrata (S-388). 
W.mrakii produced 93% reduction in growth of the sensitive and P.subpellicosa 3% 
reduction (data not shown). This suggested that only W.mrakii actively killed the 
sensitive strain.
The results of this study demonstrated that the killer yeast W.mrakii was 
‘microaerophilic’. Gentle agitation of the culture produced sufficient oxygen transfer for 
the growth of the yeast and the production of high levels of toxin in the extracellular
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media within 24 to 64 hours of fermentation. Using this information, attempts were 
made to increase production of active material for future purification work. W.mrakii 
was grown in two one litre fermenters over a three day period and the cultures were 
combined and processed as described in section 4.5. Table 4.2 documents the residual 
toxin activity and protein content at each stage of the processing.
Relatively high toxin titres (approximately 13,000 units) were present in both starter 
cultures, Sl^  and Slg, however, the activity was associated with low levels of protein, 
1.30 |xg/ml and 1.80 |Xg/ml respectively. Although the combined cultures had a high 
specific activity of 22000 units/mg of protein, prolonged fermentation may have 
produced further increases in toxin titres. Following microfiltration a significant loss 
(25%) in toxin activity was observed and this was associated with a 66% loss in protein. 
In all likelihood toxin protein was bound to the cellulose acetate membrane which led to 
the reduced killing activity of the preparation. Woods and Bevan (1968) reported a loss 
of activity in the S.cerevisiae killer toxin on filter sterilisation and suggested that it was 
due to surface inactivation. Shimizu et al. (1985) also reported the binding of killer 
factors from wine yeasts to nitrocellulose membranes. The cell-free supernatant was 
concentrated by Millipore ultrafiltration through Pelicon PTGC cassettes. Assay of the 
permeate, the unconcentrated fraction, suggested that there was no toxin activity 
present. A microtitre assay revealed that no lethality was produced in a sensitive strain 
of C.glabrata. Protein levels in this fraction were also negligible. However, only 20% of 
the toxin activity present before ultrafiltration was detected in the retentate. The large 
losses of protein associated with this step of the purification again suggested adsorption 
of toxin protein to the cassettes. In hindsight, it was also possible that toxin activity was 
present in the unconcentrated permeate sample but remained undetected because it fell 
below the ‘threshold limit’ of the microtitre assay (see section 6.6). The resultant 
lyophilisate was reconstituted in 10 ml of distilled water, overall a 120-fold 
concentration of the killer factor, and was assayed for activity. Although a small volume 
(6 |il) produced 100% reduction in growth of the sensitive strain, it again appeared that a 
considerable loss (42%) in activity had occurred during freeze-drying. However, only a 
small reduction in protein levels was observed. A ‘glassy’ residue remained following 
lyophilisation rather than the light, fluffy powder which should have been obtained. This 
was indicative of the solution thawing out during the freeze-drying process and may
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account for some of the losses seen (Harris, 1989). Several reports have also suggested 
that concentration of killer factors greater than 10-fold (Middelbeek et al., 1979) and 50- 
fold (Sawant et al., 1989) leads to substantial losses in killer activity. These losses may 
be explained by the aggregation of toxin molecules which results in the blockage of the 
receptor recognition sites on the surface of the sensitive yeast strain (Sawant et al:, 
1989).
Although losses of toxin activity were observed when the downstream processing was 
more critically appraised, activity remained detectable in the lyophilisate. It was deemed 
important, therefore, at this stage to produce sufficiently large amounts of this active 
material for future work. It was proposed to scale-up the fermentation of the killer yeast 
W.mrakii from several smaller fermentations (two to three litres) to 40 litres with the aid 
of the Fermentation Division at Glaxo Group Research.
The procedure followed during the initial 40 litre fermentation is outlined in Figure 
4.13. The running conditions were based on the results of the previous research. A static 
culture of the killer yeast (250 ml) was grown simultaneously to monitor any differences 
in cell growth and toxin production. After 24 hours, on-line measurements (absorbance 
at 600 nm) indicated poor growth of the yeast (an absorbance of 0.1 compared to 0.5 in 
static culture). It was assumed that if cell growth was reduced then so too would toxin 
production. The low cell biomass observed was attributed to the very low levels of 
oxygen available within the fermenter. Although earlier work had suggested that gentle 
agitation of the culture was sufficient for growth of the killer yeast, such a large vessel 
required minimal aeration. The fermentation was prolonged for a further 24 hours with
n
aeration of 1.5 litres/min. At completion the cell count of 3.7x10 cells/ml was 40% of 
that achieved in static culture. The fermentation broth was harvested as outlined in 
section 2.8.2 by centrifugation, microfiltration and ultrafiltration to produce three litres 
of concentrated material with a molecular weight greater than 10 kDa. The retentate was 
freeze-dried to produce 59.87 g of lyophilisate. Results in Table 4.3 suggested that very 
little killer factor was produced by the yeast during fermentation. Unconcentrated 
samples taken after 48 hours, microfiltration and from the permeate, showed no killing 
activity against C316. When concentrated only 28% reduction in growth of the indicator 
strain was observed after 24 hours, however, this did increase to 80% after 48 hours.
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The enhanced killing activity i.e . more active toxin molecules present in the 
extracellular medium, was in all likelihood a response to the increase in cell growth 
between 24 and 48 hours. The low toxin titres produced during the fermentation were 
further highlighted when compared to the static culture. The same toxic action against 
C316 was observed in the 24 (100 jxl) and 48 hour sample (50 jxl). Although the 
retentate was active against the indicator strain the response observed did not reflect the 
large concentration step involved. Analysis of the freeze-dried material suggested that a 
large proportion (77%) of the end-product was carbohydrate. The reduced cell growth 
meant a high proportion of the media carbohydrate remained unused and was 
concentrated during processing. Only a small amount of the lyophilisate was 
proteinaceous (0.06%) which was also indicative of low toxin production.
A second fermentation was performed and the same procedure described above was 
followed except the culture was aerated at 3.5 litres/min in an attempt to enhance 
growth of the killer yeast. Cells entered stationary phase at approximately 28 hours and 
a mean generation time of 4.07 hours was comparable to earlier fermentations. After 48 
hours a maximum cell growth of 1.25x10** cells/ml was produced. The levels of protein 
detected in the extracellular medium were constant until late exponential phase when a 
dramatic increase from 0.8 to 4.8 (Xg/ml was observed. As cells progressed into 
stationary phase, there was a further increase to 5.8 jig/ml before levels began to fall 
(Figure 4.15). Previous studies suggested that the increases in extracellular protein 
during fermentation of the yeast W.mrakii was indicative of toxin production. The 
culture was processed to produce 25.06 g of freeze-dried material, and at each stage an 
assessment was made of toxin activity and protein content. Table 4.6 again highlighted 
problems associated with the processing scheme used. Microfiltration accounted for a 
43% loss in protein and a subsequent 20% loss in toxin activity. The adsorption of the 
killer toxin to the membranes was the most probable cause of these losses. 
Ultrafiltration appeared to fractionate the cell-free supernatant without significant loss 
of protein. However, it was surprising to note that the majority of the toxin activity was 
detected in the permeate fraction (65%), material less than 10 kDa in size. Only 1% of 
the total activity was found in the retentate. The presence of toxin activity in both the 
retentate and permeate samples was not unusual. Ideally all molecules greater than 10
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kDa will not pass through a membrane during ultrafiltration, whilst those smaller than 
10 kDa will. However, due to the distribution of pore sizes in membranes there is also a 
distribution in the molecular weight of the molecules able to pass through. Thus, the 
filtrate will contain a certain percentage of molecules with molecular weights less than 
the nominal cut-off of the membrane and a similar percentage with a higher molecular 
weight (Harris, 1989). Table 4.7 summarises results from both large-scale 
fermentations. It was apparent that very low amounts of protein were associated with the 
killing activity of the yeast W.mrakii, with only milligram amounts being produced from 
40 litres of culture. The yield was, however, improved five-fold between the two 
fermentations yet still accounted for less than 1% of the freeze-dried material produced.
The second fermentation yielded approximately only 50% of the material from the first,
25.06 g compared to 59.87 g. The vast difference between the two can probably be 
attributed to less media carbohydrate being present at the end of fermentation because of 
the enhanced cell growth of the killer yeast. Attempts were made to ‘clean-up’ the toxin 
preparations using dialysis. The process of dialysis involved placing the toxin solution 
in a bag of semi-permeable membrane which was submerged in distilled water. Small 
molecules, such as salts and carbohydrates, passed freely across the membrane whilst 
larger molecules were retained. Lyophilisate (500 mg/ml) from the initial fermentation 
was reconstituted and dialysed against distilled water for a period of 24 hours. The 
starting material, dialysate, dialysing solution and washings from the surface of the 
tubing were assessed for protein and carbohydrate content and toxin activity. The results 
in Table 4.5 demonstrated that dialysis had successfully removed almost all the 
carbohydrate and 70% of the protein from the preparation. The dialysis tubing had a 
nominal molecular weight cut-off of 12-14 kDa, therefore, only large molecular weight 
proteins would be retained in the dialysate. The killing activity of each solution was 
assayed against the indicator strain C.glabrata (S-388). The starting material produced 
85% inhibition in S-388, however, no growth inhibition was produced by the dialysate, 
dialysing solution or the washings (data not shown). Dialysis, therefore, resulted in the 
loss of killer activity from the toxin preparation, which suggested that the molecular 
weight of the active component was certainly less than 12 kDa. If the active toxin was
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Table 4.7 - Summary of the production of protein during large-scale fermentations 
of the killer yeast W .m rakii (K-500). Lyophilisate was reconstituted at a 
concentration of 500 mg/ml and protein content determined using the Pierce 
microassay technique.
Fermentation Amount of Protein 
in Culture Broth 
(pg/ml) a
Total Yield 
of Protein 
(mg)
Percentage 
of Dry 
Weight
Fermentation 1 0.096 3.83 0.006
Fermentation 2 0.370 14.83 0.06
a - these values were calculated from the amount of protein present in each 
lyophilisate at completion of processing
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removed during dialysis it was expected that activity would be detected in the dialysing 
solution, however, no concentration of this solution was made as a confirmation.
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4.8 Conclusions
The killer yeast W m rakii (K-500) showed comparable growth in a range of media. The 
minimal medium, YNBGS was chosen for subsequent studies although it did not 
support the greatest toxin production. Use of a minimal medium would potentially yield 
preparations of high specific activities which lacked extraneous polypeptides, a benefit 
to any subsequent purification attempts. Toxin production was a growth-related 
response and the killer factor was produced as the cells progressed from late exponential 
to early stationary phase. Protein levels in the extracellular medium mirrored toxin 
production. An agitated system with low levels of oxygen present led to the highest 
titres of killer toxin being produced. Anaerobic or oxygenated systems, whilst 
supporting growth, inhibited toxin production or destabilised the toxin structure.
Losses in protein and, hence, toxin activity during downstream processing suggested 
that the killer factor was adsorbed to cellulose acetate membranes and to polysulfone 
ultrafiltration cassettes. Assumptions that the killer factor was larger than 10 kDa were 
misleading and permeate samples were not fully analysed. Latter work proceeded to 
suggest that the toxin molecule was in fact smaller than 10 kDa and loss of toxin activity 
following dialysis supported the hypothesis of a reduced molecular weight.
Further work is necessary to optimise killer toxin production in the yeast W.mrakii (K- 
500) and several problems associated with downstream processing and scale-up 
production could be addressed.
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CHAPTER FIVE
Characterisation and Purification of 
Wittiopsis mrakii Killer Toxin
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5.1 Introduction
In light of the numbers of killer yeasts which have now been formerly identified, only a 
few killer toxins have been fully characterised. The most notable is that of the 
S.cerevisiae K1 killer yeast. Palfree and Bussey (1979) isolated a proteinaceous killer 
toxin from concentrates of the extracellular medium and determined its molecular 
weight to be 11.5 kDa by SDS-PAGE and amino acid analysis. Its activity was stable 
over only a narrow temperature and pH range. The killer toxin produced by a strain of 
W.mrakii (LKB 169) was isolated and partially purified by Yamamoto et al. (1986a). It 
was found that the toxin was a molecule of 10.7 kDa which, in contrast to the findings 
of Palfree and Bussey (1979), was stable over a wide range of temperature and pH.
The aim of this work was to determine the biochemical nature of the killer factor 
produced by W.mrakii (K-500), assess its pH and temperature stability and to attempt a 
partial purification of the killer toxin using the techniques of FPLC and gel filtration 
chromatography.
5.2 Temperature Stability of W.mrakii (K-500) Killer Toxin
Crude toxin was concentrated 20-fold by freeze-drying cell-free supernatants and 
reconstituting the resultant lyophilisate in distilled water. Samples of the toxin 
preparation were incubated at a range of temperatures (section 2.9.1) and at specific 
intervals, aliquots were removed and assayed for activity using a microtitre plate assay 
(section 2.6.3).
Figure 5.1 shows the residual activity which remained after incubation of the toxin at 4, 
18,25, 30 and 37°C. The activity was expressed in terms of the percentage reduction in 
growth produced in a sensitive strain.
The results showed that toxin activity was stable at 4°C and 18°C (ambient 
temperature) over a 7 hour period and only a 10% reduction in its activity occurred over 
a 24 hour period. The activity at 25°C was stable for 7 hours, but a 20% loss resulted 
after 24 hours. At 30°C a rapid loss was seen in residual toxin activity between 7 and 24 
hours, with only 5% of the activity remaining after the latter time. At 37°C toxin
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Figure 5.1 - Stability of the crude toxin from W.mrakii (K-500) to a range of incubation 
temperatures. At intervals residual toxin activity was measured against a sensitive strain 
C.glabrata (S-388) using a microtitre bioassay.
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lethality decreased rapidly between 4 and 7 hours (70% loss) and the toxin was found to 
be inactive after an incubation of 24 hours at this temperature.
Temperatures of 50°C and 70°C resulted in a complete loss of toxin activity after 
incubation for 15 minutes, and the toxin was also unstable to boiling (data not shown).
5.3 pH Optimum of W.mrakii (K-500) Killing Activity
Crude toxin was prepared from a culture of K-500, which had been incubated with 
gentle agitation at 25°C for 72 hours. The effect of pH variation on the killing of 
C.glabrata (S-388) and a clinical isolate, C.albicans (S-214392), was examined using 
the agar diffusion bioassay (see Section 2.9.2). The results are shown in Table 5.1.
The killer factor was more active against S-388 than the clinical isolate S-214392, a 
much larger zone of inhibition, 16.5 mm compared to 11.0 mm, was produced at this 
pH. However, it can be seen that the toxin activity against both sensitive strains 
decreased as the pH of the assay medium was increased, and complete loss of activity 
occurred at pH 5.0. At the higher range of pH values investigated, 7.0-8.0, S-388 failed 
to grow as a lawn within the agar. The response of both sensitive strains to the action of 
the killer toxin suggested that a pH of 3.5 was optimal for its killing action.
5.4 pH Stability of W.mrakii (K-500) Killer Toxin
W.mrakii (K-500) killer toxin was buffered over a range of values, pH 2.4 to 6.1, using
0.1 M citrate-phosphate buffer (see section 2.9.3). The solutions were incubated at 
ambient temperature (18°C) for 18 hours and the remaining toxin activity assessed 
using a microtitre assay (section 2.6.3). The percentage reduction in growth of the 
indicator strain, C.glabrata (S-388), produced by each solution, was calculated with 
respect to toxin-free buffer controls of equivalent pH.
Figure 5.2 shows the relative killing activity of each solution when compared to 
unbuffered toxin (pH 2.3). The killer factor of W.mrakii was stable over the pH range
2.4 to 4.0. Between pH 2.8 and 4.0, 100% of the activity was detected, however, at 
lower values of pH 2.4 to 2.6, only 70% of the original activity was apparent. 
Inactivation of the killer factor occurred at values greater than pH 4.0.
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Table 5.1 - Effect of pH on the killing activity of W.mrakii (K-500). The pH of the 
assay medium was buffered to a range of values and 30pl of crude toxin was added 
to wells cut in the seeded agar. Subsequent zones of inhibition (mm) were measured 
after incubation at 25°C for 72 hours.
Sensitive
Organism
pH of Media
3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0
C.glabrata
(S-388)
16.5 15.5 15.0 0 0 0 0 No
Growth
No
Growth
No
Growth
C.albicans 
(S-214392)
11.0 10.5 9.5 0 0 0 0 0 0 0
Figure 5.2 - The effect of pH on toxin stability. Concentrated toxin was buffered to a 
range of pH values with 0.1 M citrate-phosphate buffer. After incubation at 18°C for 
18 hours, toxin activity was assessed using a microtitre assay.
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5.5 PhastSystem Analysis of W.mrakii (K-500) Killer Toxin
(a) Isoelectric Focussing (IEF)
IEF is a high resolution technique for separating proteins on the basis of their isoelectric 
points (pi) and the Pharmacia PhastSystem allowed rapid analysis of toxin preparations. 
A partially purified sample of the killer toxin (cell-free supernatant which had 
undergone Amicon ultrafiltration, section 2.8.1) was loaded onto the gradient gel IEF 3- 
9 (lanes 2 and 5) along with a medium (YNBGS) control (lane 4) and a sample of toxin 
which had been boiled (lane 3). Calibration markers with known isoelectric points were 
run alongside (lanes 1 and 8). After focussing the gel was developed using a silver 
staining technique (see section 2.9.5b).
Plate 5.1 shows the separation of proteins present within the toxin preparation and Table
5.2 the distances moved by the markers. Using a calibration graph (Figure 5.3), an 
estimate could be made of the isoelectric points of the components of the partially 
purified toxin (Table 5.3). A strong and diffuse band was seen at a distance of 20.0 mm 
from the cathode and this coincided with a pi of 6.15, the single band seen in the media 
control migrated the same distance. A second crisp band was observed at a distance of
31.5 mm (pi 4.35) from the cathode and two weakly stained doublets were apparent at
22.5 mm (pi 5.80) and 23.5 mm (pi 5.65), and 29.0 mm (pi 4.75) and 30.0 mm (pi 4.70) 
respectively. No bands were visible in the sample of toxin which had previously been 
boiled.
(b) Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Rapid SDS-PAGE electrophoresis to accurately determine molecular weight 
distributions was also possible using the Pharmacia PhastSystem. The same partially 
purified sample of killer toxin was prepared by addition to boiling mix and was heated 
to 100°C for 3 minutes (see Section 2.9.5a). It was noted that the normal colour of the 
solution, due to the Coomassie Blue in the mix, was in fact changed from blue to yellow 
on addition of the toxin. The samples and molecular weight markers were loaded onto a 
homogenous PhastGel and after separation developed by silver staining.
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Figure 5.3 - Calibration graph to estimate the isoelectric points of components in a
partially purified preparation of W .m rakii (K-500) killer toxin.
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Table 5.2 - Table showing the isoelectric points (pi) and migration (mm) of the 
molecular weight markers used for calibration of the PhastSystem DEF gel (IEF 3-9).
Name of Marker pi Migration Distance (mm)
Amyloglucosidase 3.50 34.5
Soybean Trypsin Inhibitor 4.55 31.0
B-lactoglobulin A 5.20 27.0
Bovine Carbonic Anhydrase B 5.85 22.0
Human Carbonic Anhydrase B 6.55 17.0
Horse Myoglobin (acidic) 6.85 14.0
Horse Myoglobin (basic) 7.35 11.0
Lentil Lectin (acidic) 8.15 7.0
Lentil Lectin (middle) 8.45 4.5
Lentil Lectin (basic) 8.65 3.5
Trypsinogen 9.30 2.0
Table 5.3 - The estimated isoelectric points (pi) of the components of the partially 
purified W.mrakii (K-500) killer toxin (calculated from the calibration graph shown 
in Figure 5.3).
Migration Distance (mm) pi Migration Distance (mm) pi
20.0 6.15 29.0 4.75
22.5 5.80 30.0 4.70
23.5 5.65 31.5 4.35
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Inconsistent results were obtained, however, a very weak band was apparent which 
coincided with a molecular weight of approximately 16 kDa (data not shown). 
Subsequent attempts to repeat this separation on PhastGels and Mini-gels were 
unsuccessful.
5.6 Effect of Proteolytic Enzymes on Toxin Activity in Two Strains of W.mrakii
(a) Prior to investigation of the effects of pronase, pepsin and trypsin on toxin activity, 
the enzymes were standardised against a haemoglobin substrate (section 2.9.4). The 
concentration of each enzyme which hydrolysed the substrate to the same extent was 
determined and used in studies to further characterise the killer toxin.
It was found that concentrations of pepsin (0.50 mg/ml) and pronase (2.25 mg/ml) 
produced the same extent of hydrolysis, which correlated to a measured absorbance of
1.000 at 280 nm (Figure 5.4). Trypsin, however, at the concentration assayed, failed to 
hydrolyse the haemoglobin to the same extent. Increasing the concentration of the 
enzyme failed to produce a comparable response, therefore, only the effect of pronase 
and pepsin on the killer factor was further investigated.
(b) The effects of native and denatured enzymes on killer activity in W.mrakii (K-500 
and K-LKB) was assessed relative to the appropriate control solutions (section 2.9.4). 
The residual toxin activity was determined using a microtitre assay (section 2.6.3).
The results in Figure 5.5 suggested that from a single microtitre assay the killer factor in 
both strains of W.mrakii was resistant to the action of the proteolytic enzymes tested. 
100% of the toxin activity was maintained after incubation with native and denatured 
enzymes, or control solutions, distilled water (pepsin control) and 5 mM CaC^ (pronase 
control). K-500 killer factor was inactivated by high temperature treatment, however, K- 
LKB maintained 60% and 80% of its activity following incubation with pepsin and 
pronase respectively.
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Figure 5.4 - Standardisation of the proteolytic enzymes against a haemoglobin 
substrate. Increasing concentrations of pepsin, pronase and trypsin were incubated with 
the substrate for 18 hours at 20°C. The absorbance of TCA-soluble protein, at 280 nm, 
was used to indicate the extent of hydrolysis.
0 .0 0  0 .50  1.00 1.50 2 .0 0  2 .5 0  3 .0 0
Concentration of enzyme (mg/ml)
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Figure 5.5a - The effect of pepsin (0.50 mg/ml) on the activity of W.mrakii K-500 and 
K-LKB killer toxins. Each solution was incubated at 20°C for 18 hours and the 
remaining toxin activity was assessed against the sensitive strain C.glabrata  (S-388) 
using a microtitre assay.
Incubations
K EY:
Tox + Enz - killer toxin incubated with pepsin (0.50 mg/ml)
Tox + B.Enz - killer toxin incubated with heat denatured enzyme
Tox + Con - killer toxin incubated with distilled water control
B.Tox + Enz - heat-treated killer toxin incubated with pepsin (0.50 mg/ml)
Page 136
Figure 5.5b - The effect of pronase (2.25 mg/ml) on the activity of W.mrakii K-500 and 
K-LKB killer toxins. Each solution was incubated at 20°C for 18 hours and the 
remaining toxin activity was assessed against the sensitive strain C.glabrata  (S-388) 
using a microtitre assay.
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KEY:
Tox + Enz - killer toxin incubated with pronase (2.25 mg/ml)
Tox + BJEnz - killer toxin incubated with heat denatured enzyme
Tox + Con - killer toxin incubated with 5 mM CaCl2 control
B.Tox + Enz - heat-treated killer toxin incubated with pronase (2.25 mg/ml)
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5.7 Fast Protein Liquid Chromatography (FPLC) Purification of W .m rakii Killer 
Toxin
A Mono Q anion-exchange column was used for separation of the components of 
W.mrakii killer toxin. The toxin preparation used in the following separations was cell- 
free supernatant concentrated by Millipore ultrafiltration (10 kDa cut-off). The retentate 
was concentrated further by freeze-drying and the lyophilisate reconstituted in a reduced 
volume of distilled water. The toxin preparations were applied to the column and eluted 
with a range of buffer systems, see section 2.10.1 for technical details.
Buffer system 1
Buffer A : 20 mM TRIS, pH 8.0
Buffer B : 20 mM TRIS + 1.0 M NaCl, pH 8.0
The first buffer system (pH 8.0) used, produced the elution profile seen in Figure 5.6a 
and five main protein peaks were eluted from the column. A large peak of unbound 
material (A) passed straight through the column, followed by a distinct peak (B) which 
was removed by a 15-20% gradient of Buffer B. A smaller peak (C) was removed by 
25% Buffer B and two others, tightly bound to the column, were removed by 100% 
Buffer B. Fractions from peaks A-D were assayed for activity using a microtitre assay 
(Figure 5.6b). Increasing ‘activity’ was displayed by fractions from peak B through to 
peak D and those from the initial unbound material showed only 40% reduction in 
growth of the sensitive strain.
Buffer System 2
Buffer A : 20 mM N-methylpiperazine, pH 4.0
Buffer B : 20 mM N-methylpiperazine + 1M NaCl, pH 4.0
The second separation of toxin proteins used an acidic (pH 4.0) buffer system which 
produced a similar, but less defined, elution profile (Figure 5.7a) than that obtained from 
buffer system 1. Five peak areas were eluted (A-E), however fractions were only 
collected from the peaks A (unbound material) and D (removed by 25% gradient of 
Buffer B) to assay for activity (Figure 5.7b). Microtitre assays showed that the bulk of 
the activity was eluted in the unbound fraction, approximately 100% reduction in
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Figure 5.6a - Elution profile of W .m ra k ii (K-500) killer toxin on a Mono Q HR 5/5
column using a 20 mM TRIS +/- 1.0 M  NaCl, pH 8.0 buffer system.
Figure 5.6b - Toxin activity of fractions collected from peaks A-D was measured 
against the indicator strain C.glabrata (S-388) using a microtitre assay.
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Figure 5.7a - Elution profile of W .m ra k ii (K-500) killer toxin on a Mono Q HR 5/5
column using a 20 mM N-methylpiperazine +/- 1.0 M  NaCl, pH 4.0 buffer system.
Figure 5.7b - Toxin activity of fractions collected from peaks A and D was measured 
against the indicator strain C.glabrata (S-388) using a microtitre assay.
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growth of the sensitive was produced by 25 pi of this sample. This compared to 
fractions from peak D in which 100 pi produced a 40% reduction in sensitive growth.
Buffer System 3
Buffer A : 20 mM bis TRIS, pH 6.0
Buffer B : 20 mM bis TRIS + 1.0 M NaCl, pH 6.0
The next separation used an intermediate (pH 6.0) buffer system which produced a 
similar elution profile (Figure 5.8a) of 5 main peak areas (A-E). Fractions (1 ml) were 
collected during the elution programme and all were assayed for activity by the 
microtitre assay (Figure 5.8b). Strong activity was recorded in a single fraction, fraction 
3, and moderate activity in fractions 30-39. A repeat of this assay verified that sample 3, 
a fraction of the unbound material, produced lethality in a sensitive strain. The 
increasing activity from fraction 20 onwards, especially that observed in fractions 30- 
39, suggested an effect of increasing salt concentrations in the elution buffer. This was 
verified by assaying fractions from a blank gradient control against the same indicator 
strain (data not shown).
Buffer System 4
Buffer A : 20 mM bis TRIS propane, pH 6.5
Buffer B : 20 mM bis TRIS propane + 1.0 M NaCl, pH 6.5
Elution of proteins with a pH 6.5 buffer system (Figure 5.9a) resulted in a profile with 7 
main peak areas (A-G). A large unbound sample was removed (A) and 4 other distinct 
protein peaks (B-E) were eluted by the linear gradient of buffered NaCl. A significant 
amount of protein was tightly bound to the column (F and G), and was removed with 
100% Buffer B. The activity of all the fractions was assayed (Figure 5.9b). No 
significant toxin activity was observed in any of the fractions, although traces were 
apparent in the unbound fractions 1 and 2. The same pattern of increased growth 
inhibition produced by the latter fractions was observed.
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Figure 5.8a - Elution profile of W .m ra k ii (K-500) killer toxin on a Mono Q HR 5/5
column using a 20 mM bis TRIS +/- 1.0 M  NaCl, pH 6.0 buffer system.
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Figure 5.8b - Toxin activity of eluted fractions 1-39 was measured against the indicator 
strain C.glabrata (S-388) using a microtitre assay.
F r a c t i o n  n u m b e r
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Figure 5.9a - Elution profile of W .m ra k ii (K-500) killer toxin on a Mono Q HR 5/5
column using a 20 mM bis TRIS propane +/-1.0 M  NaCl, pH 6.5 buffer system.
Figure 5.9b - Toxin activity of eluted fractions 1-45 was measured against the indicator 
strain C.glabrata (S-388) using a microtitre assay.
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5.8 Development of a Colourimetric Assay of Toxin Activity
The tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] 
(MTT) is a pale yellow substrate which is changed to a dark blue product (MT.T- 
Formazan) through its reduction by the mitochondrial dehydrogenase enzymes of living 
cells (Slater et al., 1963). The aim was to use this redox indicator to develop a rapid 
quantitative assay of activity which would detect living, but not dead cells, and 
accurately reflect sensitive cell viability after toxin treatment.
(a) A comparison was made of the ability of live and dead cells to convert MTT to 
MTT-Formazan. The relationship between cell numbers and the amount of MTT- 
Formazan generated was also investigated. Increasing numbers (approximately 5.0x10^-
n
5.0x10 ) of live and heat-killed Candida blastospores were incubated with toxin-free 
media prior to incubation with the MTT dye (section 2.6.4). The absorbance (570 nm) 
of the resultant supernatants was measured, which correlated to the extent of MTT 
conversion to MTT-Formazan.
From Figure 5.10 it can be seen that the absorbance produced was proportional to the 
numbers of live cells present in the assay, however, there was no significant conversion 
of the dye by cell numbers below 1.0x10 .^ The results also demonstrated that dead cells 
produced a negligible response.
(b) Sensitive cells of C.glabrata (S-388) were incubated with different amounts of a 
concentrated crude toxin preparation (freeze-dried cell-free supernatant) of W.mrakii (K- 
500), and the effect on the reduction of the MTT dye was assayed as outlined in section 
2.6.4. The absorbance (570 nm) of each incubation was measured and the results 
recorded in Figure 5.11.
Results showed that the assay was sensitive to the presence of toxin from the killer yeast 
strain K-500 and subsequently the conversion of MTT to MTT-Formazan was greatly 
affected. As the amount of toxin in the assay system was increased then less MTT- 
Formazan was produced, thus, the measured absorbance decreased.
(c) It was necessary to correlate the reduction in conversion of the dye produced by the 
killer factor, with a loss of mitochondrial enzyme activity and, hence, sensitive cell
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Figure 5.10 - Relationship between the number of live cells and MTT-Formazan 
production. Log-phase cells of C.glabrata (S-388) were incubated with MTT for 2 hours 
at 30°C and reduction to MTT-Formazan was measured spectrophotometrically at 570 
nm. A comparison was made of heat killed (70°C for 20 minutes) blastospores.
No. of cells (xlO^)
Page 145
Figure 5.11 - Sensitvity of C.glabrata (S-388) blastospores to W.mrakii (K-500) killer
o
toxin. Log-phase cells (1.1x10° cells/ml) of S-388 were exposed to different 
concentrations of killer toxin for 90 minutes at 20°C. After incubation, MTT-Formazan 
production was measured spectrophotometrically at 570 nm.
Concentration of toxin (jil/ml)
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viability. A subsequent experiment attempted to link the reduction in MTT-Formazan 
production in toxin-treated cells with the number of viable cells remaining, by plating 
out dilutions from each incubation on SDA.
Figure 5.12 shows the percentage reduction in viability produced by K-500 killer toxin 
as measured by the colourimetric MTT assay and a more traditional method which 
measured colony forming activity on agar plates. The effect on viability was measured 
with respect to a toxin-free control in each case. A good correlation between the two 
methods was displayed and both were sensitive to the increases in toxin concentration. 
The numbers of viable cells decreased, as did the measured absorbance of the final 
supernatants, as the amount of toxin present in the assay increased. This indicated a 
direct relationship between sensitive cell viability and the conversion of MTT to MTT- 
Formazan.
(d) A time-course was also conducted to investigate the relationship between the period 
of toxin exposure and sensitive cell viability. The sensitive cells of C.glabrata  were 
incubated with a concentrated preparation of killer toxin for set periods of time, 0, 15, 
30,45, 60 and 90 minutes, before a sample was removed and incubated with MTT. The 
absorbance of the resultant supernatants was measured and the percentage reduction in 
viability of the sensitive cells calculated at each stage.
Figure 5.13 displayed that there was approximately a 60% reduction in viability of the 
sensitive strain after a 15 minute exposure to the killer toxin. There was no further 
conversion of MTT to MTT-Formazan and, therefore, no further reduction in cell 
viability, after an exposure time of 60 minutes.
(e) It was hoped that this method could be used as a rapid and accurate assay of toxin 
activity and that it would be insensitive to the presence of salt in fractions eluted from 
FPLC columns. FPLC buffers, 20 mM bis TRIS propane, pH 6.5 (buffer A) and 20 mM 
bis TRIS propane + 1.0 M NaCl, pH 6.5 (buffer B) were prepared and combined to 
produce solutions of 0-100% buffer B. A concentrated preparation of killer toxin was 
diluted 1:5 in these solutions and their effect on the conversion of MTT to MTT- 
Formazan by cells of the sensitive strain C.glabrata, were investigated with respect to 
toxin-free buffer controls.
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Figure 5.12 - Comparison of the MTT-colourimetric assay of toxin activity with 
traditional plating techniques for monitoring sensitive cell viability. C.glabrata (S-388)
o
(1.2x10° cells/ml) was exposed to different concentrations of killer toxin for 90 minutes 
at 20°C.
Concentration of toxin (jil/ml)
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Figure 5.13 - Time-course to investigate the relationship between the period of 
toxin exposure and sensitive cell viability. Cells of the indicator strain 
C.glabrata (S-388) were exposed to killer toxin of the yeast W.mrakii (K-500). 
At specific intervals samples were removed and the percentage reduction in 
viable cells determined with respect to a toxin-free control using the MTT- 
colourimetric assay.
Time (minutes)
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Table 5.4 - Effect of FPLC buffers on the MTT-colourimetric assay of toxin activity. 
Concentrated toxin was diluted in a range of buffers comprising buffer A, 20 mM bis TRIS 
propane, pH 6.5, and buffer B, 20 mM bis TRIS propane + 1.0 M NaCl. Residual toxin 
activity was measured as the reduction in viability of a sensitive strain , C .glabrata  (S-388), 
with respect to toxin-free buffer controls.
Buffer Solutions Absorbance (570 nm) 
+ Toxin
Absorbance (570 nm) 
- Toxin
% Reduction in 
Viability
100% Buffer A 0.232 0.464 50.0
10% Buffer B 0.210 0.502 58.8
20% Buffer B 0.181 0.500 63.8
30% Buffer B 0.179 0.475 62.3
40% Buffer B 0.157 0.414 62.0
50% Buffer B 0.172 0.404 57.4
60% Buffer B 0.175 0.441 60.3
70% Buffer B 0.184 0.397 53.7
80% Buffer B 0.197 0.403 51.1
90% Buffer B 0.157 0.370 57.6
100% Buffer B 0.156 0.325 52.0
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Table 5.4 shows the amount of MTT-Formazan produced in terms of absorbance 
readings at 570 nm, and the effect of each solution on sensitive cell viability was 
calculated. It was possible to detect toxin activity in the test solutions as reductions in 
absorbance when compared to toxin-free control solutions. The killer toxin produced a 
consistent 50-64% reduction in sensitive cell viability in the presence o f increased 
concentrations of salt in the buffers.
5 .9  A n a ly sis  o f W.mrakii (K -5 0 0 ) K ille r  T oxin  U sin g  G el F iltr a t io n  
Chromatography
(a) Preliminary analysis of the toxin using PhastSystem SDS-Page suggested that the 
molecular weight of the killer factor released by W .m rakii (K-500) during growth was 
approximately 16 kDa. To ‘clean up’ the toxin preparation, by removal of salts and low 
molecular weight material, it was proposed to use a small (9 ml bed volume), 
commercial, pre-packed column containing G-25 Sephadex (fractionation range 1000- 
5000 Da). The column was prepared as described in section 2.10.2 prior to the 
application of crude toxin (1 ml of 100 mg/ml dry weight of lyophilisate). The sample 
was eluted with distilled water and 1 ml fractions were collected. The protein content of 
these fractions was determined by measurement of absorbance at 280 nm and 100 |xl 
amounts were assayed for toxin activity, against C.glabrata  (S-388), using a microtitre 
assay (section 2.6.3).
The elution and activity profiles obtained from this separation are represented in Figure 
5.14. Two major proteins were separated on the column. Protein (A) (fractions 3-6), 
eluted at the void volume of the column, was associated with a relatively low activity, 
only producing a 24% reduction in growth of the sensitive strain. However, the second 
smaller protein (B) (fractions 7-13) displayed very high killing activity, with a 98% 
reduction in growth of the indicator strain.
(b) A second separation was performed using a larger, prepared Sephadex G-25 column 
(70 ml bed volume). A more concentrated sample of toxin (1 ml of 200 mg/ml dry 
weight) was loaded onto the column and eluted with distilled water. The collected 
fractions were assayed for both protein content and toxin activity.
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Figure 5.14 - Elution profile of W .m rakii (K-500) killer toxin on a commercial pre-packed Sephadex G-25 column (9 ml bed volume).
Toxin (100 mg/ml dry weight) was eluted with distilled water and the protein profile of the collected fractions (1 ml) measured at 280
nm. Toxin activity was measured against the indicator strain C .g la b ra ta (S-388) using a microtitre assay.
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A much higher resolution of separation was achieved with the larger column (Figure 
5.15) but the profiles indicated that the active protein (B) was eluted at the same stage of 
the separation. However, with the increase in the bed volume of the column, dilution of 
toxin activity occurred during the separation so it became necessary to freeze-dry and 
concentrate samples 10-fold prior to assay.
(c) A third separation was achieved using a prepared Sephadex G-25 column of 700ml 
bed volume. The crude toxin preparation (10 ml of 276 mg/ml dry weight) was loaded 
onto the column and 5 ml fractions were collected after elution with distilled water. 
Samples of each fraction were concentrated 100-fold and subsequently assayed for 
activity.
The larger column enhanced the resolution o f the separation of the proteinaceous 
components of the killer factor. Strong killing activity (approximately 100% growth 
inhibition of the sensitive strain) was not directly attributed to any one of the separated 
proteins (A-C) but appeared to lie between the doublet (B and C) eluted in fractions 80- 
89. This separation was repeated several times and a consistent and reproducible activity 
and protein profile (Figure 5.16) was achieved.
(d) Samples of the active fractions (80-89) from the latter separation were pooled, 
freeze-dried and concentrated 40-fold. The activity of this preparation was confirmed by 
microtitre assay. A 750 pi sample was loaded onto a P2 Biogel column (100 ml bed 
volume), which has a fractionation range of 100-1800 Da, and eluted with distilled 
water. One ml fractions were collected and assayed for activity.
Figure 5.17 shows the elution profile obtained and the separation of four components 
(A-D) was achieved. Consecutive fractions were pooled and concentrated 10-fold prior 
to assay. The activity profile determined suggested that the two peaks eluted near the 
void volume of the column possessed killing activity.
A second separation using this column yielded the same profiles and two pairs o f 
fractions, 35+36 (X) and 37+38 (Y), were combined for measurement of a UV spectra. 
The results in Figure 5.18 suggested that the wavelength o f maximum absorption 
(^max) ° f 111686 fractions was 257 nm.
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Figure 5.15 - Elution profile of W .m rakii (K-500) killer toxin on a prepared Sephadex G-25 column (70 ml bed volume). Toxin (200
mg/ml dry weight) was eluted with distilled water and the protein profile of the collected fractions (1 ml) measured at 280 nm. Toxin
activity was measured against the indicator strain C .g la b ra ta (S-388) using a microtitre assay.
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Figure 5.16 - Elution profile of W .m rakii (K-500) killer toxin on a prepared Sephadex G-25 column (700 ml bed volume). Toxin (276
mg/ml dry weight) was eluted with distilled water and the protein profile of the collected fractions (5 ml) measured at 280 nm. Toxin
activity was measured against the indicator strain C .g la b ra ta  (S-388) using a microtitre assay.
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Figure 5.17 - Elution profile of Wmrakii (K-500) killer toxin on a prepared P2 
Biogel column (45ml bed volume). Active fractions 80-89 (from separation in 
Figure 5.16) were pooled and concentrated 40-fold. 750 pi was applied to the 
column and eluted with distilled water. Protein content of the fractions was
measured at 280 nm and toxin activity by microtitre assay against C.glabrata 
(S-388).
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Figure 5.18 - UV spectra of combined fractions eluted from the P2 Biogel separation of W m r a k li (K-500) killer toxin. Fractions 35+36
(X) and 37+38 (Y) were used to determine the UV spectra of eluted samples over the range of wavelengths 220-320 nm.
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(e) A 10 ml sample of a concentrated crude toxin preparation was applied to the largest 
G-25 Sephadex column and was eluted with distilled water. The activity present in the 
initial sample and that in the eluted fractions was assessed using a microtitre bioassay. 
Table 5.5 shows the total units of activity applied to, and recovered from the column. 
2500 units of activity where present in the initial preparation and 1000 units were 
applied to the column. A direct assay for activity of 100 pi amounts from each of the 
eluted fractions did not conclusively detect toxin activity, however, there were traces of 
activity in fraction 69. The fractions were, therefore, reassayed after a 10-fold 
concentration and the results highlighted toxin activity in fractions 67-75 (Figure 5.19). 
Although a different profile was obtained, the volume of eluant required to remove 
active fractions (400-450 ml), was consistant with previous separations. The total toxin 
activity present in these fractions (54 units) was, however, only a small percentage (5%) 
of the activity originally loaded.
(f) The binding of the active component of the toxin to the Sephadex beads during 
separation by gel filtration chromatography was also investigated. The same toxin 
preparation from the previous study was used and the procedure followed is outlined in 
section 2.10.2.1. The toxin solution (Al) was incubated with a small amount of pre­
swollen Sephadex G-25, the slurry was then centrifuged and the resultant supernatant 
assayed for activity (A2). The Sephadex was washed twice with distilled water (A3 and 
A4) and once with 0.1 M NaCl (A5). The effect of 0.1 M NaCl on the assay system was 
also assessed. Toxin activity in 10-100 pi amounts of each solution was measured using 
a microtitre bioassay.
From the results in Figure 5.20 it would appear that approximately 60% of the toxin 
activity was recovered in the initial centrifugation. No activity was recovered from 
washing the Sephadex with distilled water and only negligble amounts from the salt 
washing. 0.1 M NaCl did not inhibit growth of the indicator strain.
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Table 5.5 - Assessment of toxin activity during fermentation, processing and gel filtration
chromatography. Killing activity was assayed against C .g la b r a ta  (S-388) using a microtitre
bioassay.
Toxin
Preparation
Volume
(ml)
Equivalent Unita 
of Activity (jil)
Total Activity 
(units)
Loss of*3 
Activity (%)
Cell-free Supernatant 
Freeze-dried and 
Concentrated (x20)
25 10 2500 0
Sample Loaded onto 
G-25 Sephadex Gel 
Filtration Column
10 10 1000 0
Fractions Collected 
(6 ml); 67-75 
Showed Toxin Activity
54 1000 54 95
a - 1 unit of activity is defined as that volume which results in approximately 10 0 % 
reduction in growth of the indicator strain in a microtitre assay, 
b - the percentage loss of activity is relative to the previous step in the table.
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Figure 5.19 - Elution profile of W .m ra kii (K-500) killer toxin on a prepared Sephadex G-25 column (700 ml bed volume). Toxin
(concentrated 20-fold) was eluted with distilled water and the protein profile of the collected fractions (6 ml) measured at 280 nm.
Toxin activity was measured against C .g la b ra ta (S-388) using a microtitre assay.
0.700
0.600
0.500
0.400
0.300
0.200
0 .1 0 0
0 .0 0 0
30 40 50 60 70 80 90 100 H O
F r a c t i o n  n u m b e r
100
90
80
70
60
50
40
30
20
10
O
% r
edu
ctio
n 
in 
gro
wth
Figure 5.20 - Binding of W.mrakii (K-500) killer factor to G-25 Sephadex. 
Killer toxin (Al) was incubated with G-25 Sephadex for 1 hour at 20°C and 
removed by centrifugation. Residual toxin activity (A2) in the supernatant, and 
in subsequent water and salt washes (A5), was measured by microtitre assay 
against C.glabrata (S-388). The effect of 0.1 M NaCl (A6) on the assay system 
was also investigated.
Volume of toxin (jil)
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5.10 Discussion
It was the purpose of the work reported in this chapter to characterise the killer toxin of 
W.mrakii (K-500) in terms of its biochemical properties and to attempt a purification of 
the killer factor produced using the techniques of FPLC and gel filtration 
chromatography.
It was found that the killer toxin produced by W.mrakii K-500 was stable up to 24 hours 
at 4°C and 18°C, however, the inherent stability was reduced as incubation 
temperatures were increased. 80% of the toxin activity remained at 25°C over the same 
time period, but was reduced to 5% at a temperature of 30°C. The toxin was stable at 
this temperature for up to 6 hours, but a steady decrease in activity followed thereafter. 
At 37°C, toxin activity was reduced after 5 hours and was completely inactivated 
between 7 and 24 hours (Figure 5.1). The killer factor was readily inactivated at 
temperatures exceeding 50°C and showed no resistance to high temperature treatment. 
The optimum pH of the killing activity of the toxin in an agar diffusion bioassay was 
found to be pH 3.5 (Table 5.1). However, the killing action of the toxin was reduced at 
pH’s up to pH 4.5, and inactivation occurred at pH 5.0. It cannot be discounted, 
however, that the pH of the agar system directly affected the growth of the sensitive 
strain, as can be seen by the failure of S-388 to grow at pH 7.0 and above. It may be that 
pH 3.5 was the optimum growth pH for the sensitive Candida strains or the pH of the 
surrounding medium affected receptor development on the sensitive yeast cell. Using a 
microtitre assay of toxin activity it was found that the killer factor was stable between 
pH 2.4 and 4.0 over a period of 18 hours. The killer factor was, however, rapidly 
inactivated at pH’s above this (Figure 5.2). Therefore, it is feasible that the optimum 
killing activity does in fact lie within this range at pH 3.5. The range of toxin stability 
may be extended if preparations are maintained at specific values for shorter periods of 
time.
The information obtained further distinguished the killer factor produced by K-500 from 
that produced by the strain LKB 169. A previous report by Ashida et al. (1983), stated 
that the killer toxin produced by a strain of W.mrakii, LKB 169, was stable to boiling at 
100°C for 3 minutes when maintained at pH 4.0, and was stable over the range pH 2.0- 
11.0. No mention was made of the stability of the toxin at reduced temperatures.
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Extreme variation in the temperature and pH profiles of toxin action exists between 
killer yeasts from different genera and between strains of the same species. Woods et al. 
(1974) reported that a toxin of the killer yeast S.cerevisiae was stable between pH 4.6-
4.8 and was totally inactivated after incubation at 32°C for 30 minutes. Shimizu et al. 
(1985), however, observed that the toxin from another S.cerevisiae  killer yeast was 
stable between pH 2.9-4.9 and at a temperature of 30°C for several days, but was 
inactivated at 48°C after 10 minutes. The numerous reports agree, however, that the 
killer factors produced are generally inactivated above pH 5.0 and are labile to 
temperatures exceeding 45°C. Exceptions to this include the toxin of LKB 169 (Ashida 
et al., 1983) and a chromosomally-inherited toxin in S.cerevisiae (Goto et al., 1990) 
which was stable to pH 7.5. The potential of toxin preparations to be used directly as 
novel therapeutics may, therefore, be limited because of their narrow range of stabilities. 
However, the differences observed in the physical properties further indicates that 
structurally distinct killer factors are produced by different killer yeasts, a property 
which could be exploited further in their classification.
The effect of the proteolytic enzymes pepsin and pronase on killer toxin activity in two 
strains of W.mrakii, K-500 and K-LKB, was investigated. The toxins were incubated 
with each enzyme or a suitable control, which assessed the effect of the enzyme’s 
diluent, distilled water (pepsin) or CaC^ (pronase), on toxin activity. Boiled controls 
also insured that any toxin inactivation produced was dependent on the catalytic activity 
of the enzyme.
The results (Figure 5.5) suggested that both toxins were insensitive to the action of 
pronase and pepsin. This is similar to the findings of Young and Yagui (1978), however, 
their study indicated that the killer factor of W.mrakii K-500 was also sensitive to native 
papain at a pH of 4.2 or pH 4.6. Components present within the concentrated culture 
supernatants may protect the toxin from proteolytic digestion and this would explain the 
insensitivity of the toxin preparations to pepsin and pronase. Alternatively, the toxin 
may contain a carbohydrate moeity, as in the K.lactis toxin (Stark et al., 1990), which 
interfered with proteolytic digestion. However, in all likelihood, the amino acid 
composition of the killer factors are such that there were insufficient, or incorrect, sites
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for proteolytic cleavage by the two enzymes investigated. High temperature treatment 
(boiling for 10 minutes) destroyed all activity in the killer factor produced by strain K- 
500, however, 60-80% of the activity of the killer toxin of K-LKB remained. This 
stability to high temperatures was suggested by the earlier work of Ashida et al. (1983).
Initially killer toxin activity was detected in the retentate fraction, greater than 10 kDa, 
following Amicon ultrafiltration of the extracellular medium (see section 4.3). The 
media used and the subsequent processing of cultures, suggested that the amount of 
extraneous proteins and polypeptides present in the retentate would be minimal. 
Therefore, it was hoped that analysis of this fraction would yield valuable information 
concerning the killer factor of W.mrakii (K-500).
The Pharmacia PhastSystem allowed a fast, high resolution and reproducible 
electrophoresis and isoelectric focussing to be performed on proteinaceous material. A 
microprocessor within the system regulated all parameters during the separation and 
development of gels and results were available within 2 hours. It was hoped that the 
system would allow a rapid, preliminary assessment of some of the characteristics of 
W.mrakii (K-500).
IEF is a high resolution method in which proteins are separated in the presence of a 
continuous pH gradient. Under these conditions, the proteins migrate according to their 
charges until they reach the pH values at which they have no charge i.e. their isoelectric 
points (pi). The proteins achieve a steady state of zero migration and they are 
concentrated and focussed into narrow zones (Dunn, 1989). The estimated isoelectric 
points of the components of the crude toxin lay between pH 4.35 and pH 5.80, which 
was consistent with the toxin of W.mrakii being acidic (Table 5.3). This also explained 
the change in colour from blue to yellow when the toxin was prepared in boiling mix for 
SDS-PAGE analysis. A protein with an isoelectric point of 6.15 was present in both the 
toxin sample and the media control, therefore, it was assumed that this did not 
contribute to the action of the toxin. Five other proteins with distinct isoelectric points 
were visualised following silver staining, but it was not determined which, if any, of 
these bands possessed killer activity. No bands were visible after high temperature 
treatment which suggested that the proteins were denatured and their physical structure 
irreversibly damaged.
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Sodium dodecyl sulphate, SDS, an ionic detergent is an effective solubilising agent for a 
wide range of proteins. The detergent binds to, and masks, the intrinsic charge of the 
polypeptide chains, so the net charge per unit mass becomes constant. Therefore, 
subsequent electrophoretic separation is dependent only on molecular size (Dunn, 
1989). A weakly-stained band was detected on the silver-stained PhastGel, with an 
apparent molecular weight of 16 kDa. It was suprising that only a single band was 
present in such a crude preparation, especially when previous IEF analysis highlighted 
the presence of five protein bands, however, they may have been present in amounts 
below which they could be detected. Further attempts to detect protein bands in toxin 
preparations, by electrophoresis on Mini-Gels or PhastSystem gels, were unsuccessful. 
This suggested that the band previously visualised was not in fact toxin protein. If 
present, small polypeptides and peptides, generally less than 10 kDa, cannot be 
separated by the traditional SDS-PAGE system. The small molecules form SDS-protein 
complexes of the same dimension and charge which migrate rapidly during 
electrophoresis and fail to be resolved or distinguished from the dye front. However, 
addition of urea, a solute which reduces the size of detergent micelles, can overcome 
this problem (Swank and Munkres, 1971). Subsequent work suggested that the 
molecular weight of the toxin was in fact smaller than 5 kDa (see section 5.9), therefore, 
use of this modified system may have allowed separation of the toxin proteins. Sawant 
et al. (1989) suggested that the appearance of unusually large molecules during 
electrophoresis, and the shift of peaks during purification of the killer toxin of
P.anomala by ion-exchange chromatography, was a result of the aggregation of toxin 
molecules. Therefore, the appearance of a band corresponding to a size of approximately 
16 kDa, may have been due to the aggregation of several smaller toxin molecules.
The separation of components present in crude toxin preparations was necessary to 
further investigate the properties of the secreted killer factor of W.mrakii (K-500). 
Electrophoretic patterns suggested a simple mixture of proteins was present in partially 
purified extracts, therefore, immediate use of Fast Protein Liquid Chromatography 
(FPLC) appeared to be the most profitable approach.
FPLC was developed for a high performance separation of biomolecules such as 
proteins, peptides and amino acids. The separations are rapid, of a high resolution and
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have full biocompatibility for the maximum recovery of biological activity. A Mono Q 
ion-exchange column was used for the separation of the components of W.mrakii (K- 
500) killer toxin. Mono Q is an anion exchange column carrying a positively charged 
ligand which will bind and exchange negatively charged molecules. When a protein is at 
its isoelectric point (pi), it possesses no net overall charge, at pH’s above its pi it is 
negatively charged and pH’s below it is positively charged. The column was 
equilibrated with a buffer of specific pH before a sample of killer toxin was loaded. 
Components of the crude preparation passed over the column if positively charged, or 
they were bound to the column by varying degrees depending on the overall charge. 
Bound proteins were removed by a linear gradient of buffered NaCl, negatively charged 
proteins were replaced by Cl" ions, and washed out in the eluant. Fractions were 
collected and assayed for activity.
An initial separation using 20 mM TRIS, pH 8.0 yielded four main protein peaks 
(Figure 5.6a). The increasing activity displayed by fractions from these peaks, A 
through to D (Figure 5.6b), was in all likelihood, a direct effect of the increasing salt 
concentrations present in the eluting buffer. Selected fractions from a blank gradient 
control produced increased growth inhibition of the indicator strain in a microtitre assay 
(data not shown). Inhibition increased as the amount of buffer B and, therefore, salt, 
present in the elution buffer increased. The pH of the system was much greater than the 
pi’s determined previously for the components of the crude toxin, therefore, a negative 
charge would be imparted on the proteins. This would result in strong binding of the 
proteins to the column and their subsequent detection may have been masked by the 
high concentrations of Cl" ions present in the samples. A pH 4.0 (20 mM N- 
methylpiperazine) buffer system was used and the results indicated (Figure 5.7a and 
5.7b) that the active toxin was present in the unbound fraction and, at a pH below their 
pi, the active components carried a positive charge. The pH of the following buffer 
systems were raised to impart a slight negative charge on the protein, so that it bound 
early on the column and would be readily eluted by low levels of Cl" ions. Use of a pH
6.0 (20 mM bis TRIS) buffer system yielded a single fraction with lethality against a 
sensitive strain (Figure 5.8b). A further increase to pH 6.5 (20 mM bis TRIS propane) 
resulted in the separation of several proteins (Figure 5.9a), however, none could be 
conclusively assigned toxin activity (Figure 5.9b).
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Toxin activity was consistently detected in unbound material removed from the column 
when buffer systems between pH 4.0 and 6.0 were used. However, when the pH of the 
buffer system was increased to above pH 6.0, toxin activity was ‘lost’ from the unbound 
fractions. Interference in the microtitre assay, caused by increasing salt concentrations in 
the elution buffer, appeared to be delayed to later fractions (36-45) in buffer system 4 
(Figure 5.9b). In buffer system 3 (Figure 5.8b) the ‘salt effect’ was observed in fractions 
20 to 40. This suggested the presence of toxin protein in fractions removed from the 
column in the former system, however, activity could not be accurately assigned to any 
of the bound proteins. Repeated attempts were made to apply, and separate, components 
of the toxin at pH’s above their isoelectric points, but no clear toxin activity was 
detected. It is possible, therefore, that the killer factor was inactivated by the increased 
pH of the buffer systems used, there was irreversible binding of active components to 
the column or, the activity present in the eluted fractions fell below the threshold limit 
of the assay system.
Due to difficulties experienced in the purification of the killer factor produced by 
W.mrakii using FPLC, an alternative method involving gel filtration chromatography 
was attempted. The separation of material using this technique depends on the different 
abilities of the sample molecules to enter pores in the gel matrix which contain the 
stationary phase. Very large molecules which do not have access to the stationary phase 
pass rapidly through the chromatographic bed. Smaller molecules which can enter the 
gel pores, move more slowly through the column since they spend a proportion of their 
time in the stationary phase. Molecules are eluted, therefore, in order of decreasing size. 
Each Sephadex G-type has a different molecular weight range over which molecules can 
be fractionated. Those species with molecular weights above the upper limit of this 
range are totally excluded from the gel matrix and are eluted at the void volume. The 
void volume in each case was determined by the passage of the indicator molecule blue 
dextran (1x10  ^Da) through the column.
Previous work had suggested that the molecular weight of the toxin was greater than 10 
kDa, therefore, use of a G-25 Sephadex matrix (fractionation range 1-5 kDa) would 
provide a ‘clean-up’ step to remove any low molecular weight salts and carbohydrate 
from the crude toxin preparation. A molecule of known molecular weight, Ribonuclease
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A (13.7 kDa), was applied to the commercial (9 ml bed volume) column to check the 
homogeneity of the bed and the effective elution of proteinaceous material. As expected 
the protein was excluded from the Sephadex matrix and was eluted at the void volume 
of the column in fractions 4-8. Crude toxin (1 ml of 100 mg/ml dry weight of 
lyophilisate) was applied to the column and two proteins were separated (Figure 5.14). 
A large peak (A) was eluted at the void volume and was not associated with toxin 
activity, however, the smaller protein peak (B) displayed lethality against the indicator 
strain C.glabrata in a microtitre assay. Protein (B) was eluted after the void volume of 
the column which suggested that its molecular weight fell within the fractionation range 
of the dextran matrix. The relatively high activity associated with fractions 20-25 was, 
in all likelihood, an effect of salt or low molecular weight carbohydrate present in the 
crude toxin preparation.
A larger column was prepared to enhance the resolution of the separation of components 
within the toxin sample. A more concentrated preparation (200 mg/ml dry weight) was 
applied to a 70 ml column of G-25 Sephadex and a very similar elution profile was 
achieved (Figure 5.15). Protein (A), the large molecular weight material excluded from 
the column, was eluted in fractions 16-22 and possessed no killing activity. Toxin 
activity was, however, associated with fractions 32-38. Similarly, toxin activity was 
associated with fractions 80-89 (Figure 5.16), when components of the toxin were 
separated on a 700 ml column. In both cases, toxin activity did not appear to be 
associated directly with a protein peak, but rather the area between the eluted doublet, 
(B) and (C).
It was surprising that the proteins eluted at the void volume showed no toxin activity, 
but the active component of the preparations was separated on the column. The 
molecular weight, hitherto assumed to be a minimum of 10 kDa may be as low as 5 
kDa. The active fractions from the latter separation, were pooled and concentrated by 
freeze-drying. They were applied to a P2 Biogel (fractionation range 100-1800 Da), to 
confirm that the active component of the killer toxin preparation was not a large protein 
but a small peptide. The two protein peaks eluted at the void volume of the column 
(Figure 5.17) displayed killing activity, which suggested that the active component 
possessed a minimum molecular weight of 1800 Da. This molecular weight was 
significantly smaller than any other previously reported. The K1 killer toxin of
P age 168
S.cerevisiae has a molecular weight of 20,658 Da (Zhu et al., 1987), the glycoprotein 
toxin of P.anomala WC 65, a molecular weight of 83,300 Da (Sawant et al., 1989) and 
P.kluyveri 19,000 Da (Middelbeek et al., 1979). However, the smallest toxins reported 
to date are produced by yeast of the same genus, W.mrakii LKB 169, produces a toxin 
of 8,900 Da (Ashida et al., 1983), and W.satumus one of 8,500 Da (Ohta et al., 1984). 
The size of the molecule was consistent with the killer factor acting as an ionophore on 
sensitive yeast strains (section 6.5). Similarly, the bacteriocins nisin and subtilin 
produced by Streptococcus lactis and Bacillus subtilis respectively, are low molecular 
weight peptides with broad-spectrum activity against Gram-positive bacteria, including 
many pathogenic food spoilage organisms (Hansen et al., 1989).
Most proteins exhibit an absorption maximum at 280 nm which is attributable to the 
phenolic group of tyrosine and the indolic group of tryptophan. The UV spectra of the 
active fractions 35+36 (X) and 36+37 (Y), eluted at the void volume of the P2 Biogel 
column were measured (Figure 5.18). The absorption maximum (^max) of the active 
fractions was approximately 257 nm and there was very little absorption at 280 nm. This 
explained why the toxin activity appeared to lie between the two protein peaks separated 
by gel filtration chromatography. If the molecular weight of the active toxin molecule 
was small, approximately 15-20 amino acid residues, it was not surprising that 
tryptophan and tyrosine were absent, hence, the reduced A,max. A similar situation to 
that observed was reported by Sawant et al. (1989) when attempting to purify the killer 
toxin produced by P.anomala WC 65. Very little absorption at 280 nm was found and a 
failure to detect the toxin protein by Bio-Rad dye-binding procedures led to the 
suggestion that hydrophobic residues in the tertiary structure of the glycoprotein were 
masked by a carbohydrate moeity, or there were in fact almost no hydrophobic sites.
A 10 ml sample of concentrated crude toxin was applied to the largest (700 ml bed 
volume) column in an attempt to ‘bulk up’ active material for further analysis. A 
slightly different elution profile was obtained during this separation (Figure 5.19), 
however, the active protein was eluted in fractions 67-75, the same volume of eluant 
being required to remove the active components as in earlier separations. Total toxin 
activity was measured (Table 5.5) and only 5% of that originally loaded was removed. 
Earlier stability experiments suggested that the toxin was stable to ambient temperatures 
for up to 24 hours (Figure 5.1), therefore, it was unlikely that toxin activity was lost as a
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result of the separation. The killer toxin of S.cerevisiae was reported (Woods and 
Bevan, 1968) to exhibit a tendency to be adsorbed to Sephadex during purification, 
therefore, it was proposed to investigate the potential adsorption of W.mrakii killer toxin 
to Sephadex G-25.
A sample of W.mrakii killer toxin was incubated with pre-swollen Sephadex and then 
the slurry was centrifuged to remove the dextran matrix. Toxin activity in the resultant 
supernatant was measured (A2) and it was found that 60% of the initial activity (Al) 
was recovered at this stage. Negligible levels of toxin activity were detected following 
distilled water washes of the Sephadex, and only low levels following a salt wash (A5).
0.1 M NaCl was found not to significantly affect the indicator strain used in the 
microtitre assay (A6) (Figure 5.20). The results suggested that the remaining 40% of 
toxin activity was bound to the Sephadex. However, it was possible that following 
centrifugation it was present within the bed volume of the dextran matrix. Consequently, 
if the toxin was removed during the washing stages it may have been diluted to the 
extent that its activity fell below the threshold of the microtitre assay. Although the 
results of this experiment were inconclusive, they do suggest that binding of toxin 
molecules to the chromatographic bed alone would not explain the extensive loss of 
toxin activity observed during gel filtration. It was possible that there was a dissociation 
of the active components of the toxin during separation and this resulted in a reduction 
in the activity recovered from the column. Complementation studies were conducted 
where all fractions, or groups of fractions, eluted from the column were combined and 
assayed for toxin activity. No lethality against the indicator strain C.glabrata (S-388) 
was detected (data not shown).
The microtitre assay used to assess the toxin activity of culture supernatants, or partially 
purified material, relied on growth or no growth of the seeded indicator strain. The assay 
was sensitive to relatively low concentrations of killer factor present in culture broths, 
however, it displayed a marked ‘threshold limit’ below which no activity was detectable 
(Figure 5.21). This threshold covered a very narrow range (x) and only a small increase 
in toxin concentration was necessary to produce extensive inhibition of the sensitive 
strain. This suggested that a critical number of toxin molecules were required to bind to, 
or react with, the sensitive strain to produce a toxic effect. Dilution of the toxin activity
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Figure 5.21 - Theoretical plot to show the ‘threshold limit’ of the growth reduction 
microtitre assay.
Volume of toxin (jil)
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to below the threshold limit during separation by gel filtration chromatography led to 
inconclusive results. Concentration of the fractions was, therefore, necessary to detect 
lethality in the sensitive strain. The simplicity of the growth reduction microtitre assay 
also led to its sensitivity to salt concentrations in FPLC buffers, thus toxin activity was 
‘masked’ by the salt present in the eluted fractions. It was hoped to develop an assay 
system which was sensitive to low toxin concentrations and was unaffected by salt in 
the buffer systems employed in the separation techniques.
Many biological assays require the measurement of surviving or proliferating cells. This 
can be achieved by several methods including the counting of cells which include or 
exclude a dye, measurement of the incorporation or release of a radioactive label or a 
spectrophotometric assay which relies on a distinct colour change. Ideally a 
colourimetric assay for living cells will utilise a substrate that is modified to a coloured 
product. Tetrazolium salts measure the activity of dehydrogenase enzymes in living 
cells (Slater et al„ 1963), the tetrazolium ring is cleaved only by active mitochondria. 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] has been used to 
develop a quantitative assay for mammalian cell survival, cytotoxicity and proliferation 
(Mosmann, 1983), to measure candidacidal activity of mouse neutrophils (Ashman,
1986) and more recently in an assay system to assess the biological activities of toxins 
produced by the plant pathogen Alternaria alternata (Lee et al., 1991). Based on the 
assumption that the killer toxin of W.mrakii affects sensitive cell viability (see section 
6.1), MTT could be used to develop a colourimetric assay system which quantitatively 
assessed toxin-treated cells.
The growth phase of the indicator strain C.glabrata was important to the success of the 
assay. Log-phase cells, presumably with increased mitochondrial activity, were 
necessary for the reduction of the MTT-dye to MTT-Formazan. Stationary-phase cells 
had no effect on the cleavage of MTT to the blue end-product (data not shown). The 
time course conducted (Figure 5.13) suggested that a 60-90 minute incubation period of 
the toxin with the sensitive cells was sufficient for maximum reduction of MTT by 
Candida blastospores. Based on this result, a 90 minute incubation system was used as 
the standard in following experiments. The MTT-Formazan reaction product is only 
partially soluble, therefore, acidified isopropanol was used to fully dissolve the product
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and produce a homogenous solution for absorbance measurements to be made 
(Mosmann, 1983).
Figure 5.10 showed that the conversion of the dye, and measured absorbance, increased 
with cell numbers and that dead yeast cells produced no reduction of MTT. The 
inactivation of the heat-killed cells was verified by a failure to grow on SDA plates. 
Successive experiments showed that a minimum of 1x10  ^cells/ml were also required 
for significant conversion of the dye. This ability to distinguish between live and dead, 
hence, viable cells was the basis for the assay system which developed.
After exposure to W.mrakii killer toxin the sensitive cells were reduced in their ability to 
produce MTT-Formazan (Figure 5.11). At high toxin concentrations (0.20 pl/ml) there 
was very little conversion of MTT to MTT-Formazan, hence, the low absorbance value 
of 0.059. At lower toxin concentrations (0.008 pl/ml), extensive conversion of the dye 
occurred (absorbance = 0.465), indicating that mitochondrial enzyme activity was intact 
in these cells.
To confirm that W.mrakii killer toxin was affecting sensitive cell viability and hence, 
MTT-dye conversion, a comparison was made between the colourimetric assay and 
traditional plating techniques (Figure 5.12). The reduction in viability of the sensitive 
cells with respect to increasing toxin concentrations was measured, and the subsequent 
reduction in the numbers of colonies produced, correlated with the decreased conversion 
of MTT to MTT-Formazan.
It was important also to determine if the assay was applicable to the detection of killer 
toxin activity in solutions which contained high levels of salt i.e. eluted fractions from 
FPLC separations. A toxin preparation was diluted in solutions containing a range of 
concentrations of the FPLC buffers 20 mM bis TRIS propane (buffer A) and 20 mM bis 
TRIS propane + 1.0 M NaCl (buffer B). Although an increase in the amount of buffer B, 
hence, the amount of salt present in the solutions, reduced the conversion of MTT to 
MTT-Formazan, residual levels of toxin activity were still detectable. Over the range of 
0-100% buffer B a 50-64% reduction in viability of a sensitive strain indicated that the 
assay was sensitive to the same number of toxin molecules in each case.
Concentrated toxin preparations were used to develop the assay, however, results 
suggested that toxin activity could be detected directly from cell-free supernatants at the 
completion of fermentation of the killer yeast, but it may not be sensitive to the initially
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low levels of toxin produced. The assay also provided a rapid system (5 hours from the 
initial incubation) for analysis of samples when compared to agar diffusion bioassays 
(2-3 days) and microtitre assays (24 hours), which is an important consideration in 
downstream processing and purification. These results confirmed the potential of the 
dye-reduction assay as a means of quantitatively assessing the action of killer toxins on 
sensitive strains of Candida.
P age 174
5.11 Conclusions
W.mrakii (K-500) killer toxin was stable for several hours at temperatures up to 37°C, 
but was readily inactivated within minutes at temperatures exceeding 50°C. The killer 
factor was stable only over a narrow range of pH 2.4-4.0 and above pH 5.0, killing 
activity in agar bioassay systems was lost. The toxin was insensitive to the action of the 
proteolytic enzymes pepsin and pronase, however, further evidence suggested that the 
toxin molecule was proteinaceous. The isoelectric points of components of the crude 
toxin, pi 4.35-5.80, were consistent with the toxin being acidic.
Purification attempts using FPLC ion-exchange techniques achieved separation of the 
components of the toxin preparation, however, it was not possible to accurately assign 
activity to the fractions when eluted by the linear salt gradient. Gel filtration of crude 
toxin using Sephadex G-25 and P2 Biogel columns suggested that the molecular weight 
of the killer factor was between 1800-5000 Da. The wavelength of maximum absorption 
of the active fractions was found to be 257 nm, which was consistent with the toxin 
being a small polypeptide, devoid of large aromatic residues. Both findings were in 
agreement with the hypothesis that the killer toxin of W.mrakii acts as an ionophore on 
sensitive yeast strains. Purification has been hampered by the large losses of toxin 
activity observed during chromatographic procedures. Although it remains unexplained 
this may be due to partial binding of the killer factor to the chromatographic bed, or 
dissociation of the active components during separation.
The microtitre assay of toxin activity relied on growth, or no growth, of an indicator 
strain and was sensitive, therefore, to increasing salt concentrations in the elution 
buffers. An MTT-colourimetric assay was developed which was based on the reduction 
of a dye by viable cells with intact mitochondrial enzyme activity. The assay accurately 
distinguished between live and dead, or toxin-treated, cells of a sensitive strain of 
C.glabrata, was sensitive to increasing amounts of toxin and was able to detect toxin 
activity at high salt concentrations. This assay has the potential to accurately assess 
toxin activity and, therefore, would be important in any future purification work.
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CHAPTER SIX
Mode of Action of W illio p sis  m ra k ii Killer 
Toxin Against Sensitive Yeast Strains
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6.1 Introduction
Most studies which are concerned with the mode of action of yeast killer toxins have 
been conducted with the K1 killer protein of S.cerevisiae. The toxin must adsorb to a 
primary receptor located on the sensitive yeast cell wall (Al-Aidroos and Bussey, 1978; 
Bussey, 1991), but although this cell wall receptor is necessary for toxin action it does 
not appear to be the only component involved in the killing process. Evidence suggests 
the involvement of a second receptor on the plasma membrane (Bussey et al., 1979). 
Binding at this level results in the disruption of ion gradients, interrupting the coupled 
transport of H+ and amino acids (de la Pena et al., 1981), and the formation of leak 
pathways across the membrane (Kagan, 1983).
Preliminary studies were conducted to investigate the mode of action of W.mrakii (K- 
500) killer toxin on sensitive strains of Candida. The effect of growth phase on 
sensitivity to the killer toxin and the effect of the killer factor on growth kinetics and 
sensitive cell viability were investigated. The possibility that K-500 killer toxin 
produced lethality in Candida strains by causing membrane damage was also 
investigated.
6.2 Effect of Growth Phase on Sensitivity to W.mrakii Killer Toxin
Initially, a profile of the growth of the indicator strain C.glabrata (S-388) was 
determined. Stationary phase cells were inoculated into fresh media and incubated at 
30°C, with shaking. At hourly intervals cells were removed and their numbers 
determined using a haemocytometer. Figure 6.1 shows a typical growth curve for the 
sensitive strain. Under the conditions described, cells entered an exponential phase of 
growth after an initial lag period of two to three hours, and then progressed into 
stationary phase after seven hours.
The activity of the killer factor against cells removed at the different stages of the 
growth cycle was assessed using a microtitre assay (section 2.11.1). ‘Sensitivity 
profiles’, showing the response to increasing amounts of killer toxin, were determined 
for each group of cells (Figures 6.2 A and B). Figure 6.3 further highlighted the growth 
inhibition produced by various concentrations of toxin assayed against cells of different
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Figure 6.1 - Typical growth curve of the indicator strain C.glabrata (S-388). Stationary 
phase cells were transfered to fresh media (YNBGS) and incubated, with shaking, at 
30°C. Cell counts were made using a New Improved Nebauer haemocytometer.
Sample tim e (hours)
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Figure 6.2 - The effect of growth phase of the indicator strain on sensitivity to W.mrakii 
(K-500) killer toxin. Cells from various stages of growth (A, 1-3 hours; B, 5-8 hours) 
were removed and their sensitivity to 10-100 pi of concentrated cell-free supernatant 
from a five day batch culture was assessed using a microtitre plate assay.
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F igu re  6.3 - Sensitiv ity  o f  cells o f  C .g la b r a ta  (S -388) from su ccessive  stages o f  the
growth cycle  to 10-100 |xl o f  concentrated cell-free supernatants from a five  day batch
culture o f  W .m rakii (K-500).
Age of ce lls  (hours)
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ages. At high toxin levels (100 pi) the effect on sensitive cells was the same irrespective 
of the phase of growth from which they were removed, in all samples complete 
inhibition of growth was produced. At lower toxin levels (75 pi) the effect was more 
pronounced, with stationary phase cells being more susceptible to toxin action than 
exponential phase cells. The latter, in a phase of active growth, were 30-40% less 
sensitive to toxin action. At very low toxin levels (25-10 pi) cells showed little response 
to the killer factor irrespective of their growth phase.
6.3 Effect of W.mrakii Killer Toxin on the Growth Kinetics of Sensitive Candida
The effect of W.mrakii (K-500) killer toxin on the growth kinetics of three strains of 
C.albicans, 2005E, 2402E and C316, was investigated. A microtitre plate assay was set 
up as described in section 2.11.2 and was incubated at 30°C in an automated 
spectrophotometer. Growth of each strain, in the presence of different amounts (10-100 
pi) of killer toxin, was monitored by measurement of absorbance (450 nm) at 15 minute 
intervals. Growth was measured over a 24 hour period and the data collated in situ to 
produce growth curves for each incubation.
W.mrakii killer toxin produced growth inhibition in three isolates of C.albicans. The 
effect of critical volumes of toxin on the growth of each isolate are displayed in Figures 
6.4, 6.5 and 6.6. As the amount of toxin present in the assay system increased above a 
critical level, there was an increase in the lag phase before entry of the cells into an 
exponential phase of growth. The extent of growth, as measured by absorbance readings 
at 450 nm, was also reduced over a 24 hour period.
The effect of increasing amounts of toxin on the growth rate, hence, cell division, during 
the exponential phase of growth of each isolate was calculated (Figure 6.7). Each strain 
displayed a differential sensitivity to toxin action. C316 was the most sensitive and 
incubation with 10 pi of killer toxin directly affected the rate of cell division. Complete 
inhibition of growth was produced when C316 was incubated with 40 pi of toxin. 
Higher volumes of toxin, 40 pi and 80 pi, were required to affect the growth rates in 
strains 2402E and 2005E, respectively.
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F ig u re  6 .4  - T he e ffec t o f  critical vo lum es o f  W .m ra k ii  (K -500) k iller toxin  on the
growth kinetics o f  a sensitive strain o f C .a lb ic a n s  (2402E). Growth was monitored over
a 24 hour period using an automated spectrophotometer.
Figure 6.5 - The effect of critical volumes of W.mrakii (K-500) killer toxin on the 
growth kinetics of a sensitive strain of C.albicans (2005E). Growth was monitored over 
a 24 hour period using an automated spectrophotometer.
Page 182
F ig u re  6 .6  - The e ffec t o f  critical vo lu m es o f  W .m ra k ii  (K -500) k iller tox in  on the
growth kinetics o f  a sensitive strain o f  C .a lb ica n s  (C316). Growth was monitored over a
24 hour period using an automated spectrophotometer.
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Figure 6.7 - The effect o f  W .m rakii (K -500) killer toxin on the growth rates o f  sensitive
strains o f C. a lb ica n s , 2402E, 2005E and C316 over a 24 hour period.
V olum e toxin  (jil)
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The effect of concentrated crude toxin preparations on the sensitive strain C.glabrata S- 
388, was conducted as described in section 2.11.3. Late-log phase cells of S-388 were 
incubated with the toxin (cell-free supernatants were concentrated five and 10-fold by 
freeze-drying and reconstitution in fresh media) and, at intervals, samples were removed 
to assess the number of viable cells which remained and also the extent of toxin binding 
to the sensitive cells. The latter was assessed by measurement of the residual toxin 
activity, after removal of the cells by centrifugation, in the supernatants in comparison 
to activity present in the starting material.
The first incubation of sensitive cells with the killer factor of W.mrakii (concentrated 
five-fold) showed that toxin binding closely paralleled the decrease in sensitive cell 
viability (Figure 6.8). A slight loss of toxin activity present in the supernatants indicated 
the onset of toxin binding within the first 15 minutes of incubation. After 30 minutes, 
90% viable cells remained and 10% of the available toxin was bound. Between 30 
minutes and 2 hours there appeared to be a slight recovery in the number of viable cells 
present and this coincided with an apparent loss of bound toxin from the sensitive cells. 
However, over the remainder of the experiment a steady decrease in sensitive cell 
viability occurred and 66% of the cells were viable after a 20 hour period. At this time, 
50% of the original activity was bound to the cells. After 67 hours, only 6% of the 
remaining cells were viable and produced colonies on SDA and 34% of the initial killer 
activity was detectable (data not shown). To confirm that the observed decrease in toxin 
activity was not as a direct result of its instability under the conditions of the 
experiment, a separate sample of killer toxin was assayed for activity. It was found that 
the toxin maintained its activity over the period of the experiment.
Incubation of the sensitive cells with higher amounts of toxin (10-fold concentration) 
produced a more distinct effect (Figure 6.8). A small amount of toxin again bound to the 
sensitive cells within the first 15 minutes, however, this resulted in a 75% loss of 
sensitive cell viability. Within 2 hours 65% of the toxin activity was bound to the 
sensitive cells but with no further effect on viability. At the conclusion, only 20% of the 
original activity remained in solution and 3% of the cells were viable.
6.4 E ffect o f  W .m ra k ii K iller Toxin on Sensitive Cell V iability
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Figure 6.8 - The effect of W.mrakii (K-500) killer toxin on sensitive cell viability. Cells 
of C.glabrata  (S-388), at a seeding density of 3x10^ cells/ml, were incubated with 
concentrated preparations (5- and 10-fold) of crude toxin. At intervals the numbers of 
viable cells were determined by colony forming activity on SDA plates and toxin 
binding by measurement of residual toxin activity in the supernatants.
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A sample of crude W.mrakii killer toxin was tested in a membrane damage assay 
developed by Glaxo Group Research (see section 2.6.5). The assay involved the uptake 
of a radioactively-labelled non-metabolisable amino acid by actively dividing sensitive 
cells of C.albicans (2005E). Cells were incubated with toxin, or a toxin-free control 
(distilled water), in the wells of a microtitre plate and then harvested onto filter papers. 
The radioactivity of each incubation was measured and the extent of membrane damage, 
based on released radioactivity, was calculated with respect to the controls.
Results in Figure 6.9 showed that the extent of membrane damage caused in sensitive 
cells of C.albicans, increased as the amount of W.mrakii killer toxin, or protein, per well 
of the assay was increased. The amount of radioactive label released from the sensitive 
cells increased with the extent of damage caused by toxin treatment. A minimum 
inhibitory concentration (MIC) of 3.0 [ig/ml (relevant to the amount of protein in the 
assay) was observed. An initial sharp increase (15-95%) in the extent of membrane 
damage was produced over a narrow range of toxin concentrations (5.0-10.0 pg/ml), 
however, no further increase in membrane damage was seen at concentrations exceeding 
12.0 pg/ml.
6.5 W .m ra k ii (K-500) K iller Toxin Causes Membrane Damage
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Figure 6.9 - The effect of treatment of sensitive cells of C .glabrata  (S-388) with 
W.mrakii (K-500) killer toxin. The extent of membrane damage produced was expressed 
as the amount of radioactivity released from pre-loaded cells after toxin treatment, with 
respect to a non-treated control.
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6.6 Discussion
The mode of action and the lethal effects exerted by yeast killer toxins on sensitive cells 
have been investigated for only a few toxins. The K1 killer toxin of S.cerevisiae  is 
characterised by leakage of K+ (Skipper and Bussey, 1977), ATP and inhibition of 
macromolecular synthesis (Bussey and Sherman, 1973). The toxin of K.lactis causes the 
arrest of cell proliferation in Gj phase of the cell cycle (White et al., 1989), however, its 
exact mechanism of action still remains unknown. Previous studies with a strain of 
W.mrakii (LKB 169), suggested that this killer yeast produced a toxic protein which 
preferentially inhibited p-(l,3)-glucan synthesis (Yamamoto et al., 1986b), and it was 
hoped that the preliminary studies undertaken would give an insight into the mode of 
action of W.mrakii (K-500) killer toxin.
The growth phase of the sensitive strain plays an important role in the killer yeast 
phenomenon (Polonelli et al., 1991a). The killer toxin of W.mrakii (K-500) was more 
active against stationary phase cells of the indicator strain C .g la b ra ta , which 
contradicted all previous reports (Pietras and Bruenn, 1976; Tipper and Bostian, 1984). 
Woods (1966) reported that sensitive cells were more susceptible during active growth 
but were completely resistant during their stationary phase, and similar effects have 
been documented for the action of the bacteriocin megacin on strains of B a c illu s  
megaterium (Holland, 1962).
The susceptibility of C.glabrata was studied by comparing the extent of killing, or the 
percentage reduction in growth of the indicator strain, by killer toxin at different stages 
of the growth cycle. By assessing the effect of increasing amounts of toxin, ‘sensitivity 
profiles’ for each phase of cells were determined (Figure 6.2 A and B). An increase in 
the amount of toxin present in the assay resulted in further reductions in the growth of 
the sensitive yeast cells irrespective of their growth phase. All groups of cells were 
sensitive, to a greater or lesser degree, to the action of the killer toxin of W.mrakii, 
however, at certain toxin levels, differences in their susceptibilities became apparent. 
Figure 6.3 showed the effect of different amounts of toxin on cells from each growth 
phase. The highest amount of toxin in the assay (100 p,l) produced the same effect, 
complete growth inhibition, in cells sampled from each stage of the growth cycle. If a
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critical number of toxin molecules were required for inhibition of sensitive cell growth, 
it was possible that at these levels a ‘saturation point’ was reached where excess toxin 
molecules were present in relation to the number of available receptors on the sensitive 
yeast cell wall. At lower toxin levels (75 pi), the cells from each phase of growth 
showed differences in their sensitivity to the killer toxin. A 60-66% reduction in growth 
was produced in stationary phase cells (one and eight hour old cells), however, the same 
preparation produced only 20-40% reduction in exponential phase cells. This indicated 
that a critical level of toxin molecules had been reached, above the threshold limit of the 
assay (see section 5.10), which could differentiate between cells from various stages of 
growth. If the killer toxin of W.mrakii, in common with other killer yeasts, acted at the 
level of the cell wall, it was possible that fewer receptors were available for interaction 
with toxin molecules in exponential phase cells, or the receptors had less affinity for the 
toxin during their active phase of growth. Either of these possibilities could explain the 
reduction in growth inhibition observed in exponential phase cells. At lower 
concentrations, the levels of toxin molecules fell below the threshold limit of the assay, 
hence, the less pronounced effect observed.
The microtitre assay used to assess killer toxin activity displayed a threshold limit above 
which a very small increase in the concentration of toxin molecules present resulted in a 
pronounced reduction in sensitive cell growth. This suggests that more than one receptor 
site must be occupied on the sensitive cell for a lethal effect to be exerted, or there must 
be an aggregation of several toxin molecules at each receptor site.
The addition of W.mrakii killer toxin to cultures of sensitive strains of C.albicans led to 
an inhibition in the accumulation of cells over a 24 hour period (Figures 6.4-6.6). At 
critical volumes of toxin there was a reduction, or no further increase (C316, Figure 6.6) 
in the turbidity of the cultures. The killer toxin maintained cells in a lag phase and 
prevented, or inhibited, their progression into exponential growth and an increase in cell 
numbers. During lag phase, cells normally enlarge in size and there is extensive 
macromolecular synthesis. This period can be termed a ‘tooling up’ stage, during which 
growth of the cells occurs without cell division and there is an accumulation of 
molecules essential for cell division. Especially important are molecules of ATP which 
represent the supply of energy, ribosomes, required for protein synthesis, and any
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enzymes which may be required for growth (Nester et al., 1978). The killer factor of 
W.mrakii may cause an arrest early in the cell cycle, thereby preventing cells from 
enlarging and reaching the critical size necessary for continued growth and cell division. 
In a similar manner, the killer toxin of K.lactis is thought to arrest cells in the phase 
of growth. The addition of K.lactis toxin to cultures of sensitive cells of S.cerevisiae led 
to a block in the accumulation of cells and concomitant to this was a rapid and 
progressive loss in cell viability. Also in treated cultures, the proportion of budding cells 
in the population fell rapidly, and because Gj is the only phase of the cell cycle during 
which cells are unbudded, this was a clear indication of arrest in G j after toxin addition 
(White et a l, 1989). It was not determined at this time if the cessation of cell growth by 
W.mrakii killer toxin was linked to a loss of sensitive cell viability, or if there was a 
direct effect on the budding process.
During the exponential phase of growth, cells divide at their maximum rate. Sub-critical 
concentrations of toxin led to the slowing of growth rates in all three sensitive strains 
(Figure 6.7), therefore, fewer cells were accumulating over the same period of time 
when compared to a toxin-free control. The killer toxin may have reduced the number of 
viable cells in the culture, therefore, fewer cells entered cell division which resulted in 
slower growth rates, or fewer cells had enlarged to the size at which they were ready to 
divide.
The dose-response of the sensitive strains to the effects of the killer toxin again 
supported the hypothesis that a critical number of toxin molecules were associated with, 
or bound to, the sensitive cell to elicit a lethal or inhibitory event. The differential 
sensitivity observed between the three strains of C. albicans may, therefore, be a result 
of different numbers of receptors being available on the sensitive cell wall for toxin- 
receptor interactions.
According to de la Pena et al. (1980), killer toxin from a strain of S.cerevisiae bound to 
sensitive cells immediately after addition. However, 50% mortality was produced only 
after 40 minutes. A lag phase before the killer toxin exerted its action had previously 
been reported (Kotani et al., 1977; Skipper and Bussey, 1977), but de la Pena et al. 
(1981) later described an immediate effect on the co-transport of amino acids and H+.
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The early work conducted with the killer toxin of W.mrakii suggested that extensive 
growth inhibition was produced in sensitive strains of C.albicans, however, there was 
no direct evidence that the toxin produced a cidal effect. Subsequent studies showed that 
after initial toxin binding there was an immediate effect on sensitive cell viability 
(Figure 6.8), and the lag period prior to toxin action, previously reported, was not 
observed.
Two toxin preparations were employed to monitor the effect of W.mrakii killer toxin on 
the indicator strain C.glabrata (S-388), five-fold and 10-fold concentrated cell-free 
supernatants. Figure 6.8 shows the response of the sensitive cells to each preparation 
over a 20 hour period. In both cases, a minimal amount of toxin binding was apparent 
within 15 minutes, however, distinct differences in their effects on sensitive cell 
viability were observed. Binding of toxin from the more concentrated solution resulted 
in a 75% loss in the number of viable cells remaining within this 15 minute period. The 
initial response was followed by an increase (3-65%) in toxin binding over a two hour 
period, however, this only produced a further 10% loss in viable cells. This suggested 
that toxin molecules were possibly binding to dead, as well as, live cells and that the 
ultrastructure of the dead cells remained intact following toxin action. This allowed 
continued binding of the toxin to saturation.
When fewer toxin molecules were present, the effect on the sensitive cells was less 
pronounced. The same initial period of toxin binding led to only a 10% decrease in the 
number of viable cells remaining, and this was followed by an apparent recovery in both 
viability and the amount of toxin which was bound. The effect observed may have been 
the result of an intrinsic repair mechanism which existed within the sensitive yeast 
strain. Kotani et al. (1977) proposed a similar model for the action of the sake killer 
toxin. Cells exposed to killer toxin entered a transient state from which an irreversible 
reaction proceeded, this was enhanced by ATP and inhibited by Ca . It is, therefore, 
possible that when low levels of toxin were bound to the sensitive yeast a repair action 
allowed the reversal of sensitive cells to a normal state and continued growth. However, 
in time sufficient toxin molecules became bound (50%) to override the repair processes 
and this action was coupled to a loss in viability (34%). When a comparison is made 
between the two toxin preparations, it can be seen that for the less concentrated solution
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During a period of active research within Glaxo Group Research the killer toxin of 
W.mrakii was tested in a routine screen which assayed natural products for their ability 
to cause membrane damage in strains of C.albicans. Mid-log phase cells of the strain 
2005E were incubated with the radioactively labelled 2-[^C]-aminoisobutyric acid. 
The actively dividing cells took up the labelled amino acid which was not incorporated 
into protein by the cells, therefore, a ‘bag of radioactive label’ was produced. The 
loaded cells were incubated with increasing amounts of the killer factor or toxin-free 
controls. In the latter, the cell membrane remained intact and all radioactivity was 
maintained within the cells. Damaged cells, however, released the labelled amino acid 
because of an alteration in the integrity of the cell membrane.
Figure 6.9 shows the percentage membrane damage caused by increasing amounts of the 
killer toxin. Below concentrations of 3.0 |xg/ml no membrane damage was caused, 
perhaps an indication that insufficient toxin molecules were present in the assay to affect 
the cell membrane. Between 5.0 and 10.0 pg/ml there was a rapid increase in the extent 
of damage caused as a critical number of toxin molecules attached to, and acted upon, 
the sensitive cells. However, at concentrations exceeding 12.0 pg/ml there was no 
further damage caused when a saturation point was reached. It would appear, therefore, 
that in common with P.kluyveri and S.cerevisiae killer toxins, that the killer factor of 
W.mrakii causes membrane damage in sensitive yeast strains.
Genetic and biochemical studies of the action of the K1 killer toxin of S.cerevisiae  
indicated a series of specific cell surface interactions. The initial step involved the 
binding to a p-(l,6)-D-glucan-containing cell wall receptor (Boone et a l., 1990). 
Following binding to the cell wall, lethal physiological changes occurred at the plasma 
membrane and intoxicated cells showed reduced proton gradients, K+ efflux (de la Pena 
et al., 1981) and loss of ATP and small metabolites (Skipper and Bussey, 1977). It was 
suggested that these effects were as a result of the toxin forming transmembrane protein 
channels. Kagan (1983) showed that partially purified extracts of P.kluyveri induced the 
formation of ion-permeable channels in vitro in a lipid bilayer membrane. The measured 
conductance of the channels was sufficient to account for the in vivo K+, H+ and Cl"
a longer period o f  time was necessary for a comparable loss in viability to occur, after
which time a similar amount o f toxin binding had occurred.
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efflux, and the concomitant influx of Na+. More recently Martinac et al. (1990) 
demonstrated that the K1 killer toxin induced conductances in sensitive yeast 
sphaeroplasts and in artificial liposomes, and implicated these channels in the killing 
process. However, reports (Zhu and Bussey, 1991) that the K1 toxin killed sphaeroplasts 
of toxin insensitive whole cells of C.albicans, C .utilis and K .la ctis  but failed to kill 
those from W.mrakii and P.kluyveri suggests that perhaps other discriminatory events 
and components, apart from channel formation, are also necessary for the in vivo action 
of killer toxins.
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6.7 Conclusions
Growth phase of the sensitive yeast strain is an important consideration in the action of 
yeast killer toxins. In apparent contradiction to several previous reports, the killer factor 
of W.mrakii at its critical concentration exerts a greater effect on stationary phase cells 
than actively dividing cells in an exponential phase of growth.
Toxin-binding experiments suggested evidence for the presence of receptors on the 
surface of the sensitive cell wall, however, their exact nature remains unknown. At low 
concentrations, the killer toxin produces a fungistatic effect on sensitive yeast but at 
higher concentrations a capacity to cause membrane damage accounts for the fungicidal 
effects of the killer factor. The cidal nature of the toxin was reflected in a rapid loss of 
sensitive cell viability.
The lethality produced in sensitive yeast strains by W.mrakii killer toxin is likely to be a 
receptor-mediated action in common with other killer toxins and bacteriocins. These 
preliminary studies give an important starting point for understanding the undoubtedly 
complex nature of the interaction between the killer factor and its target sensitive yeast.
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CHAPTER SEVEN
Concluding Discussion
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7.1 Conclusions
Early findings during this research indicated the potential of killer yeasts and their 
toxins to be used as ‘natural antifungals’ against the medically important, opportunistic 
pathogen C. albicans.
A screen of putative killer strains showed that certain yeasts caused growth inhibition, 
or lethality, in other ‘sensitive’ strains by the release of a killer factor. The killer trait 
was not confined solely to any one genus or species and six of the eight genera tested 
displayed some degree of killing against each other or known sensitive strains of 
Candida and S.cerevisiae. The spectrum of action observed was, generally, not directed 
against one genus but rather an interspecific killing action was seen. Killer strains of 
S.cerevisiae, however, predominantly showed intraspecies killing as reported by Stumm 
et al. (1977). The killer-sensitive relationships observed between the killer strains 
allowed a grouping of the yeasts both in terms of killer and resistance phenotypes. As a 
means of further classifying the yeasts it was certainly less complex than biochemical 
analysis of the killer factor produced by each. Certain similarities with an earlier study 
(Young and Yagui, 1978) were apparent. However, the conditions of the agar diffusion 
bioassay can easily discriminate against either the killer or sensitive strain in terms of 
their optimal conditions for growth and production of the killer factor. Therefore, it was 
not unusual for such a study to show contrasting relationships between the different 
yeasts screened.
The highest proportion of killer strains were found in the genera Pichia  and W illiopsis 
(formerly Hansenula) which is in agreement with several earlier reports (Philliskirk and 
Young, 1975; Kazantseva and Zimina, 1989). A strain of W.mrakii (K-500) consistently 
showed a broad spectrum of activity against a range of yeasts and the killer factor 
produced was lethal to several strains of Candida. Strains of C.albicans have also been 
shown to be sensitive to toxins produced by Pichia  and Kluyveromyces (Morace et al., 
1984). As a consequence W.mrakii, and the toxin it produced, were investigated further 
in an attempt to provide information on a novel therapeutic approach which could help 
address the ever increasing problem of controlling Candida infections in hospitalised, or 
compromised individuals.
To further highlight the clinical importance of the killer factor produced, a screen 
against Candida strains isolated directly from clinical specimens was conducted. Initial
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findings suggested that a differential sensitivity to the killer yeast and its toxin existed 
amongst yeasts isolated from disparate sites within the body. W.mrakii was more active 
against lung and tracheal isolates than vaginal isolates, implying that a niche-specific 
response was being observed. This study was expanded to consider a larger number of 
specimens and although similar trends were apparent, no clear-cut relationship between 
the site of isolation and susceptibility to the killer toxin was found. Similarly, no 
correlation was observed between biotype and specimen collection site in a study 
conducted by Kandel (1988), although a significantly high proportion of blood isolates 
were found to be resistant to toxin action. As a commensal organism Candida species 
have been isolated from almost every site in the body and if the host is predisposed to 
infection or there is a disruption in the balance between the host and its indigenous flora, 
the occurrence of certain species is heightened. It was possible, therefore, that the 
patterns of sensitivity observed during this work were directly related to the species of 
the yeasts found. Of the isolates positively identified, 84% were C.albicans which is by 
far the most proliferate yeast found in healthy or diseased individuals. These findings 
suggested that the killer-sensitive relationships observed were not simply dependent on 
the isolation site or the identity of the yeast, but more probably the result of a 
combination of factors. The lethality produced in a sensitive yeast strain is generally 
thought to involve an interaction between the toxin molecule and a receptor on the cell 
wall (Bussey et al., 1979). The site of isolation, status of the host and species-type will 
all contribute to the success of this interaction. The presence of the correct receptor on 
the cell wall, the number present and their availability or avidity for the toxin molecules 
will govern the susceptibilty of any one isolate to the action of the killer factor.
Several studies were designed to further investigate the mode of action of W.mrakii 
killer toxin on sensitive Candida strains. It was observed that cells from various stages 
of the growth cycle showed a differential susceptibility to the killer factor. Contrary to 
several other reports (Woods, 1966; Pietras and Bruen, 1976; Tipper and Bostian, 1984) 
these studies suggested that stationary phase cells were more susceptible to toxin than 
cells in an active phase of growth. However, the differences in sensitivity were only 
observed at ‘critical concentrations’ of the killer toxin. At high concentrations, complete 
inhibition of growth was produced in each cell type possibly due to the saturation of all 
available receptor sites by excess toxin molecules. At ‘critical concentrations’, cells
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from each phase were readily distinguishable from one another because of their different 
responses to the killer factor. The implication that exponential phase cells were less 
susceptible was perhaps due to the fact that different numbers of receptors were 
available for interaction at different stages of growth, or that the receptors possessed a 
reduced affinity for the toxin during the exponential phase. At lower concentrations, the 
levels of toxin molecules possibly fell below the threshold limit of the assay system 
which may explain the less pronounced effect observed. This in itself suggests that more 
than one receptor site on the sensitive cell must be occupied, or there must be an 
aggregation of several toxin molecules at the same site, for the threshold to be exceeded 
and a toxic effect produced.
A more accurate assessment of the effect of the killer factor on sensitive cell growth was 
made using an automated spectrophotometer which could measure cell growth 
constantly over a 24 hour period. A dose-response to increasing concentrations of toxin 
was observed, as the number of toxin molecules increased the effect on the indicator 
strain became more pronounced. This further supported the hypothesis that a critical 
number of toxin molecules were required to bind to the sensitive cell to produce a lethal 
effect. As toxin levels increased there was an increase in the lag phase prior to entry of 
the cells into their active phase of growth and a reduction in the rate of cell division 
leading to a decrease in final cell numbers. It was possible that the killer factor of 
W.mrakii caused an arrest early in the cell cycle in a similar manner to the K.lactis toxin 
(White et al., 1989). This would prevent cells from enlarging and reaching the critical 
size required for continued growth and cell division. It was not determined at this stage, 
however, if the cessation of cell growth was linked to a loss in sensitive cell viability. If 
the killer toxin had reduced the number of viable cells in the culture then fewer would 
enter exponential growth resulting in the slower growth rates observed, or alternatively 
fewer cells were of sufficient size to divide. A subsequent experiment did show that the 
killer factor produced a cidal effect in the sensitive cells. At high toxin concentrations 
there was a 75% loss in the number of viable cells after a 15 minute exposure to the 
killer toxin, in which time only a small proportion of the toxin appeared to have been 
bound to the cells. In contrast, de la Pena et al. (1980) reported that the killer toxin from 
S.cerevisiae bound to sensitive cells immediately after addition, yet there was a lag 
period of 40 minutes before a 50% reduction in viability was observed. At lower toxin
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concentrations a longer incubation period was required for the same effect to be seen. 
The results also suggested that at sub-critical concentrations of toxin the cells were able 
to recover from the toxic effect of the killer factor. Kotani et al. (1977) had previously 
suggested that sensitive cells entered a transition period prior to irreversible damage, 
during which time an intrinsic repair mechanism allowed the cells to revert to a normal 
state and continued growth.
The exact mechanism by which the killer toxin of W.mrakii exerts its lethal action on 
sensitive Candida strains remains unclear and further investigations were not possible 
during the time remaining. However, there is some evidence to suggest that the killer 
toxin produces channels in the sensitive cell which may promote the loss of ions such as 
K+ and H+ and also ATP which, ultimately, leads to cell death. The ‘leak pathway’ is 
probably the result of a secondary action of the killer factor at the level of the plasma 
membrane. An assay developed by Glaxo Group Research demonstrated that the toxin 
was in fact membrane damaging and caused the release of a radioactively-labelled 
amino acid from pre-loaded cells. Although this avenue of research was only given 
preliminary consideration it suggested that the killer toxin of W.mrakii acts in a similar 
manner to the K1 killer toxin of S.cerevisiae (Martinac et al.> 1990) and the toxin of 
P.kluyveri (Kagan, 1983).
With the knowledge that the killer factor of W.mrakii displayed extensive anti-Candida 
activity against clinically important isolates, it was the intention that the remainder of 
the research concentrated on the production and purification of the killer toxin. Any 
advances towards producing a novel antifungal preparation or critically assessing the 
mechanism of action of the toxin against Candida strains relied on determining the 
physical characteristics of the toxin and the biochemical nature of its structure. 
However, prior to such investigations this work concentrated on the production and 
processing of cultures of the killer yeast to yield workable amounts of material.
The simple nutritional requirements of the killer yeast W.mrakii enabled well supported 
growth in the minimal medium YNBGS. This chemically-defined medium was 
supplemented with magnesium and ammonium sulphate following the work of O’Leary 
(1987) in an attempt to potentiate toxin production. The lethality of the killer factor 
produced in the minimal medium was less than that produced in the richer YEPD
Page 200
medium, but the former was used to aid processing and purification. The production of 
an active toxin by the killer yeast directly followed increases in cell biomass and was 
detectable in the extracellular medium as cells progressed through late exponential and 
into stationary phase. This is in agreement with earlier reports by Woods and Bevan 
(1968) and Palfree and Bussey (1979). Increases in the amount of protein in cell-free 
supernatants further confirmed production of the killer factor.
Small-scale static fermentations resulted in the production of active toxin albeit that 
extended periods of incubation were required to produce significant yields. Larger, 
agitated systems reduced the fermentation times involved and produced a more active 
preparation. Gentle agitation prevented pellicle formation by the yeast, maintained cells 
in suspension enhancing cell growth, reduced the mean generation time of cells during 
cell division and, it would appear, increased toxin production. Attempts to further 
promote toxin production under anaerobic or oxygenated conditions were unsuccessful, 
less toxin was produced and, in the latter, activity was lost completely. This was in all 
likelihood a result of the toxin being destabilised in the presence of high levels of 
oxygen or, alternatively, production of extracellular proteolytic enzymes was promoted 
under these conditions which led to inactivation of the toxin molecules. The hypothesis 
that the toxin structure was degraded was supported by a reduction in extracellular 
protein levels. Although growth of the killer yeast under anaerobic conditions was 
possible, reduced levels of active toxin were produced. The enhanced protein production 
observed in the anaerobic and oxygenated cultures suggested that not all of the protein 
could be attributed to active toxin. Under these conditions it was considered possible 
that the yeast produced significant amounts of ‘stress proteins’ . This area of work 
demonstrated that the killer yeast W.mrakii grew favourably in a minimal medium and 
was "microaerophilic" in its requirement for oxygen. Growth and toxin production were 
possible in the presence of only minimal levels of oxygen in a simple, chemically 
defined medium. It was hoped that this information would be directly applied to scale- 
up production of the killer factor in a 40 litre fermentation in a future collaboration with 
Glaxo Group Research.
A simple procedure for processing small-scale fermentations was developed which 
involved clarification, by centrifugation and microfiltration, and ultrafiltration steps. It 
was thought that the simplicity of the growth medium would benefit this procedure and
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allow a rapid, partial purification of the killer factor. Preliminary findings, using 
PhastSystem SDS-PAGE analysis, suggested that the toxin possessed a molecular 
weight of approximately 16 kDa, hence, an ultrafiltration membrane with a nominal 
molecular weight cut-off of 10 kDa was used. Toxin activity at each stage of the 
procedure was assessed using an agar diffusion bioassay. The results demonstrated 
increasing activity i.e. larger zones of inhibition, in the cell-free supernatant, retentate 
and freeze-dried material. No activity was apparent in the permeate fraction which 
further indicated, at this stage, that the toxin molecule was larger than 10 kDa.
The transition from small-scale (two litres) to large-scale (40 litres) fermentations 
highlighted a range of technical problems involved in the production and processing of 
W.mrakii killer toxin. Gentle agitation of cultures during small-scale fermentations 
provided sufficient oxygen exchange for growth and the production of an active killer 
factor. However, the size of the vessel used, which had a 70 litre working capacity, may 
have created different surface:volume ratios affecting not only oxygen exchange rates 
but surface properties and growth patterns of the yeast. An initial fermentation supplied 
no oxygen directly to the system but the culture was gently agitated. As a direct 
consequence, cell growth over a 24 hour period was greatly reduced. Therefore, oxygen 
was supplied at 1.5 litres/min and a marked improvement in cell growth in the following 
24 hour period was observed. The toxin activity in the cell-free supernatant after 48 
hours was, however, low when compared to a static fermentation over the same period. 
Direct aeration of the culture in the second fermentation at a rate of 3.5 litres/min 
improved cell growth further, with subsequent increases in toxin production.
Toxin activity and protein levels were monitored during the downstream processing of 
the culture from the second fermentation, highlighting several of the difficulties 
encountered;
(1) significant losses of protein and toxin activity occurred during microfiltration which 
was purely designed as a clarification step following centrifugation. It was considered 
likely that the killer factor had been adsorbed to the filtration membranes as reported by 
Woods and Bevan (1968) and Shimizu et al. (1985).
(2) small losses in toxin activity and protein levels occurred during ultrafiltration, but 
the highest proportion of the killer factor was detected in the permeate fraction. 
Distribution of the killer toxin between the two fractions was not unexpected, however,
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it was surprising that only a minimal amount was detected in the retentate. Initial 
findings concerning the size of the toxin molecules would appear at this later stage to 
have been misleading. Previously, permeate samples were not concentrated prior to 
analysis, therefore, toxin activity may have fallen below the threshold of the assay and 
remained undetected.
(3) dialysis of the resultant freeze-dried material, containing large amounts of unused 
media, removed all carbohydrate and substantial amounts of low molecular weight 
proteins. However, analysis of the dialysate revealed no detectable levels of toxin 
activity. This provided further evidence that the molecular weight was smaller than 10 
kDa.
It was anticipated that this period of research would have led to the optimisation of the 
growth of the killer yeast W.mrakii and allowed the production of the killer factor in 
bulk for further studies. However, significant losses in toxin activity resulted during 
processing and only small amounts of workable material were obtained. Despite the low 
recovery of toxin this material remained active against other sensitive strains, including 
C.glabrata  and C.albicans. It was considered important, therefore, within the time 
constraints of the project to concentrate on the characterisation and purification of the 
killer factor.
Although stable at low temperatures for relatively long periods of time (2-3 days at 
4°C), the killer toxin of W.mrakii was sensitive to increasing incubation temperatures. 
The killer factor was stable at 37°C for several hours but rapidly inactivated thereafter 
and was completely unstable to temperatures exceeding 50°C. This is unlike the killer 
toxin produced by another strain of W.mrakii, LKB 169 (Ashida et al., 1983), which 
was stable to temperatures exceeding 100°C for two to three minutes. The toxin 
maintained its activity over a range of pH 2.4-4.0 and displayed an optimal killing 
activity in agar diffusion bioassays at pH 3.5. No activity was detectable at values 
exceeding pH 5.0. In common with several other killer toxins, this information 
displayed obvious problems associated with the direct use of W.mrakii killer factor as an 
antifungal preparation. It would still appear feasible, however, that preparations 
containing the active component could be applied topically to superficial lesions rather 
than be used for administration, in any form, orally or intravenously. The killer was
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found to be insensitive to the action of the proteolytic enzymes papain and pronase. This 
does not suggest that the killer factor is not proteinaceous but rather the amino acid 
composition is such that it may contain insufficient, or incorrect, sequences for cleavage 
by these site-specific enzymes, or the "cleavage" sites are buried within the tertiary 
folding of the toxin molecule. An alternative explanation is that other components 
present in the extracellular medium protect the toxin molecules from degradation or 
perhaps a carbohydrate moiety present in the toxin structure interferes with enzyme 
action. However, the inactivation of the killer factor at elevated temperatures suggests 
that the toxin contains a proteinaceous component necessary for its activity against 
sensitive yeast strains.
Preliminary studies of W.mrakii killer toxin involved PhastSystem SDS-PAGE and IEF 
analysis. Five proteins not present in the original media were detected which had 
distinct isoelectric points between pH 4.35 and 5.80, suggesting that the toxin was 
acidic. This was further confirmed by the acidification of the Coomassie blue (to 
yellow) present in the boiling mix used for preparation of samples for SDS-PAGE. 
Although the PhastSystem does not allow a critical assessment of the killer factor, it 
provided valuable information for future work involving FPLC purification. SDS-PAGE 
analysis revealed a protein of approximately 16 kDa in size. It was unusual that only a 
single band was detected (albeit a crude preparation) but it was possible that other 
proteins were present in amounts too small to be detected. No toxin activity was directly 
attributed to this band and several attempts to repeat this separation were unsuccessful. 
Significant input into the research which followed was based on these findings but with 
hindsight they were perhaps misleading. Subsequent studies involving gel filtration 
chromatography revealed that the toxin molecule may be as small as 5000-1800 Da. A 
modified SDS system would, therefore, be required to detect this polypeptide. The 
protein with an apparent molecular weight of 16 kDa was perhaps the result of an 
aggregation of several smaller toxin molecules. Considerable effort was expended on 
establishing a preliminary characterisation of W.mrakii killer toxin of which little has 
been previously reported. This study provided valuable information for continued 
investigations into the nature and structure of the killer factor.
A ‘simple mix’ of components was suggested from PhastSystem analysis of the crude 
toxin, therefore, use of FPLC techniques appeared to be the most profitable approach in
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an attempt to purify the killer factor. With the knowledge of the isoelectric points of the 
toxin components a Mono Q anion-exchange column was used. As expected, the use of 
a buffer system with a pH of 4.0 (below the pH of the lowest isoelectric point) resulted 
in all of the activity being removed in the unbound fractions. At pH 6.0, a single fraction 
of the unbound material showed lethality against the indicator strain. The pH of the 
buffer system was, therefore, raised to pH 6.5 so that the active material would be 
separated early on the column. It appeared that the toxin was eluted on the salt gradient, 
however, it was difficult to accurately assign toxin activity to any one fraction because 
of ‘salt interference’ in the microtitre assay. The problems associated with analysis of 
the FPLC fractions at this stage required us to adopt a simpler approach to the 
purification of the killer factor using gel filtration techniques. Separation of 
proteinaceous material using this method is based on molecular weight distributions 
rather than on the specific charge on a molecule, therefore, this excludes the use of 
buffers with high pH or ionic strength which could directly affect toxin stability, or the 
assay system used to detect activity. A ‘clean-up’ step to remove low molecular weight 
material was proposed using a small, commercial G-25 Sephadex column (fractionation 
range 1-5 kDa). The active component was not eluted at the void volume as expected, 
but was separated on the column which immediately suggested that the molecule had a 
molecular weight of less than 5 kDa. The same separation profiles were consistently 
observed on larger, prepared columns (70 to 700 ml bed volume). With the enhanced 
resolution of these larger columns it was apparent that the active fractions did not 
directly coincide with the eluted protein peaks but lay between a protein doublet. U.V 
spectra of the active fractions had an Amax of 257 nm rather than 280 nm, similar to the 
phenomenon observed by Sawant et a l., 1989. This may be indicative of the toxin 
molecules lacking large hydrophobic residues, such as tryptophan and tyrosine, and 
further supported the hypothesis that the toxin was a polypeptide of perhaps 15-20 
amino acid residues. As further confirmation of the low molecular weight of the toxin 
molecule the killer factor was applied to a P2 Biogel column (fractionation range 100- 
1800 Da). The toxin activity was eluted at, or near, the void volume of the column 
which suggested an approximate molecular weight of between 1800 and 5000 Da. These 
findings confirmed that the killer toxin of W .m rakii may act as an ionophore on 
sensitive yeast cells, causing membrane damage and the subsequent release of
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intracellular components. Further purification of the killer factor was hampered by the 
large losses of activity observed during separation on the Sephadex columns. Only 5% 
of the original activity was present in the active fractions eluted from the column. It was 
considered possible that the toxin molecules were adsorbed to the chromatographic bed 
since a similar problem to that observed by Woods and Bevan (1968) with the killer 
toxin of S.cerevisiae. Alternatively, active components of the killer factor may have 
dissociated during the separation, or some losses were incurred during the concentration 
of samples for analysis. An experiment was therefore designed which demonstrated that 
not all of the observed losses in activity were due to the adsorption of the killer factor to 
the column. Forty percent of the toxin activity was unaccounted for, but it was not 
necessarily bound to the dextran matrix. Toxin activity may have been diluted in the 
washing stages and, therefore, remained undetected by the microtitre assay, or 
alternatively was maintained within the bed volume of the matrix. Complementation 
studies were conducted where all of the fractions eluted from the column were 
recombined and assayed for activity, however, no lethality against an indicator strain 
was observed. It is possible that during gel filtration chromatography the active material 
was separated from other components which normally stabilised the toxin structure. 
This could account for the large losses in activity.
Although there were problems associated with maintaining the stability of the killer 
factor of W.mrakii during purification, the low molecular weight material remained 
active against pathogenic yeast strains of C.albicans. Whilst this must have important 
implications for the epidemiological typing of such strains, it still remains a realistic 
target to exploit the interaction between the killer toxin and the sensitive yeast cell. 
Despite the low molecular weight of the killer factor, it is probably still too large to be 
used in systemic fungal therapy without eliciting an immune response because 
molecules as small as 1000 Da are known to produce a weak response. However, it is 
possible that the active component of this molecule may, when fully identified and 
sequenced, be useful in the design and synthesis of a synthetic derivative for use as an 
antifungal agent.
A consistent problem apparent during this period of research was the inability to 
accurately assess killer toxin activity in the fractions eluted from FPLC and gel filtration
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columns. The microtitre assay was based on the growth/no growth of an indicator strain 
and was, consequently, susceptible to the osmotic effects of high salt concentrations and 
also displayed a threshold limit below which activity was not detectable. A novel assay 
of killer activity was formulated and developed in an attempt to overcome these 
difficulties and to aid any subsequent purification studies. This assay was based on the 
reduction of a yellow tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide] (MTT) to a dark blue product MTT-Formazan by the 
mitochondrial dehydrogenase enzymes of living cells (Slater et al., 1963). The assay 
was found to be able to readily distinguish between live and dead, hence, viable cells 
and also toxin-treated cells of a sensitive strain of Candida. Earlier work had suggested 
that W.mrakii killer toxin caused a rapid decrease in the viability of some strains of 
Candida  and the colourimetric assay provided further confirmation of this. Toxin 
activity could, using this assay, be expressed as the percentage reduction in viability of 
an indicator strain. An experiment was also designed to investigate the deleterious 
effects of high salt concentrations on the assay system. A constant residual toxin activity 
was detected in the presence of increasing concentrations of salt, indicating the potential 
of this assay in analysis of fractions eluted during chromatographic techniques. The 
colourimetric MTT assay, previously used in the measurement of the candidacidal 
activity of mouse neutrophils (Ashman, 1986), was successfully adapted as a novel and 
rapid measure of the lethality of the killer factor of W.mrakii against sensitive strains of 
Candida. This method has the potential to be used as a standard assay of killer toxin 
activity to circumvent the use of traditional agar diffusion bioassays which are time- 
consuming and less quantitative.
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7.2 Future work
The findings presented in this thesis provide a basis for the further development of a 
number of areas and the following may be important lines to follow;
(1) Purification of the killer toxin of W.mrakii to homogeneity using FPLC techniques 
(the accurate assessment of toxin activity being facilitated using the MTT-colourimetric 
assay developed in this current study).
(2) The use of purified material to further investigate possible host receptor responses. 
This would facilitate studies of the mechanism of action of the killer toxin and may 
enable the elucidation of potential targets for new antifungal agents.
(3) By utilising available human cell lines a number of investigations concerning the 
toxicity of the killer factor could be made. Furthermore, the use of animal model 
systems would enable preliminary data on the immunogenic response to be determined.
(4) On a more fundamental note, efforts could be directed towards a molecular and 
genetic study of W .m rakii. Contemporary techniques such as PCR-based DNA 
sequencing technology would allow;
(a) sequencing of the toxin molecule for comparison to sequence data bases for 
homology to known proteins.
(b) the development of a diagnostic probe for the killer trait.
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CHAPTER NINE
Appendices
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9 .1  P h a s t S y s t e m  A n a ly s i s
1. SEPARATION METHOD - SDS-PAGE
Sample applicator Down at 1.1 0001 Vh
Sample applicator Up at 1.1 0010 Vh
SEP 1.1 0250 V 10.0 mA 3.0 W 15°C 0065 Vh
SEP 1.2 0050 V 00.1 mA 0.5 W 15°C 0000 Vh
2. SEPARATION METHOD - IEF (3-9)
Sample applicator Down at 4.2 0000 Vh
Sample applicator Up at 4.3 0000 Vh
SEP 4.1 2000 V 02.5 mA 3.5 W 15°C 0075 Vh
SEP 4.2 0200 V 02.5 mA 3.5 W 15°C 0015 Vh
SEP 4.3 2000 V 02.5 mA 3.5 W 15°C 0410 Vh
3. STAINING METHOD - SILVER STAINING (SDS-PAGE)
Solution Volume (per run) ml
50 % ethanol/10% acetic acid 100 ml
10% ethanol/5% acetic acid 500 ml
8.3% gluteraldehyde 100 ml
0.25% silver nitrate 100 ml
40 pi of 37% formaldehyde stock 200 ml
in 100 ml 2.5% sodium carbonate
5% acetic acid 100 ml
10% acetic acid/5% glycerol 100 ml
Ultrapure water 500 ml
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Step No. Solution IN-port OUT-port Time Temperature
1 50% EtOH/10% HAc 2 0 2 min 50°C
2 10% EtOH/5% HAc 3 0 2 min 50°C
3 10 EtOH/5% HAc 3 0 4 min 50°C
4 8.3% glut.CHO 4 0 6 min 50°C
5 10% EtOH/5% HAc 3 0 3 min 50°C
6 10% EtOH/5% HAc 3 0 5 min 50°C
7 Ultrapure H2O 5 0 2 min 50°C
8 Ultrapure H2O 5 0 2 min 50°C
9 0.25% AgN03 6 0 13 min 40°C
10 Ultrapure H2O 5 0 0.5 min 30°C
11 Ultrapure H2O 5 0 0.5 min 30°C
12 Developer 7 0 0.5 min 30°C
13 Developer 7 0 4 min 30°C
14 5% HAc 8 0 2 min 50°C
15 10% HAc/5% gly. 9 0 3 min 50°C
Samples for SDS-PAGE analysis were prepared in Boiling Mix;
Stacking gel buffer (see below) 1.0 ml
25% sodium dodecyl sulphate polyacrylamide (SDS) 0.8 ml
p-mercaptoethanol 0.5 ml
Bromophenol blue (powder), to colour
Stacking gel buffer (pH 6.7) was prepared by dissolving TRIS base (5.9 g) and 
SDS (0.4 g) in 80 ml distilled water and adjusting to pH 6.7 using HC1. The 
solution was made up to a final volume of 100 ml with distilled water. 
Working aliquots were stored at 4°C.
Samples were added to an equal volume of boiling mix, heated to 100°C for 3 
minutes, cooled and centrifuged at 4,500 rpm for 5 minutes prior to loading.
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4. STAINING METHOD - SILVER STAIN (IEF 3-9)
Solution 
20% TCA
50% ethanol/10% acetic acid 
10% ethanol/10% acetic acid 
8.3% gluteraldehyde
0.50% silver nitrate 
40 (0,1 of 37% formaldehyde stock 
in 100 ml 2.5% sodium carbonate 
5% acetic acid 
Ultrapure water
Volume (per run) ml 
100 ml 
100 ml 
500 ml 
100 ml 
100 ml 
200 ml
100 ml 
500 ml
Samples were prepared by dissolving freeze-dried material in a minimum 
volume of distilled water. Prior to loading, solutions were centrifuged at 
4,500 rpm for 5 minutes.
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9 .2  F P L C  A n a ly s is
EQUILIBRATION PROGRAM FOR MONO Q HR 5/5 COLUMN
Volume Function Value
0 cone % B 0
0 ml/min 1.5
0 cm/ml 0.5
5 cone % B 0
5 cone % B 100
15 cone % B 100
15 cone % B 0
20 cone % B 0
SEPARATION PROGRAM FOR MONO Q HR 5/5 COLUMN
Volume Function Value
0 cone % B 0
0 ml/min 1
0 cm/ml 0.5
0 portset 6.1
4 cone % B 0
24 cone % B 35
28 cone % B 100
32 cone % B 100
32 cone % B 0
32 portset 6.0
36 cone % B 0
All buffers were filtered through a 0.22 gm filter preferably using an all 
glass filtration apparatus. All samples were filtered through 0.22 \im 
syringe filters prior to loading. At end of run, the pumps and column
were stored in 20% ethanol (filter sterilised).
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